| 12415 |
11-deoxy-11-methylene-15-keto Prostaglandin D2
|
|
- |
>98%
|
|
|
|
141.014502762431
|
11-deoxy-11-methylene-15-keto-prostaglandin-d2
|
11-deoxy-11-methylene-15-keto PGD2
|
prostaglandins 11-deoxy-11-methylene-15-keto-PGD2 CRTH2 receptors eosinophils stable ligands |
141.014502762431
|
| 12410 |
11-deoxy-11-methylene Prostaglandin D2
|
|
100648-29-1 |
>98%
|
|
|
|
59.518939226519
|
11-deoxy-11-methylene-prostaglandin-d2
|
11-deoxy-11-methylene PGD2
|
11-deoxy-11-methylene-PGD2 vasodilation prostaglandins analogs |
59.518939226519
|
| 14570 |
11-deoxy-16,16-dimethyl Prostaglandin E2
|
|
53658-98-3 |
>98%
|
|
|
|
102.436629834254
|
11-deoxy-16-16-dimethyl-prostaglandin-e2
|
11-deoxy-16,16-dimethyl PGE2
|
11-deoxy-16,16-dimethyl-PGE2 prostaglandins agonists EP2 EP3 receptors |
102.436629834254
|
| 13510 |
11-deoxy Prostaglandin E1
Exclusive |
|
37786-00-8 |
>96%
|
|
✓ |
|
80.190193370165
|
11-deoxy-prostaglandin-e1
|
11-deoxy PGE1
|
11-deoxy-PGE1 prostaglandins agonists analogs EP2 receptors |
80.190193370165
|
| 14520 |
11-deoxy Prostaglandin E2
|
|
35536-53-9 |
>99%
|
|
|
|
63.425635359116
|
11-deoxy-prostaglandin-e2
|
11-deoxy PGE2
|
11-deoxy-PGE2 bronchoconstriction analogs |
63.425635359116
|
| 15512 |
11-deoxy Prostaglandin F1α
|
|
37785-98-1 |
>99%
|
|
|
|
2.673977900552
|
11-deoxy-prostaglandin-f1
|
11-deoxy PGF1α
|
prostaglandins 11-deoxy-PGF1.alpha. 11-deoxy-PGF1alpha |
2.673977900552
|
| 15510 |
11-deoxy Prostaglandin F1β
|
|
37785-99-2 |
>99%
|
|
|
|
0.127071823204
|
11-deoxy-prostaglandin-f1
|
11-deoxy PGF1β; 9β,11-deoxy PGF1α
|
9.beta.,11-deoxy PGF1.alpha. prostaglandins 9beta-11-deoxy-PGF1alpha 11-deoxy-PGF1.beta. 9b-11-deoxy-PGF1alpha 11-deoxy-PGF1beta |
0.127071823204
|
| 16500 |
11-deoxy Prostaglandin F2α
|
|
37786-06-4 |
>98%
|
|
|
|
43.856022099448
|
11-deoxy-prostaglandin-f2
|
11-deoxy PGF2α
|
11-deoxy-PGF2alpha 11-deoxy-PGF2.alpha. prostaglandins analogs agonists |
43.856022099448
|
| 16510 |
11-deoxy Prostaglandin F2β
|
|
37786-07-5 |
>98%
|
|
|
|
2.102762430939
|
11-deoxy-prostaglandin-f2
|
11-deoxy PGF2β
|
11-deoxy-PGF2beta 11-deoxy-PGF2.beta. prostaglandins analogs 9.beta.-11-deoxy-PGF2.alpha. 9beta-11-deoxy-PGF2alpha 9b-11-deoxy-PGF2alpha |
2.102762430939
|
| 16783 |
11-keto Fluprostenol
|
|
- |
≥98%
|
|
|
|
32.866386740331
|
11-keto-fluprostenol
|
Fluprostenol Prostaglandin D2
|
11-keto-fluprostenol analogs DP receptors PGD2 agonists prostaglandins |
32.866386740331
|
| 16540 |
11β-13,14-dihydro-15-keto Prostaglandin F2α
|
|
107615-77-0 |
>98%
|
|
|
|
28.142265193370
|
11-13-14-dihydro-15-keto-prostaglandin-f2
|
11β-13,14-dihydro-15-keto PGF2α
|
11.beta.-13,14-dihydro-15-keto-PGF2.alpha. 11beta-13,14-dihydro-15-keto-PGF2alpha prostaglandins 11b-13,14-dihydro-15-keto-PGF2alpha |
28.142265193370
|
| 13825 |
11β-Misoprostol
|
|
58717-36-5 |
>98%
|
|
|
|
6.457546961326
|
11-misoprostol
|
|
cytoprotection PGE1 analogs agonists EP2 EP3 EP4 receptors SC29333 RU-486 RU486 cytotec SC-29333 |
6.457546961326
|
| 13450 |
11β-Prostaglandin E1
|
|
24570-01-2 |
>98%
|
|
|
|
52.812762430939
|
11-prostaglandin-e1
|
11β-PGE1
|
11-epi-PGE1 prostaglandins 11b-PGE1 11beta-PGE1 11.beta.-PGE1 epimers C-11 |
52.812762430939
|
| 14510 |
11β-Prostaglandin E2
Exclusive |
|
38310-90-6 |
≥98%
|
|
✓ |
|
103.549558011049
|
11-prostaglandin-e2
|
11β-PGE2
|
11-epi-PGE2 prostaglandins 11.beta.-PGE2 11b-PGE2 11beta-PGE2 11-iso-PGE2 |
103.549558011049
|
| 15450 |
11β-Prostaglandin F1β
|
|
37785-86-7 |
>99%
|
|
|
|
2.673977900552
|
11-prostaglandin-f1
|
11β-PGF1β; 9β,11β-PGF1α
|
9.beta.,11.beta.-PGF1.alpha. stereoisomers prostaglandins 11.beta.-PGF1.beta. 11beta-PGF1beta 9beta,11beta-PGF1alpha 9b,11b-PGF1alpha 11b-PGF1beta |
2.673977900552
|
| 16520 |
11β-Prostaglandin F2α
|
|
38432-87-0 |
>99%
|
|
|
|
38.379309392265
|
11-prostaglandin-f2
|
11β-PGF2α
|
11.beta.-PGF2.alpha. 11beta-PGF2alpha metabolites PGD2 prostaglandins 9.beta.-11-deoxy-PGF2.alpha. 9beta-11-deoxy-PGF2alpha 9b-11-deoxy-PGF2alpha |
38.379309392265
|
| 10008989 |
11β-Prostaglandin F2α-d4
|
|
- |
≥99% deuterated product
|
|
|
2006-09-15
|
38.688508287292
|
11-prostaglandin-f2-d4
|
|
GC/MS deuteriums isotopes internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry spectoscopy signalling 11β-PGF2α 11βa-PGF2α metabolites PGD2 prostaglandins 9.beta.-11-deoxy-PGF2α 9beta-11-deoxy-PGF2α 9b-11-deoxy-PGF2alpha |
38.688508287292
|
| 516521 |
11β-Prostaglandin F2α EIA Kit
|
|
- |
|
|
|
|
192.259160220995
|
11-prostaglandin-f2-eia-kit
|
11β-Prostaglandin F2α ELISA Kit
|
solid plates metabolites mastocytosis 11beta-PGF2alpha prostaglandins measures kits eias enzyme immunoassays ELISAs 11.beta.-PGF2.alpha. 11b-PGF2alpha assays |
192.259160220995
|
| 16522 |
11β-Prostaglandin F2α Ethanolamide
|
|
714966-38-8 |
≥95%
|
|
|
|
13.400883977901
|
11-prostaglandin-f2-ethanolamide
|
11β-PGF2α-EA
|
ethanolamides cannabinoids prostaglandins 11.beta.-PGF2.alpha. 11beta-PGF2alpha 11b-PGF2a COX-2 COX2 PGHS-2 PGHS2 synthases cyclooxygenases prostamides AEA arachidonoyl neuroscience ethanolamines |
13.400883977901
|
| 10007224 |
11β-Prostaglandin F2α Lipid Maps MS Standard
|
|
38432-87-0 |
>99%
|
|
|
2008-12-11
|
30.763370165745
|
11-prostaglandin-f2-lipid-maps-ms-standard
|
11β-PGF2α
|
11.beta.-PGF2.alpha. 11beta-PGF2alpha metabolites PGD2 prostaglandins 9.beta.-11-deoxy-PGF2.alpha. 9beta-11-deoxy-PGF2alpha MS Mass spectrometry standards |
30.763370165745
|
| 18212 |
13,14-dehydro-15-cyclohexyl Carbaprostacyclin
|
|
145375-81-1 |
>98%
|
|
|
|
60.902646609463
|
13-14-dehydro-15-cyclohexyl-carbaprostacyclin
|
|
PGI2 analogs vasodilation prostaglandins 13,14-dihydro-15-cyclohexyl-carbaprostacyclin |
60.902646609463
|
| 10260 |
13,14-dihydro-15-keto Prostaglandin A2
|
|
74872-89-2 |
>98%
|
|
|
|
49.699999999999
|
13-14-dihydro-15-keto-prostaglandin-a2
|
13,14-dihydro-15-keto PGA2
|
13,14-dihydro-15-keto-pga2 metabolites prostaglandins 13,14-dihydro-15-keto-pge2 |
49.699999999999
|
| 10007200 |
13,14-dihydro-15-keto Prostaglandin A2 Lipid Maps MS Standard
|
|
74872-89-2 |
≥98%
|
|
|
2008-07-24
|
50.889198895027
|
13-14-dihydro-15-keto-prostaglandin-a2-lipid-maps-ms-standard
|
13,14-dh-15-k PGA2
|
13,14-dihydro-15-keto-pga2 metabolites prostaglandins mass spectrometry |
50.889198895027
|
| 10010425 |
13,14-dihydro-15-keto Prostaglandin D1
Exclusive |
|
- |
>98%
|
|
✓ |
2008-05-09
|
0.494944751381
|
13-14-dihydro-15-keto-prostaglandin-d1
|
13,14-dihydro-15-keto PGD1
|
PGD1 prostaglandins metabolites DGLA dihomo-.gamma.-linolenic acid dihomo-gamma-linolenic dihomo-y-linolenic PGDs pathways |
0.494944751381
|
| 12610 |
13,14-dihydro-15-keto Prostaglandin D2
|
|
59894-07-4 |
>98%
|
|
|
|
153.472906077348
|
13-14-dihydro-15-keto-prostaglandin-d2
|
13,14-dihydro-15-keto PGD2
|
metabolites 13,14-dihydro-15-keto-PGD2 prostaglandins DK PGD2 diketo DKPGD2 CRTH2 DP2 |
153.472906077348
|
| 10007978 |
13,14-dihydro-15-keto Prostaglandin D2-d4
|
|
- |
≥99% deuterated product
|
|
|
2006-02-10
|
141.153950276243
|
13-14-dihydro-15-keto-prostaglandin-d2-d4
|
13,14-dihydro-15-keto PGD2-d4
|
GC/MS deuteriums isotopes internal standards deuterateds LC/MS GC-MS LC-MS mass spectrometry metabolites 13,14-dihydro-15-keto-PGD2 prostaglandins |
141.153950276243
|
| 13650 |
13,14-dihydro-15-keto Prostaglandin E1
|
|
5094-14-4 |
>98%
|
|
|
|
26.675773480662
|
13-14-dihydro-15-keto-prostaglandin-e1
|
13,14-dihydro-15-keto PGE1
|
13,14-dihydro-15-keto-PGE1 metabolites prostaglandins |
26.675773480662
|
| 9000288 |
13,14-dihydro-15-keto Prostaglandin E1-d4
|
|
- |
≥99% deuterated product
|
|
|
2004-05-05
|
51.286110497237
|
13-14-dihydro-15-keto-prostaglandin-e1-d4
|
13,14-dh-15-k PGE1-d4
|
PGE0 metabolites 13,14-dihydro-15-ketoPGE1 prostaglandins deuterium deuterateds |
51.286110497237
|
| 14650 |
13,14-dihydro-15-keto Prostaglandin E2
|
|
363-23-5 |
>98%
|
|
|
|
57.050290055248
|
13-14-dihydro-15-keto-prostaglandin-e2
|
13,14-dihydro-15-keto PGE2
|
metabolites 13,14-dihydro-15-keto-PGE2 prostaglandins |
57.050290055248
|
| 10010606 |
13,14-dihydro-15-keto Prostaglandin E2-d4
Exclusive |
|
- |
>99% deuterated product
|
|
✓ |
2008-03-18
|
14.858931860037
|
13-14-dihydro-15-keto-prostaglandin-e2-d4
|
13,14-dh-15-keto PGE2-d4
|
deuterated metabolites 13,14-dihydro-15-keto-PGE2 prostaglandins PGE2 deuterium |
14.858931860037
|
| 10007214 |
13,14-dihydro-15-keto Prostaglandin E2 Lipid Maps MS Standard
|
|
363-23-5 |
>98%
|
|
|
2008-11-12
|
42.806883977900
|
13-14-dihydro-15-keto-prostaglandin-e2-lipid-maps-ms-standard
|
13,14-dihydro-15-keto PGE2
|
metabolites 13,14-dihydro-15-keto-PGE2 prostaglandins GC LC MS mass spectrometry standards GC/MS LC/MS GC-MS LC-MS |
42.806883977900
|
| 15670 |
13,14-dihydro-15-keto Prostaglandin F1α
Exclusive |
|
29044-75-5 |
>99%
|
|
✓ |
|
3.174375690607
|
13-14-dihydro-15-keto-prostaglandin-f1
|
13,14-dihydro-15-keto PGF1α
|
metabolites prostaglandins 13,14-dihydro-15-keto-PGF1.alpha. 13,14-dihydro-15-keto-PGF1alpha |
3.174375690607
|
| 16670 |
13,14-dihydro-15-keto Prostaglandin F2α
|
|
27376-76-7 |
>98%
|
|
|
|
5.675071823204
|
13-14-dihydro-15-keto-prostaglandin-f2
|
PGFM; 13,14-dihydro-15-keto PGF2α
|
13,14-dihydro-15-keto-PGF2alpha 13,14-dihydro-15-keto-PGF2.alpha. metabolites prostaglandins |
5.675071823204
|
| 10007793 |
13,14-dihydro-15-keto Prostaglandin F2α-d4
|
|
- |
≥99% deuterated product
|
|
|
2006-02-06
|
10.659723756905
|
13-14-dihydro-15-keto-prostaglandin-f2-d4
|
PGFM-d4
|
GC/MS deuteriums isotopes internal standards deuterateds LC/MS GC-MS LC-MS mass spectrometry 13,14-dihydro-15-keto-PGF2a 13,14-dihydro-15-keto-PGF2.alpha. metabolites prostaglandins |
10.659723756905
|
| 516671 |
13,14-dihydro-15-keto Prostaglandin F2α EIA Kit
|
|
- |
|
|
|
|
169.429953959484
|
13-14-dihydro-15-keto-prostaglandin-f2-eia-kit
|
13,14-dihydro-15-keto Prostaglandin F2α ELISA Kit; PGFM EIA Kit
|
solid plates metabolites EIAs enzyme immunoassays kits measures ELISAs 13,14-dh-15-k-PGF2.alpha. 13,14-dihydro-15-keto-PGF2.alpha. 13,14-dh-15-k-PGF2alpha 13,14-dihydro-15-keto-PGF2alpha 13,14-dh-15-k-prostaglandins 13,14-dihydro-15-keto-prostaglandins prostaglandins assays |
169.429953959484
|
| 16671 |
13,14-dihydro-15-keto Prostaglandin F2α isopropyl ester
|
|
199920-18-8 |
>98%
|
|
|
|
24.153784530387
|
13-14-dihydro-15-keto-prostaglandin-f2-isopropyl-ester
|
13,14-dihydro-15-keto PGF2α isopropyl ester
|
prostaglandins 13,14-dihydro-15-keto-PGF2alpha 13,14-dihydro-15-keto-PGF2.alpha. esters |
24.153784530387
|
| 10007226 |
13,14-dihydro-15-keto Prostaglandin F2α Lipid Maps MS Standard
|
|
27376-76-7 |
>99%
|
|
|
2008-12-04
|
2.571955801104
|
13-14-dihydro-15-keto-prostaglandin-f2-lipid-maps-ms-standard
|
13,14-dihydro-15-keto PGF2α; PGFM; 13,14-dh-15-k PGF2α
|
13,14-dihydro-15-keto-PGF2alpha 13,14-dihydro-15-keto-PGF2.alpha. metabolites prostaglandins MS mass spectrometry PGs marker plasma |
2.571955801104
|
| 10008840 |
13,14-dihydro-15-keto Prostaglandin J2
|
|
- |
>97%
|
|
|
2006-08-14
|
24.474337016574
|
13-14-dihydro-15-keto-prostaglandin-j2
|
|
13,14-dihydro-15-keto PGJ2 13,14-dihydro-15-keto PGD2 Prostaglandin J2 PGJ2 15-hydroxy PGDH metabolite platelet aggregation antitumor antiviral |
24.474337016574
|
| 13100 |
13,14-dihydro-15-keto-tetranor Prostaglandin D2
Exclusive |
|
- |
≥95%
|
|
✓ |
2009-10-28
|
70.577546961326
|
13-14-dihydro-15-keto-tetranor-prostaglandin-d2
|
|
PGDM metabolites PGD2 CRTH2 DP2 tetranors agonists prostaglandins receptors CRTH2/DP2 |
70.577546961326
|
| 13101 |
13,14-dihydro-15-keto-tetranor Prostaglandin E2
Exclusive |
|
20675-85-8 |
≥95%
|
|
✓ |
2009-10-23
|
22.652292817679
|
13-14-dihydro-15-keto-tetranor-prostaglandin-e2
|
|
PGEM metabolites 13,14-dihydro-15-keto PGE2 CRTH2 PGs tetranorPGEM tetranor-PGEM |
22.652292817679
|
| 13571 |
13,14-dihydro-15-keto-tetranor Prostaglandin F1α
Exclusive |
|
24379-94-0 |
≥98%
|
|
✓ |
2009-11-05
|
0.044198895027
|
13-14-dihydro-15-keto-tetranor-prostaglandin-f1
|
|
metabolites PGF1α PGF2α tetranors PGFM prostaglandins PGs urinary metabolites prostanoic acids C13 C-13 C14 C-14 C15 C-15 |
0.044198895027
|
| 16853 |
13,14-dihydro-15-keto-tetranor Prostaglandin F1β
|
|
23015-45-4 |
≥98%
|
|
|
2009-03-27
|
65.033278084714
|
13-14-dihydro-15-keto-tetranor-prostaglandin-f1
|
9β-13,14-dihydro-15-keto-tetranor Prostaglandin F1α; 9β,11α-dihydroxy-15-oxo-2,3,4,5-tetranor-Prostanoic Acid; 5β, 7α-dihydroxy-11-ketotetranor-Prostanoic Acid
|
PGE2 metabolite urine prostaglandin |
65.033278084714
|
| 13630 |
13,14-dihydro-15(R)-Prostaglandin E1
|
|
201848-10-4 |
>98%
|
|
|
|
52.812762430939
|
13-14-dihydro-15-r-prostaglandin-e1
|
13,14-dihydro-15(R)-PGE1
|
analogs 13,14-dihydro-15(R)-PGE1 prostaglandins metabolites 13,14-dihydro-15R-PGE1 |
52.812762430939
|
| 9000406 |
13,14-dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2009-12-02
|
40.317983425414
|
13-14-dihydro-15-r-s-hydroxy-16-16-difluoro-prostaglandin-e1-d4
|
15-hydroxy Lubiprostone
|
lubiprostone chloride channel epithelial cell constipation gastrointestinal amitiza RU-0211 RU0211 SPI-0211 SPI0211 PGE1 PGE2 Prostaglandin E2 gastroprotection 15-hydroxy Lubiprostone 475992-30-4 |
40.317983425414
|
| 13612 |
13,14-dihydro-16,16-difluoro Prostaglandin D2
Exclusive |
|
- |
≥95%
|
|
✓ |
2010-01-27
|
9.654242304656
|
13-14-dihydro-16-16-difluoro-prostaglandin-d2
|
13,14-dihydro-16,16-difluoro PGD2
|
prostaglandins D2 PGD2 vascular smooth muscles relaxation platelets aggregation asthma allergy allergies anaphylaxism analogs PGs prostanoids delay degradation fluorines |
9.654242304656
|
| 9000405 |
13,14-dihydro-16,16-difluoro Prostaglandin E1
|
|
475992-30-4 |
≥98%
|
|
|
2009-12-03
|
46.936767955801
|
13-14-dihydro-16-16-difluoro-prostaglandin-e1
|
15-hydroxy Lubiprostone
|
prostaglandins E1 PGE1 chloride channels Amitiza constipation irritable bowel syndrome platelets dilation vasodilation hypotension metabolite of lubiprostone |
46.936767955801
|
| 13609 |
13,14-dihydro-16,16-difluoro Prostaglandin F2α
Exclusive |
|
- |
≥95%
|
|
✓ |
2010-01-27
|
10.948604972375
|
13-14-dihydro-16-16-difluoro-prostaglandin-f2
|
13,14-dihydro-16,16-difluoro PGF2α
|
prostaglandins F2α PGF2α smooth muscles contractions luteolysis analog SPGs .alpha. alpha |
10.948604972375
|
| 13635 |
13,14-dihydro-16,16-difluoro Prostaglandin J2
Exclusive |
|
- |
≥95%
|
|
✓ |
2010-02-02
|
11.317209944751
|
13-14-dihydro-16-16-difluoro-prostaglandin-j2
|
13,14-dihydro-16,16-difluoro PGJ2
|
Prostaglandins J2 PGJ2 platelets aggregation cells growth analogs PGs fluorines |
11.317209944751
|
| 13660 |
13,14-dihydro-19(R)-hydroxy Prostaglandin E1
|
|
- |
>98%
|
|
|
|
21.454295580110
|
13-14-dihydro-19-r-hydroxy-prostaglandin-e1
|
19(R)-hydroxy PGE0; 13,14-dihydro-19(R)-hydroxy PGE1
|
13,14-dihydro-19(R)-hydroxy-PGE1 13,14-dihydro-19R-hydroxy-PGE1 prostaglandins metabolites 13,14-dihydro-19(R)-OH-PGE113,14-dihydro-19R-OH-PGE1hydroxylated |
21.454295580110
|
| 13610 |
13,14-dihydro Prostaglandin E1
|
|
19313-28-1 |
>98%
|
|
|
|
50.608674033149
|
13-14-dihydro-prostaglandin-e1
|
PGE0; 13,14-dihydro PGE1
|
PGE0 metabolites 13,14-dihydro-PGE1 prostaglandins |
50.608674033149
|
| 9000281 |
13,14-dihydro Prostaglandin E1-d4
|
|
- |
>99% deuterated product
|
|
|
2004-05-06
|
48.194263351749
|
13-14-dihydro-prostaglandin-e1-d4
|
13,14-dh PGE1-d4; Prostaglandin E0-D4
|
PGE0 metabolites 13,14-dihydro-PGE1 prostaglandins GC/MS deuterium isotopes PGA2-d4 internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry gas liquid chromatography spectroscopy |
48.194263351749
|
| 10006845 |
13,14-dihydro Prostaglandin E1 Quant-PAK
|
|
- |
|
|
|
2005-08-10
|
3.112412523020
|
13-14-dihydro-prostaglandin-e1-quant-pak
|
|
Quant-PAKs PGE0 metabolites 13,14-dihydro-PGE1 prostaglandins GC/MS deuterium isotopes PGA2-d4 internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry gas liquid chromatography spectroscopy packs |
3.112412523020
|
| 15610 |
13,14-dihydro Prostaglandin F1α
|
|
20592-20-5 |
>99%
|
|
|
|
2.864585635359
|
13-14-dihydro-prostaglandin-f1
|
13,14-dihydro PGF1α; PGFα
|
PGF0 metabolites prostaglandins 13,14-dihydro-PGF1alpha 13,14-dihydro-PGF1.alpha. |
2.864585635359
|
| 16660 |
13,14-dihydro Prostaglandin F2α
|
|
27376-74-5 |
>98%
|
|
|
|
2.460497237569
|
13-14-dihydro-prostaglandin-f2
|
13,14-dihydro PGF2α
|
13,14-dihydro-PGF2.alpha. 13,14-dihydro-PGF2alpha metabolites prostaglandins endocrinology |
2.460497237569
|
| 13679 |
13,14-epoxy Fluprostenol isopropyl ester
Exclusive |
|
- |
≥95% (epoxide mixture)
|
|
✓ |
2010-04-12
|
29.297313535911
|
13-14-epoxy-fluprostenol-isopropyl-ester
|
13,14-epoxy Travoprost
|
travoprost FP receptors agonists ocular hypotensive agents glaucoma impurity |
29.297313535911
|
| 11169 |
13(R),14(R)-epoxy Fluprostenol isopropyl ester
New |
|
- |
≥95%
|
|
|
2012-01-24
|
103.724504077874
|
13-r-14-r-epoxy-fluprostenol-isopropyl-ester
|
13(R),14(R)-epoxy Travoprost
|
travoprosts FP receptors agonists ocular hypotensive agents glaucoma impurity prostaglandins PGs prodrugs chiral enantiomer epoxide |
103.724504077874
|
| 11170 |
13(S),14(S)-epoxy Fluprostenol isopropyl ester
New |
|
- |
≥95%
|
|
|
2012-01-24
|
107.391170744541
|
13-s-14-s-epoxy-fluprostenol-isopropyl-ester
|
13(S),14(S)-epoxy Travoprost
|
travoprost FP receptors agonists ocular hypotensive agents glaucoma impurity prostaglandins PGs prodrugs chiral enantiomers |
107.391170744541
|
| 16710 |
15-cyclohexyl pentanor Prostaglandin F2α
|
|
58611-97-5 |
≥96%
|
|
|
|
2.102762430939
|
15-cyclohexyl-pentanor-prostaglandin-f2
|
15-cyclohexyl pentanor PGF2α
|
analogs prostaglandins 15-cyclohexyl-pentanor-PGF2.alpha. 15-cyclohexyl-pentanor-PGF2alpha |
2.102762430939
|
| 10065 |
15-deoxy-Δ12,14-Prostaglandin A1
|
|
573951-20-9 |
>95%
|
|
|
|
83.502375690608
|
15-deoxy-12-14-prostaglandin-a1
|
15-deoxy-Δ12,14-PGA1
|
PPARs 15-deoxy-.DELTA.12,14-pga1 15-deoxy-DELTA12,14-pga1 prostaglandins peroxisome proliferator-activated receptors antitumor antimitotic 15-deoxy-d12,14-PGA1 ligands analogs PPAR.gamma. PPARgamma |
83.502375690608
|
| 10265 |
15-deoxy-Δ12,14-Prostaglandin A2
Exclusive |
|
112839-31-3 |
>98% (isomer mixture)
|
|
✓ |
|
23.680257826887
|
15-deoxy-12-14-prostaglandin-a2
|
15-deoxy-Δ12,14-PGA2
|
15-deoxy-.DELTA.12,14-PGA2 15-deoxy-DELTA12,14-PGA2 PPARs prostaglandins peroxisome proliferator-activated receptors 15-deoxy-d12,14-PGA2 ligands |
23.680257826887
|
| 12700 |
15-deoxy-Δ12,14-Prostaglandin D2
|
|
85235-11-6 |
>95%
|
|
|
|
147.658839779006
|
15-deoxy-12-14-prostaglandin-d2
|
15-deoxy-Δ12,14-PGD2
|
PPARs prostaglandins peroxisome proliferator-activated receptors 15-deoxy-DELTA12,14-PGD2 15-deoxy-.DELTA.12,14-PGD2 15-deoxy-d12,14-PGD2 leukemia cells cancer 15d-pgd2 |
147.658839779006
|
| 18570 |
15-deoxy-Δ12,14-Prostaglandin J2
|
|
87893-55-8 |
≥95%
|
|
|
|
157.498670963781
|
15-deoxy-12-14-prostaglandin-j2
|
15-deoxy-Δ12,14-PGJ2
|
PPARγ PPARgamma prostaglandins 15-deoxy-delta12,14-PGJ2 15-deoxy-d12,14-PGJ2 nuclear receptors 15-deoxy-Δ12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands 15dpgj2
atherosclerosis |
157.498670963781
|
| 18570.1 |
15-deoxy-Δ12,14-Prostaglandin J2
|
|
87893-55-8 |
>98% (isomer mixture)
|
|
|
|
88.400607734806
|
15-deoxy-12-14-prostaglandin-j2
|
15-deoxy-Δ12,14-PGJ2
|
PPAR.gamma. PPARgamma prostaglandins 15-deoxy-delta12,14-PGJ2 15-deoxy-d12,14-PGJ2 15-deoxy-.DELTA.12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands |
88.400607734806
|
| 10010132 |
15-deoxy-Δ12,14-Prostaglandin J2-2-glycerol ester
|
|
- |
≥98% (isomer mixture)
|
|
|
2008-06-09
|
26.555457335788
|
15-deoxy-12-14-prostaglandin-j2-2-glycerol-ester
|
15-deoxy-Δ12,14-PGJ2-2-glycerol ester
|
PPARgamma PPAR.gamma. PPARg PGD2 PGJ2 lipolysis prostaglandins adipocyte endocannabinoid metabolism diabetes obesity nuclear receptors COX-2 COX2 2-AG 2AG cannabinoids cbs synthetic |
26.555457335788
|
| 10141 |
15-deoxy-Δ12,14-Prostaglandin J2-biotin
|
|
- |
>98%
|
|
|
2005-10-11
|
34.721527229676
|
15-deoxy-12-14-prostaglandin-j2-biotin
|
15-deoxy-Δ12,14-PGJ2-biotin
|
affinity probes binding proteins cyclopentenones PGs prostaglandins peroxisomes proliferator-activated receptors PPARs anitmitotic antiproliferative genes expressions non-classical non-GPCR gene protein-coupled detected detection interactions biotins ligands complexes nuclear nucleic acids elucidations mechanisms biotinylated PGJ2 biotinamides |
34.721527229676
|
| 318570 |
15-deoxy-Δ12,14-Prostaglandin J2-d4
|
|
- |
≥99% deuterated product
|
|
|
|
45.031193370165
|
15-deoxy-12-14-prostaglandin-j2-d4
|
15-deoxy-Δ12,14-PGJ2-d4
|
GC/MS deuterium isotopes 15-deoxy-DELTA12,14-PGJ2-d4 15-deoxy-.DELTA.12,14-PGJ2-d4 15-deoxy-D12,14-PGJ2-d4 internal standards prostaglandins deuterated mass spectrometry GC-MS LC-MS LC/MS atherosclerosis |
45.031193370165
|
| 10007235 |
15-deoxy-Δ12,14-Prostaglandin J2 Lipid Maps MS Standard
|
|
87893-55-8 |
≥97%
|
|
|
2009-01-16
|
51.545994475138
|
15-deoxy-12-14-prostaglandin-j2-lipid-maps-ms-standard
|
15-deoxy-Δ12,14-PGJ2
|
PPARγ PPARgamma prostaglandins 15-deoxy-delta12,14-PGJ2 15-deoxy-d12,14-PGJ2 nuclear receptors 15-deoxy-Δ12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands atherosclerosis MS mass spectrometry standards |
51.545994475138
|
| 10006850 |
15-deoxy-Δ12,14-Prostaglandin J2 Quant-PAK
|
|
- |
|
|
|
2005-08-10
|
11.273918402039
|
15-deoxy-12-14-prostaglandin-j2-quant-pak
|
|
Quant-PAKs PPAR.gamma. PPARgamma prostaglandins nuclear receptors peroxisome proliferator-activated receptors PPARs activators ligands GC/MS deuterium isotopes 15-deoxy-DELTA12,14-PGJ2-d4 15-deoxy-.DELTA.12,14-PGJ2-d4 15-deoxy-D12,14-PGJ2-d4 internal standards deuterated mass spectrometry GC-MS LC-MS LC/MS packs |
11.273918402039
|
| 10070 |
15-epi Prostaglandin A1
|
|
20897-92-1 |
>98%
|
|
|
|
130.675469613260
|
15-epi-prostaglandin-a1
|
15-epi PGA1
|
15-epi-pga1 15(R)-pga1 renal vasodilation prostaglandins steroisomers |
130.675469613260
|
| 10007950 |
15-hydroxy Prostaglandin Dehydrogenase (human recombinant)
|
|
- |
≥95% by SDS-PAGE
|
|
|
2007-01-16
|
54.825201262825
|
15-hydroxy-prostaglandin-dehydrogenase-human-recombinant
|
15-hydroxy PGDH
|
15-OH PGDH 15-PGDH proteins binding enzymes dehydrogenases recombinant tumors suppressors colon thyroid breast cells |
54.825201262825
|
| 16817 |
15-keto-17-phenyl trinor Prostaglandin F2α
|
|
949564-89-0 |
>98%
|
|
|
|
17.231215469613
|
15-keto-17-phenyl-trinor-prostaglandin-f2
|
15-keto-17-phenyl trinor PGF2α
|
oxidation lantoprost bimatoprost eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors 15-keto-17-phenyl-trinor PGF2.alpha. agonists IOP pressure prostaglandins 15-keto-17-phenyl-trinor PGF2alpha prostaglandins |
17.231215469613
|
| 10010405 |
15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide
|
|
- |
>98%
|
|
|
2008-01-10
|
120.456591850828
|
15-keto-17-phenyl-trinor-prostaglandin-f2-ethyl-amide
|
15-keto-Bimatoprost; 17-phenyl trinor PGF2α ethyl amide
|
17 phenyl trinor prostaglandins PGs ethyl amide intraocular hypotensive PGF2.alpha. IOP pressure glaucoma |
120.456591850828
|
| 16785 |
15-keto Fluprostenol
|
|
- |
≥98%
|
|
|
|
4.995580110497
|
15-keto-fluprostenol
|
|
analogs luteolysis FP agonists prostaglandins receptors travoprost |
4.995580110497
|
| 16786 |
15-keto Fluprostenol isopropyl ester
Exclusive |
|
404830-45-1 |
≥98%
|
|
✓ |
|
89.645193370166
|
15-keto-fluprostenol-isopropyl-ester
|
15-keto Travoprost
|
glaucoma metabolites eyes ophthalmology ophthalmological 15-keto-fluprostenol IOP intraocular pressure hypotensive esters |
89.645193370166
|
| 10008616 |
15-keto Iloprost
|
|
- |
≥97%
|
|
|
2006-05-23
|
57.331602209944
|
15-keto-iloprost
|
|
C-15 oxidized second generation analogs prostaglandins PGI2 carbaprostacyclin |
57.331602209944
|
| 16816 |
15-keto Latanoprost
|
|
- |
>98%
|
|
|
|
77.950764272560
|
15-keto-latanoprost
|
|
eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists IOP pressure prostaglandins hypotensive |
77.950764272560
|
| 16815 |
15-keto Latanoprost (free acid)
|
|
- |
>98%
|
|
|
|
32.930455801105
|
15-keto-latanoprost-free-acid
|
|
eyes ophthalmology ophthalmological glaucoma FP receptors agonists 15-keto-17-phenyl-13,14-dihydro-trinor-PGF2.alpha. 15-keto-17-phenyl-13,14-dihydro-trinor-PGF2alpha acids metabolites hypotensive drugs impurities impurity intraocular pressure iop |
32.930455801105
|
| 13680 |
15-keto Prostaglandin E1
|
|
22973-19-9 |
>98%
|
|
|
|
70.463149171270
|
15-keto-prostaglandin-e1
|
15-keto PGE1
|
metabolites 15-keto-PGE1 prostaglandins |
70.463149171270
|
| 14720 |
15-keto Prostaglandin E2
|
|
26441-05-4 |
>99%
|
|
|
|
81.572320441989
|
15-keto-prostaglandin-e2
|
15-keto PGE2
|
15-keto-PGE2 metabolites prostaglandins |
81.572320441989
|
| 10007215 |
15-keto Prostaglandin E2 Lipid Maps MS Standard
|
|
26441-05-4 |
>99%
|
|
|
2008-12-15
|
74.332173112339
|
15-keto-prostaglandin-e2-lipid-maps-ms-standard
|
15-keto PGE2
|
15-keto-PGE2 metabolites prostaglandins MS mass spectrometry standards PGs inactive |
74.332173112339
|
| 15710 |
15-keto Prostaglandin F1α
|
|
21562-58-3 |
>99%
|
|
|
|
2.112127071823
|
15-keto-prostaglandin-f1
|
15-keto PGF1α
|
metabolites 15-keto-PGF1.alpha. 15-keto-PGF1alpha prostaglandins |
2.112127071823
|
| 16720 |
15-keto Prostaglandin F2α
|
|
35850-13-6 |
>98%
|
|
|
|
15.497845303867
|
15-keto-prostaglandin-f2
|
15-keto PGF2α
|
15-keto-PGF2alpha 15-keto-PGF2.alpha. metabolites prostaglandins endocrinology PGs |
15.497845303867
|
| 10007227 |
15-keto Prostaglandin F2α Lipid Maps MS Standard
|
|
35850-13-6 |
>98%
|
|
|
2008-12-18
|
14.450787292817
|
15-keto-prostaglandin-f2-lipid-maps-ms-standard
|
15-keto PGF2α
|
15-keto-PGF2alpha 15-keto-PGF2.alpha. metabolites prostaglandins endocrinology PGs PGF2α MS Mass Spectrometry |
14.450787292817
|
| 10270 |
15(R)-15-methyl Prostaglandin A2
|
|
- |
>98%
|
|
|
|
2.784530386740
|
15-r-15-methyl-prostaglandin-a2
|
15(R)-15-methyl PGA2
|
15(R)-15-methyl-pga2 metabolites 15-epi-15-methyl-pga2 prostaglandins |
2.784530386740
|
| 12720 |
15(R)-15-methyl Prostaglandin D2
Exclusive |
|
210978-26-0 |
>95%
|
|
✓ |
|
60.153885819521
|
15-r-15-methyl-prostaglandin-d2
|
15(R)-15-methyl PGD2
|
15(R)-15-methyl-PGD2 prostaglandins 15-epi-15-methyl-PGD2 15R-15-methyl-PGD2 |
60.153885819521
|
| 14725 |
15(R)-15-methyl Prostaglandin E2
|
|
55028-70-1 |
>98%
|
|
|
|
67.833627992633
|
15-r-15-methyl-prostaglandin-e2
|
15(R)-15-methyl PGE2; Arbaprostil
|
prostaglandins 15(R)-15-methyl-PGE2 15R-15-methyl-PGE2 |
67.833627992633
|
| 16730 |
15(R)-15-methyl Prostaglandin F2α
|
|
35864-81-4 |
>98%
|
|
|
|
11.862348066298
|
15-r-15-methyl-prostaglandin-f2
|
15(R)-15-methyl PGF2α
|
15R-15-methyl-PGF2alpha 15R-15methyl-PGF2.alpha. 15(R)-15-methyl-PGF2alpha 15(R)-15methyl-PGF2.alpha prostaglandins analogs 15-epi-15-methyl-PGF2alpha 15-epi-15-methyl-PGF2.alpha. |
11.862348066298
|
| 16734 |
15(R)-15-methyl Prostaglandin F2α methyl ester
|
|
35700-22-2 |
>98%
|
|
|
|
0.343093922652
|
15-r-15-methyl-prostaglandin-f2-methyl-ester
|
15(R)-15-methyl PGF2α methyl ester
|
15(R)-15-methyl-PGF2.alpha.-OMe 15(R)-15-methyl-PGF2alpha-OMe 15R-15-methyl-PGF2.alpha.-OMe 15R-15-methyl-PGF2alpha-OMe esters prostaglandins 15-epi-15-methyl-PGF2alpha-OMe 15-epi-15methyl-PGF2.alpha.-OMe |
0.343093922652
|
| 16814 |
15(R)-17-phenyl trinor Prostaglandin F2α
|
|
41639-71-8 |
>98%
|
|
|
|
100.920220994474
|
15-r-17-phenyl-trinor-prostaglandin-f2
|
15(R)-17-phenyl trinor PGF2α; 15(R)-Bimatoprost (free acid); 15-epi Bimatoprost (free acid)
|
prostaglandins 15(R)-17-phenyl-trinor-PGF2.alpha. unnatural isomers FP 15(R)-17-phenyl-trinor-PGF2alpha receptors agonists 15-epi-17-phenyl-trinor-PGF2alpha 15-epi-17-phenyl-trinor-PGF2.alpha. 15R-17-phenyl-trinor-PFG2.alpha. 15R-17-phenyl-trinor-PFG2alpha |
100.920220994474
|
| 10008127 |
15(R)-17-phenyl trinor Prostaglandin F2α ethyl amide
Exclusive |
|
1163135-92-9 |
≥98%
|
|
✓ |
2009-12-07
|
119.386314592135
|
15-r-17-phenyl-trinor-prostaglandin-f2-ethyl-amide
|
15(R)-Bimatoprost; 15(R)-17-phenyl trinor PGF2α ethyl amide
|
prostaglandins F2α glaucomas ocular hypertension PGF2α PGs bimatoprosts intracellular pressure IOPs 15-epi bimatoprosts hypertensive |
119.386314592135
|
| 16825 |
15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester
|
|
130273-87-9 |
>98%
|
|
|
|
95.903182934315
|
15-r-17-phenyl-trinor-prostaglandin-f2-isopropyl-ester
|
15(R)-Bimatoprost isopropyl ester; 15(R)-17-phenyl trinor PGF2α isopropyl ester; 15-epi Bimatoprost isopropyl ester
|
anaolg esters eyes intraocular hypotensive pressure lumigan bimatoprost 15(R)-17-phenyl-Prostaglandin F2.alpha.-iPr 15(R)-17-phenyl-Prostaglandin F2alpha-iPr 15(R)-17-phenyl-Prostaglandin F2a-iPr IOP 15(R)-13,14-dehydro Latanoprost prostaglandins ophthalmology glaucoma |
95.903182934315
|
| 13920 |
15(R),19(R)-hydroxy Prostaglandin E1
|
|
- |
>98%
|
|
|
|
10.562552486187
|
15-r-19-r-hydroxy-prostaglandin-e1
|
15(R),19(R)-hydroxy PGE1
|
prostaglandins hydroxylated 15R,19R-hydroxy-PGE1 15R,19R-OH-PGE1 15(R),19(R)-OH-pge1 15(R),19(R)-hydroxy-pge1 |
10.562552486187
|
| 14920 |
15(R),19(R)-hydroxy Prostaglandin E2
|
|
54142-29-9 |
>98%
|
|
|
|
48.711422651933
|
15-r-19-r-hydroxy-prostaglandin-e2
|
15(R),19(R)-hydroxy PGE2
|
prostaglandins hydroxylated 15R,19R-hydroxy-PGE2 15R,19R-OH-PGE2 15(R),19(R)-OH-pge2 15(R),19(R)-hydroxy-pge2 |
48.711422651933
|
| 15920 |
15(R),19(R)-hydroxy Prostaglandin F1α
|
|
- |
>98%
|
|
|
|
0.668494475138
|
15-r-19-r-hydroxy-prostaglandin-f1
|
15(R),19(R)-hydroxy PGF1α
|
prostaglandins hydroxylated 15R,19R-hydroxy-PGF1alpha 15R,19R-OH-PGF1alpha 15(R),19(R)-OH-pgf1alpha 15(R),19(R)-hydroxy-pgf1alpha 15R,19R-hydroxy-PGF1.alpha. 15R,19R-OH-PGF1.alpha. 15(R),19(R)-OH-pgf1.alpha. 15(R),19(R)-hydroxy-pgf1.alpha. |
0.668494475138
|
| 16920 |
15(R),19(R)-hydroxy Prostaglandin F2α
|
|
1224444-23-8 |
>98%
|
|
|
|
8.805734806629
|
15-r-19-r-hydroxy-prostaglandin-f2
|
15(R),19(R)-hydroxy PGF2α
|
prostaglandins hydroxylated 15R,19R-hydroxy-PGF2alpha 15R,19R-OH-PGF2alpha 15(R),19(R)-OH-pgf2alpha 15(R),19(R)-hydroxy-pgf2alpha 15R,19R-hydroxy-PGF2.alpha. 15R,19R-OH-PGF2.alpha. 15(R),19(R)-OH-pgf2.alpha. 15(R),19(R)-hydroxy-pgf2.alpha. |
8.805734806629
|
| 10043 |
15(R)-Iloprost
|
|
85026-51-3 |
≥97%
|
|
|
|
33.640220994475
|
15-r-iloprost
|
|
analogs PGI2 prostaglandins prostacyclin unnatural C-15 epimers |
33.640220994475
|
| 10118 |
15(R)-Prostaglandin D2
|
|
- |
>98%
|
|
|
|
59.398416206261
|
15-r-prostaglandin-d2
|
15(R)-PGD2
|
PGD2 vasodilation prostaglandins 15(R)-PGD2 15-epi-PGD2 15R-PGD2 DP2 receptors agonists CRTH2 endogenous 15d-pgj2 |
59.398416206261
|
| 13710 |
15(R)-Prostaglandin E1
|
|
20897-91-0 |
>98%
|
|
|
|
18.752417127071
|
15-r-prostaglandin-e1
|
15-epi PGE1; 15(R)-PGE1
|
15(R)-PGE1 15-epi-PGE1 15-iso-PGE1 prostaglandins 15(R)PGE1 15R-PGE1 stereoisomers |
18.752417127071
|
| 14710 |
15(R)-Prostaglandin E2
|
|
38873-82-4 |
>98%
|
|
|
|
102.357845303867
|
15-r-prostaglandin-e2
|
15-epi PGE2; 15(R)-PGE2
|
15-epi-PGE2 prostaglandins 15(R)-PGE2 15(R)PGE2 15R-PGE2 |
102.357845303867
|
| 16740 |
15(R)-Prostaglandin F2α
|
|
37658-84-7 |
>98%
|
|
|
|
43.943867403315
|
15-r-prostaglandin-f2
|
15-epi PGF2α
|
15(R)-PGF2.alpha. 15(R)-PGF2alpha 15R-PGF2alpha 15R-PGF2.alpha. prostaglandins 15(R)PGF2alpha 15(R)PGF2.alpha. 15-epi-PGF2alpha 15-epi-PGF2.alpha. |
43.943867403315
|
| 12730 |
15(S)-15-methyl Prostaglandin D2
|
|
85280-90-6 |
>95%
|
|
|
|
56.934327808471
|
15-s-15-methyl-prostaglandin-d2
|
15(S)-15-methyl PG2
|
15(S)-15-methyl-PGD2 prostaglandins vasoconstriction analogs 15S-15-methyl-PGD2 |
56.934327808471
|
| 13730 |
15(S)-15-methyl Prostaglandin E1
|
|
35700-26-6 |
>98%
|
|
|
|
52.812762430939
|
15-s-15-methyl-prostaglandin-e1
|
15(S)-15-methyl PGE1
|
15(S)-15-methyl-PGE1 prostaglandins analogs 15S-15-methyl-PGE1 |
52.812762430939
|
| 14730 |
15(S)-15-methyl Prostaglandin E2
Exclusive |
|
35700-27-7 |
>98%
|
|
✓ |
|
101.826685082872
|
15-s-15-methyl-prostaglandin-e2
|
15(S)-15-methyl PGE2
|
15(S)-15-methyl-PGE2 15S-15-methyl-PGE2 prostaglandins |
101.826685082872
|
| 16743 |
15(S)-15-methyl Prostaglandin F2α
|
|
35700-23-3 |
>98%
|
|
|
|
9.955292817679
|
15-s-15-methyl-prostaglandin-f2
|
U-32921; Carboprost; 15(S)-15-methyl PGF2α
|
15(S)-15-methyl-PGF2alpha 15(S)-15-methyl-PGF2.alpha. analogs 15S-15-methyl-PGF2alpha 15S-15-methyl-PGF2.alpha. |
9.955292817679
|
| 10010064 |
15(S)-15-methyl Prostaglandin F2α ethyl amide
Exclusive |
|
- |
≥95%
|
|
✓ |
2010-12-16
|
0.422651933701
|
15-s-15-methyl-prostaglandin-f2-ethyl-amide
|
15(S)-15-methyl PGF2α ethyl amide
|
uterus abortifacient labor prodrugs carboprosts methyl prostaglandins |
0.422651933701
|
| 10010063 |
15(S)-15-methyl Prostaglandin F2α isopropyl ester
Exclusive |
|
157283-72-2 |
≥98%
|
|
✓ |
2010-12-16
|
0.422651933701
|
15-s-15-methyl-prostaglandin-f2-isopropyl-ester
|
15(S)-15-methyl PGF2α isopropyl ester
|
abortions uterus abortifacient labor prodrugs carboprosts prostaglandins PGs esters |
0.422651933701
|
| 16744 |
15(S)-15-methyl Prostaglandin F2α methyl ester
|
|
35700-21-1 |
>98%
|
|
|
|
22.352320441989
|
15-s-15-methyl-prostaglandin-f2-methyl-ester
|
U-36384; Methyl carboprost; 15(S)-15-methyl PGF2α methyl ester
|
15(S)-15-methyl-PGF2alpha-OMe 15(S)-15-methyl-PGF2.alpha.-OMe 15S-15-methyl-PGF2alpha-OMe 15S-15-methyl-PGF2.alpha.-OMe prostaglandins esters carbaprost |
22.352320441989
|
| 16787 |
15(S)-Fluprostenol
|
|
54276-24-3 |
≥98%
|
|
|
2004-02-21
|
14.155900552486
|
15-s-fluprostenol
|
|
PGF2alpha PGF2.alpha. analogs FP agonists luteolysis prostaglandins receptors |
14.155900552486
|
| 16788 |
15(S)-Fluprostenol isopropyl ester
|
|
- |
≥98%
|
|
|
|
39.320773480662
|
15-s-fluprostenol-isopropyl-ester
|
15(S)-Flu-Ipr
|
esters prodrug FP receptors agonists intraocular hypotensive IOP glaucoma analogs prostaglandins travoprost 15(S)-Flu-Ipr 15S-Flu-Ipr ophthalmology |
39.320773480662
|
| 16818 |
15(S)-Latanoprost
|
|
145773-22-4 |
≥98%
|
|
|
|
64.382279005524
|
15-s-latanoprost
|
15-epi Latanoprost
|
eyes ophthalmology ophthalmological intraocular glaucoma isomer FP receptors IOP pressure prostaglandins standards |
64.382279005524
|
| 13800 |
16,16-dimethyl-6-keto Prostaglandin E1
|
|
75874-32-7 |
>98%
|
|
|
|
17.822302025782
|
16-16-dimethyl-6-keto-prostaglandin-e1
|
16,16-dimethyl-6-keto PGE1
|
16,16-dimethyl-6-keto-PGE1 prostaglandins analogs |
17.822302025782
|
| 10080 |
16,16-dimethyl Prostaglandin A1
|
|
41692-24-4 |
>99% deuterated product
|
|
|
|
56.506436464088
|
16-16-dimethyl-prostaglandin-a1
|
16,16-dimethyl PGA1
|
16,16-dimethyl-pga1 prostaglandins metabolism-resistant analogs inhibits inhibition inhibitors viral replication HSV HIV-1 herpes simplex virus human immunodeficiency type 1 |
56.506436464088
|
| 10280 |
16,16-dimethyl Prostaglandin A2
|
|
41691-92-3 |
>98%
|
|
|
|
3.030294659300
|
16-16-dimethyl-prostaglandin-a2
|
16,16-dimethyl PGA2
|
16,16-dimethyl-pga2 metabolites prostaglandins |
3.030294659300
|
| 12750 |
16,16-dimethyl Prostaglandin D2
|
|
64072-59-9 |
>98%
|
|
|
|
164.103259668509
|
16-16-dimethyl-prostaglandin-d2
|
16,16-dimethyl PGD2
|
16,16-dimethyl-PGD2 prostaglandins |
164.103259668509
|
| 13750 |
16,16-dimethyl Prostaglandin E1
|
|
41692-15-3 |
>98%
|
|
|
|
38.095193370165
|
16-16-dimethyl-prostaglandin-e1
|
16,16-dimethyl PGE1
|
16,16-dimethyl-PGE1 prostaglandins |
38.095193370165
|
| 14750 |
16,16-dimethyl Prostaglandin E2
|
|
39746-25-3 |
>98%
|
|
|
|
160.832246777163
|
16-16-dimethyl-prostaglandin-e2
|
16,16-dimethyl PGE2
|
16,16-dimethyl-PGE2 cytoprotection prostaglandins inhibitors inhibits |
160.832246777163
|
| 14753 |
16,16-dimethyl Prostaglandin E2 p-(p-acetamidobenzamido) phenyl ester
|
|
62873-55-6 |
>98%
|
|
|
|
144.973674033149
|
16-16-dimethyl-prostaglandin-e2-p-p-acetamidobenzamido-phenyl-ester
|
16,16-dimethyl PGE2 4-(4-acetamidobenzamido) phenyl ester
|
16,16-dimethyl-PGE2-p-acetamidobenzamido esters prostaglandins |
144.973674033149
|
| 16750 |
16,16-dimethyl Prostaglandin F2α
|
|
39746-23-1 |
>98%
|
|
|
|
43.823425414365
|
16-16-dimethyl-prostaglandin-f2
|
16,16-dimethyl PGF2α
|
prostaglandins 16,16-dimethyl-PGF2.alpha. 16,16-dimethyl-PGF2alpha analogs FP receptors |
43.823425414365
|
| 16470 |
16,16-dimethyl Prostaglandin F2β
|
|
59769-89-0 |
>98%
|
|
|
|
2.431491712707
|
16-16-dimethyl-prostaglandin-f2
|
9β,16,16-dimethyl PGF2α; 16,16-dimethyl PGF2β
|
16,16-dimethyl-PGF2.beta. 16,16-dimethyl-PGF2beta bronchospasm prostaglandins analogs 9.beta.-16,16-dimethyl-PGF2.alpha. 9b-16,16-dimethyl-PGF2alpha 9beta-16,16-dimethyl-PGF2alpha |
2.431491712707
|
| 10285 |
16-phenoxy tetranor Prostaglandin A2
|
|
51639-10-2 |
>98%
|
|
|
|
20.822729281768
|
16-phenoxy-tetranor-prostaglandin-a2
|
16-phenoxy tetranor PGA2
|
16-phenoxy-tetranor-PGA2 prostaglandins |
20.822729281768
|
| 14760 |
16-phenoxy tetranor Prostaglandin E2
|
|
- |
>98%
|
|
|
|
40.773325966850
|
16-phenoxy-tetranor-prostaglandin-e2
|
16-phenoxy tetranor PGE2
|
sulprostone metabolites prostaglandins 16-phenoxy-tetranor-PGE2 |
40.773325966850
|
| 16760 |
16-phenoxy tetranor Prostaglandin F2α
|
|
51705-19-2 |
>98%
|
|
|
|
5.610345303867
|
16-phenoxy-tetranor-prostaglandin-f2
|
16-phenoxy tetranor PGF2α
|
16-phenoxy-tetranor-PGF2alpha 16-phenoxy-tetranor-PGF2.alpha. prostaglandins analogs |
5.610345303867
|
| 10010809 |
16-phenoxy tetranor Prostaglandin F2α cyclopropyl methyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2009-10-12
|
0E-12
|
16-phenoxy-tetranor-prostaglandin-f2-cyclopropyl-methyl-amide
|
16-phenoxy tetranor PGF2α cyclopropyl methyl amide
|
FPs receptors PGF2α PGs intraocular pressure IOPs |
0E-12
|
| 10010103 |
16-phenoxy tetranor Prostaglandin F2α isopropyl ester
Exclusive |
|
130209-78-8 |
>95%
|
|
✓ |
2011-01-26
|
4.115549416820
|
16-phenoxy-tetranor-prostaglandin-f2-isopropyl-ester
|
16-phenoxy tetranor PGF2α isopropyl ester
|
prostaglandins F2a F2alpha F2.alpha. F2-a F2-alpha F2-.alpha. F2α F2-α PGF2α FP receptors PGs analogs glaucoma luteolysis reproductive biology intraocular pressure IOP |
4.115549416820
|
| 10010562 |
16-phenoxy tetranor Prostaglandin F2α methyl amide
|
|
- |
≥98%
|
|
|
2011-01-24
|
0.043204419889
|
16-phenoxy-tetranor-prostaglandin-f2-methyl-amide
|
16-phenoxy tetranor PGF2α methyl amide
|
prostaglandins F2α PGF2α FP receptors analogs glaucoma luteolysis reproductive biology intraocular pressure IOP PGs |
0.043204419889
|
| 10010102 |
16-phenoxy tetranor Prostaglandin F2α methyl ester
Exclusive |
|
51638-90-5 |
>98%
|
|
✓ |
2010-12-06
|
8.047662983425
|
16-phenoxy-tetranor-prostaglandin-f2-methyl-ester
|
16-phenoxy tetranor PGF2α
|
prostaglandins PGS PGF2α PGF2a PGF2.alpha. PGF2alpha FP receptors analogs glaucoma luteolysis reproductive biology intraocular pressures IOP |
8.047662983425
|
| 13770 |
16-phenyl tetranor Prostaglandin E1
|
|
- |
>98%
|
|
|
|
52.812762430939
|
16-phenyl-tetranor-prostaglandin-e1
|
16-phenyl tetranor PGE1
|
analogs 16-phenyl-tetranor-PGE1 prostaglandins |
52.812762430939
|
| 14770 |
16-phenyl tetranor Prostaglandin E2
|
|
38315-44-5 |
>99%
|
|
|
|
102.238397790055
|
16-phenyl-tetranor-prostaglandin-e2
|
16-phenyl tetranor PGE2
|
prostaglandins 16-phenyl-tetranor-PGE2 |
102.238397790055
|
| 16770 |
16-phenyl tetranor Prostaglandin F2α
|
|
38315-48-9 |
>99%
|
|
|
|
43.436685082873
|
16-phenyl-tetranor-prostaglandin-f2
|
16-phenyl tetranor PGF2α
|
16-phenyl-tetranor-PGF2alpha 16-phenyl-tetranor-PGF2.alpha prostaglandins analogs |
43.436685082873
|
| 13077 |
16(S)-Iloprost
|
|
74843-14-4 |
≥98%
|
|
|
2008-10-10
|
20.081736385161
|
16-s-iloprost
|
|
prostacyclin platelet aggregation IP receptors EP vasodilation pulmonary hypertension stereoisomers iloprosts inhibits inhibitors inhibition PGI2 |
20.081736385161
|
| 15790 |
17,20-dimethyl Prostaglandin F1α
|
|
- |
>98%
|
|
|
|
4.076850828729
|
17-20-dimethyl-prostaglandin-f1
|
17,20-dimethyl PGF1α
|
limaprost analogs 17,20-dimethyl-PGF1alpha 17,20-dimethyl-PGF1.alpha. prostaglandins |
4.076850828729
|
| 10010460 |
17-chlorophenyl trinor Prostaglandin F2α ethyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2010-11-29
|
11.516979742173
|
17-chlorophenyl-trinor-prostaglandin-f2-ethyl-amide
|
17-chlorophenyl trinor PGF2α ethyl amide; Chlorophenyl Bimatoprost
|
luteolysis FP receptors EP1 intraocular pressures IOP glaucomas ophthalmology opthamology |
11.516979742173
|
| 10010839 |
17-phenoxy trinor Prostaglandin F2α
|
|
- |
>98%
|
|
|
2008-02-04
|
4.803027624309
|
17-phenoxy-trinor-prostaglandin-f2
|
17-phenoxy trinor PGF2α
|
PGF2a PGF2.alpha. PGs analogs tetranors FPs receptors luteal IOP glaucoma |
4.803027624309
|
| 10010742 |
17-phenoxy trinor Prostaglandin F2α ethyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2010-11-29
|
11.291961325966
|
17-phenoxy-trinor-prostaglandin-f2-ethyl-amide
|
17-phenoxy trinor PGF2α ethyl amide
|
prostaglandins F2α PGF2α FP receptors smooth muscles contractions luteolysis IOP glaucoma PGs |
11.291961325966
|
| 10010723 |
17-phenoxy trinor Prostaglandin F2α isopropyl ester
Exclusive |
|
- |
≥98%
|
|
✓ |
2009-04-15
|
19.226972375690
|
17-phenoxy-trinor-prostaglandin-f2-isopropyl-ester
|
17-phenoxy-PGF2α isopropyl ester
|
FP receptors analogs intraocular pressure IOP FPs PGF2α |
19.226972375690
|
| 10290 |
17-phenyl trinor-13,14-dihydro Prostaglandin A2
|
|
130209-80-2 |
>98%
|
|
|
|
12.446546961326
|
17-phenyl-trinor-13-14-dihydro-prostaglandin-a2
|
17-phenyl trinor-13,14-dihydro PGA2
|
17-phenyl-trinor-13,14-dihydro-pga2 prostaglandins |
12.446546961326
|
| 10007931 |
17-phenyl trinor 8-iso Prostaglandin E2
|
|
- |
>95%
|
|
|
2006-07-25
|
5.372140883978
|
17-phenyl-trinor-8-iso-prostaglandin-e2
|
|
agonists EP1 EP3 prostaglandins receptors 17-phenyl-trinor-PGE2 |
5.372140883978
|
| 10288 |
17-phenyl trinor Prostaglandin A2
|
|
38315-51-4 |
>97%
|
|
|
|
2.908195211787
|
17-phenyl-trinor-prostaglandin-a2
|
17-phenyl trinor PGA2
|
17-phenyl-trinor-PGA2 prostaglandins analogs synthetic |
2.908195211787
|
| 12810 |
17-phenyl trinor Prostaglandin D2
|
|
- |
>98%
|
|
|
|
46.498386740331
|
17-phenyl-trinor-prostaglandin-d2
|
17-phenyl trinor PGD2
|
17-phenyl-trinor-pgd2 analogs agonists DP receptors |
46.498386740331
|
| 14810 |
17-phenyl trinor Prostaglandin E2
|
|
38315-43-4 |
>98%
|
|
|
|
56.688241252302
|
17-phenyl-trinor-prostaglandin-e2
|
17-phenyl trinor PGE2
|
agonists EP1 EP3 prostaglandins receptors 17-phenyl-trinor-PGE2 |
56.688241252302
|
| 13532 |
17-phenyl trinor Prostaglandin E2 ethyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2010-05-04
|
395.592817679557
|
17-phenyl-trinor-prostaglandin-e2-ethyl-amide
|
17-phenyl trinor PGE2 ethyl amide
|
17-phenyl trinor PGE2 agonists EP1 EP3 receptors EP4 smooth muscles contraction fertility prostaglandins PGs |
395.592817679557
|
| 10004238 |
17-phenyl trinor Prostaglandin E2 serinol amide
|
|
- |
≥95%
|
|
|
2004-05-13
|
117.110243093922
|
17-phenyl-trinor-prostaglandin-e2-serinol-amide
|
17-phenyl trinor PGE2-SA
|
agonists EP1 EP3 prostaglandins receptors 17-phenyl-trinor-PGE2 analogs 17-phenyl-PGE2SA 17-phenyl-PGE2-SA amides cannabinoids Cbs sythetic |
117.110243093922
|
| 16810 |
17-phenyl trinor Prostaglandin F2α
Exclusive |
|
38344-08-0 |
>98%
|
|
✓ |
|
120.280538073504
|
17-phenyl-trinor-prostaglandin-f2
|
17-phenyl trinor PGF2α; Bimatoprost (free acid)
|
analogs agonists FP receptors 17-phenyl-trinor-PGF2.alpha. 17-phenyl-trinor-PGF2alpha prostaglandins intraocular pressure iop |
120.280538073504
|
| 16821 |
17-phenyl trinor Prostaglandin F2α amide
|
|
155205-89-3 |
>98%
|
|
|
|
94.052771639042
|
17-phenyl-trinor-prostaglandin-f2-amide
|
Bimatoprost amide; 17-phenyl trinor PGF2α amide
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids hypotensive IOP pressure PGF2 17-phenyl-trinor-PGF2.alpha.-amide 17-phenyl-trinor-PGF2alpha-amide 17-p-PGF2.alpha.-amide 17-p-PGF2alpha-amide 17-p-PGF2a-amide N-amides |
94.052771639042
|
| 9000686 |
17-phenyl trinor Prostaglandin F2α cyclohexyl amide
Exclusive |
|
- |
≥95%
|
|
✓ |
2010-10-11
|
107.069493554328
|
17-phenyl-trinor-prostaglandin-f2-cyclohexyl-amide
|
Bimatoprost cyclohexyl amide
|
agonists FP receptors glaucoma intraocular pressure luteolysis parturition prostaglandins PGs |
107.069493554328
|
| 10010605 |
17-phenyl trinor Prostaglandin F2α cyclopropyl amide
Exclusive |
|
- |
≥95%
|
|
✓ |
2009-05-08
|
84.535162983425
|
17-phenyl-trinor-prostaglandin-f2-cyclopropyl-amide
|
17-phenyl trinor PGF2α cyclopropyl amide; Bimatoprost cyclopropyl amide
|
PGF2α FP glaucoma ocular hypertension prostaglandins amides cycoprepylamides novel analogs |
84.535162983425
|
| 10010810 |
17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide
Exclusive |
|
1138395-10-4 |
≥98%
|
|
✓ |
2011-01-25
|
148.855796082370
|
17-phenyl-trinor-prostaglandin-f2-cyclopropyl-methyl-amide
|
17-phenyl trinor PGF2α cyclopropyl methyl amide
|
prostaglandins F2α PGF2α FP receptors luteolysis analogs bimatoprosts glaucoma intraocular pressure IOP PGs |
148.855796082370
|
| 316810 |
17-phenyl trinor Prostaglandin F2α-d4
|
|
- |
≥99% deuterated product
|
|
|
|
92.959135359116
|
17-phenyl-trinor-prostaglandin-f2-d4
|
17-phenyl trinor PGF2α-d4; Bimatoprost (free acid)-d4
|
GC/MS deuterium isotopes 17-phenyl-trinor-PGF2.alpha.-3,3,4,4-d4 17-pheny-trinor-PGF2alpha-3,3,4,4-d4 GC-MS LS/MS LC-MS mass spectrometry spectroscopy chromatography deuterateds |
92.959135359116
|
| 16823 |
17-phenyl trinor Prostaglandin F2α diethyl amide
|
|
- |
>98%
|
|
|
|
88.984382087816
|
17-phenyl-trinor-prostaglandin-f2-diethyl-amide
|
17-p-PGF2α-NEt2; 17-phenyl trinor PGF2α diethyl amide; Bimatoprost diethyl amide
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids hypotensive IOP pressure 17-phenyl-trinor-PGF2.alpha.-NEt2 17-phenyl-trinor-PGF2alpha-NEt2 17-p-PGF2.alpha.-NEt2 17-p-PGF2alpha-NEt2 17-p-PGF2a-NEt2 N-ethyl amides |
88.984382087816
|
| 516821 |
17-phenyl trinor Prostaglandin F2α EIA Kit
|
|
- |
|
|
|
|
43.758553490708
|
17-phenyl-trinor-prostaglandin-f2-eia-kit
|
Bimatoprost (fee acid) ELISA Kit
|
solid plates 17-phenyl-trinor-PGF2alpha prostaglandins 17-phenyl-trinor-PGF2.alpha. measures kits eias enzyme immunoassays ELISAs EIA assays |
43.758553490708
|
| 16820 |
17-phenyl trinor Prostaglandin F2α ethyl amide
|
|
155206-00-1 |
>97%
|
|
|
|
82.716110891870
|
17-phenyl-trinor-prostaglandin-f2-ethyl-amide
|
17-phenyl trinor PGF2α ethyl amide; Bimatoprost; 15(S)-Bimatoprost
|
lumigan prostaglandins N-ethylamides intraocular hypotensive agonists IOP glaucoma 17-phenyl-trinor-pgf2alpha-ethylamide 17-phenyl-trinor-pgf2a-ethylamide 17-phenyl-trinor-pgf2.alpha.-ethylamide FP receptors ophthalmology |
82.716110891870
|
| 316820 |
17-phenyl trinor Prostaglandin F2α ethyl amide-d4
|
|
- |
≥99% deuterated product
|
|
|
|
101.781568008418
|
17-phenyl-trinor-prostaglandin-f2-ethyl-amide-d4
|
17-phenyl trinor PGF2α ethyl amide-d4; Bimatoprost-d4
|
GC/MS deuterium isotopes 8-isoprostanes 17-phenyl-trinor-PGF2.alpha.-3,3,4,4-d4 17-phenyl-trinor-PGF2alpha-3,3,4,4-d4 GC-MS LS/MS LC-MS mass spectrometry spectroscopy chromatography deuterateds |
101.781568008418
|
| 16824 |
17-phenyl trinor Prostaglandin F2α isopropyl ester
|
|
130209-76-6 |
>98%
|
|
|
|
1547.900412239694
|
17-phenyl-trinor-prostaglandin-f2-isopropyl-ester
|
17-phenyl trinor PGF2α isopropyl ester; 17-phenyl trinor PGF2α-iPr; Bimatoprost isopropyl ester
|
analogs esters eyes intraocular hypotensive pressure lumigan bimatoprost 17-phenyl-trinor-PGF2.alpha.-iPr 17-phenyl-trinor-PGF2alpha-iPr 17-phenyl-trinor-PGF2a-iPr IOP prostaglandins ophthalmology glaucoma |
1547.900412239694
|
| 10010110 |
17-phenyl trinor Prostaglandin F2α methyl ester
Exclusive |
|
38315-47-8 |
≥98%
|
|
✓ |
2011-01-19
|
136.451146408839
|
17-phenyl-trinor-prostaglandin-f2-methyl-ester
|
17-phenyl trinor PGF2α methyl ester; Bimatoprost methyl ester
|
prostaglandins F2α PGF2α FP receptors luteolysis analogs latanoprosts glaucoma intraocular pressure IOP PGs bimatoprost |
136.451146408839
|
| 10004237 |
17-phenyl trinor Prostaglandin F2α serinol amide
|
|
- |
>98%
|
|
|
2004-03-15
|
7.416194751381
|
17-phenyl-trinor-prostaglandin-f2-serinol-amide
|
17-phenyl trinor PGF2α-SA; 17-phenyl trinor PGF2α serinol amide; Bimatoprost serinol amide
|
analogs agonists receptors 17-phenyl-PGF2.alpha.SA 17-phenyl-PGF2alphaSA 17-phenyl-PGF2a-SA prostaglandins cannabinoids CBs synthetic |
7.416194751381
|
| 14995 |
17-trans Prostaglandin E3
Exclusive |
|
- |
>98%
|
|
✓ |
|
17.887458563536
|
17-trans-prostaglandin-e3
|
17-trans PGE3
|
17-trans-PGE3 w-3 omega-3 .omega.-3 prostaglandins |
17.887458563536
|
| 16995 |
17-trans Prostaglandin F3α
Exclusive |
|
211100-24-2 |
>98%
|
|
✓ |
|
2.545414364641
|
17-trans-prostaglandin-f3
|
17-trans PGF3α
|
omega-3 .omega.-3 17-trans-PGF3alpha 17-trans-PGF3.alpha. w-3 prostaglandins |
2.545414364641
|
| 15895 |
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α
|
|
- |
>98%
|
|
|
|
1.336988950276
|
17-trifluoromethylphenyl-13-14-dihydro-trinor-prostaglandin-f1
|
17-TFM-PGF1α
|
PGF1alpha PGF1.alpha. analogs FP prostaglandins eyes ophthalmology ophthalmological intraocular glaucoma esters receptors agonists IOP pressure |
1.336988950276
|
| 16895 |
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α
|
|
294856-01-2 |
>98%
|
|
|
|
30.345165745856
|
17-trifluoromethylphenyl-13-14-dihydro-trinor-prostaglandin-f2
|
17-trifluoromethylphenyl-13,14-dihydro trinor PGF2α
|
17-trifluoromethylphenyl-13,14-dihyrdotrinor-PGF2.alpha. agonists glaucoma 17-trifluoromethylphenyl-13,14-dihydro-trinor-PGF2alpha analogs FP intraocular pressure iop receptors prostaglandins ophthalmology |
30.345165745856
|
| 16890 |
17-trifluoromethylphenyl trinor Prostaglandin F2α
|
|
221246-34-0 |
>98%
|
|
|
|
11.147309392265
|
17-trifluoromethylphenyl-trinor-prostaglandin-f2
|
17-trifluoromethylphenyl trinor PGF2α
|
17-trifluoromethylphenyl-trinor-PGF2.alpha. agonists glaucoma 17-trifluoromethylphenyl-trinor-PGF2alpha analogs FP intraocular pressure iop receptors prostaglandins ophthalmology |
11.147309392265
|
| 10010061 |
17-trifluoromethylphenyl trinor Prostaglandin F2α ethyl amide
|
|
- |
>98%
|
|
|
2010-12-06
|
206.186413089672
|
17-trifluoromethylphenyl-trinor-prostaglandin-f2-ethyl-amide
|
17-trifluoromethylphenyl trinor PGF2α ethyl amide
|
trifluoro methyl phenyl trinor PGF2α amides prostaglandins PGs FP receotirs travoprost latanoprost glaucoma luteolysis reproductive bilogy |
206.186413089672
|
| 10010062 |
17-trifluoromethylphenyl trinor Prostaglandin F2α isopropyl ester
Exclusive |
|
- |
≥98%
|
|
✓ |
2010-12-13
|
0.092817679558
|
17-trifluoromethylphenyl-trinor-prostaglandin-f2-isopropyl-ester
|
17-trifluoromethylphenyl trinor PGF2α isopropyl ester
|
prostaglandins F2α PGF2α FP receptors travoprosts latanoprosts glaucoma luteolysis reproductive biology PGs IOP intraocular pressure |
0.092817679558
|
| 10010111 |
17-trifluoromethylphenyl trinor Prostaglandin F2α methyl ester
Exclusive |
|
195503-20-9 |
≥98%
|
|
✓ |
2011-01-19
|
0.074254143646
|
17-trifluoromethylphenyl-trinor-prostaglandin-f2-methyl-ester
|
17-trifluoromethylphenyl trinor PGF2α methyl ester
|
prostaglandins F2α PGF2α FP receptors travoprosts latanoprosts glaucoma luteolysis reproductive biology PGs |
0.074254143646
|
| 10295 |
19(R)-hydroxy Prostaglandin A2
|
|
52087-58-8 |
>98%
|
|
|
|
2.843149171271
|
19-r-hydroxy-prostaglandin-a2
|
19(R)-hydroxy PGA2
|
19(R)-hydroxy-pga2 19R-hydroxy-pga2 prostaglandins hydroxylated 19(R)-OH-PGA2 19R-OH-PGA2 |
2.843149171271
|
| 11910 |
19(R)-hydroxy Prostaglandin B2
|
|
- |
>98%
|
|
|
|
2.849171270717
|
19-r-hydroxy-prostaglandin-b2
|
19(R)-OH PGB2
|
19R-hydroxy-PGB2 metabolites HPLC prostaglandins hydroxylated 19(R)-OH-PGB2 19(R)-hydroxy-PGB2 19R-OH-PGB2 |
2.849171270717
|
| 13910 |
19(R)-hydroxy Prostaglandin E1
|
|
64625-55-4 |
≥95%
|
|
|
|
52.812762430939
|
19-r-hydroxy-prostaglandin-e1
|
19(R)-hydroxy PGE1
|
19(R)-hydroxy-PGE1 semen prostaglandins agonists hydroxylated 19R-hydroxy-PGE1 19(R)-OH-PGE119R-OH-PGE1 |
52.812762430939
|
| 14910 |
19(R)-hydroxy Prostaglandin E2
|
|
64625-54-3 |
>98%
|
|
|
|
65.709594843462
|
19-r-hydroxy-prostaglandin-e2
|
19(R)-hydroxy PGE2; 19(R)-OH PGE2
|
19(R)-hydroxy-PGE2 19(R)-OH-PGE2 19R-hydroxy-PGE2 19R-OH-PGE2 metabolites semen agonists EP2 prostaglandins receptors hydroxylated PGs |
65.709594843462
|
| 10007217 |
19(R)-hydroxy Prostaglandin E2 Lipid Maps MS Standard
|
|
64625-54-3 |
>98%
|
|
|
2008-12-17
|
65.798434622467
|
19-r-hydroxy-prostaglandin-e2-lipid-maps-ms-standard
|
19(R)-OH PGE2; 19(R)-hydroxy PGE2
|
19(R)-hydroxy-PGE2 19(R)-OH-PGE2 19R-hydroxy-PGE2 19R-OH-PGE2 metabolites semen agonists EP2 prostaglandins receptors hydroxylated PGs MS mass spectrometry standards |
65.798434622467
|
| 15910 |
19(R)-hydroxy Prostaglandin F1α
|
|
81371-59-7 |
>98%
|
|
|
|
0.760685082872
|
19-r-hydroxy-prostaglandin-f1
|
19(R)-hydroxy PGF1α
|
19(R)-hydroxy-PGF1.alpha. 19(R)-hydroxy-PGF1alpha 19(R)-OH-PGF1.alpha. 19(R)-OH-PGF1alpha metabolites hydroxylated |
0.760685082872
|
| 16910 |
19(R)-hydroxy Prostaglandin F2α
|
|
64625-53-2 |
>98%
|
|
|
|
0.591988950276
|
19-r-hydroxy-prostaglandin-f2
|
19(R)-hydroxy PGF2α
|
metabolites prostaglandins 19(R)-hydroxy-PGF2.alpha. 19(R)-hydroxy-PGF2alpha 19(R)-OH-PGF2alpha 19(R)-OH-PGF2.alpha. 19R-hydroxy-PGF2.alpha. 19R-hydroxy-PGF2alpha 19R-OH-PGF2alpha 19R-OH-PGF2.alpha. hydroxylated |
0.591988950276
|
| 13050 |
1a,1b-dihomo Prostaglandin E1
|
|
- |
>98%
|
|
|
|
19.342651933702
|
1a-1b-dihomo-prostaglandin-e1
|
1a,1b-dihomo PGE1
|
1a,1b-dihomo-PGE1 prostaglandins |
19.342651933702
|
| 16050 |
1a,1b-dihomo Prostaglandin F2α
|
|
57944-39-5 |
>98%
|
|
|
|
5.037292817679
|
1a-1b-dihomo-prostaglandin-f2
|
1a,1b-dihomo PGF2α
|
1a,1b-dihomo-PGF2alpha 1a,1b-dihomo-PGF2.alpha. prostaglandins |
5.037292817679
|
| 14940 |
20-ethyl Prostaglandin E2
|
|
37492-24-3 |
>97%
|
|
|
|
37.043020257827
|
20-ethyl-prostaglandin-e2
|
20-ethyl PGE2
|
prostaglandins unoprostone glaucoma FP receptors 20-ethyl-PGE2 methylene carbon EP binding ophthalmology |
37.043020257827
|
| 16940 |
20-ethyl Prostaglandin F2α
|
|
36950-85-3 |
>98%
|
|
|
|
4.186924493554
|
20-ethyl-prostaglandin-f2
|
ICI 74205; 20-ethyl PGF2α
|
analogs 20-ethyl-PGF2alpha 20-ethyl-PGF2.alpha. unoprostone intraocular hypotensive IOP FP receptors glaucoma ICI-74205 ICI74205 ophthalmology |
4.186924493554
|
| 14950 |
20-hydroxy Prostaglandin E2
|
|
57930-95-7 |
>98%
|
|
|
|
98.056823204419
|
20-hydroxy-prostaglandin-e2
|
20-hydroxy PGE2
|
20-hydroxy-PGE2 20-OH-PGE2 metabolites prostaglandins hydroxylated PGs intermediate |
98.056823204419
|
| 10007218 |
20-hydroxy Prostaglandin E2 Lipid Maps MS Standard
|
|
57930-95-7 |
≥98%
|
|
|
2008-12-15
|
98.429751381215
|
20-hydroxy-prostaglandin-e2-lipid-maps-ms-standard
|
20-hydroxy PGE2
|
20-hydroxy-PGE2 20-OH-PGE2 metabolites prostaglandins hydroxylated MS mass spectrometry standards PGs intermediates |
98.429751381215
|
| 16950 |
20-hydroxy Prostaglandin F2α
|
|
57930-92-4 |
≥98%
|
|
|
|
15.353480662983
|
20-hydroxy-prostaglandin-f2
|
20-hydroxy PGF2α
|
20-hydroxy-PGF2alpha 20-hydroxy-PGF2.alpha. prostaglandins hydroxylated 20-OH-PGF2.alpha. 20-OH-PGF2alpha |
15.353480662983
|
| 10007229 |
20-hydroxy Prostaglandin F2α Lipid Maps MS Standard
|
|
57930-92-4 |
≥98%
|
|
|
2009-01-28
|
14.770423572744
|
20-hydroxy-prostaglandin-f2-lipid-maps-ms-standard
|
20-hydroxy PGF2α
|
20-hydroxy-PGF2alpha 20-hydroxy-PGF2.alpha. prostaglandins hydroxylated 20-OH-PGF2.alpha. 20-OH-PGF2alpha MS mass spectrometry PGs |
14.770423572744
|
| 16530 |
2,3-dinor-11β-Prostaglandin F2α
|
|
240405-20-3 |
>98%
|
|
|
|
66.115060773480
|
2-3-dinor-11-prostaglandin-f2
|
2,3-dinor-11β-PGF2α
|
2,3-dinor-11.beta.-PGF2.alpha. 2,3-dinor-11beta-PGF2alpha 2,3-dinor-11b-PGF2alpha prostaglandins urine PGD2 asthmatic asthma urinary Pgs 2,3-dinor-11β-PGF2α |
66.115060773480
|
| 10007225 |
2,3-dinor-11β-Prostaglandin F2α Lipid Maps MS Standard
|
|
240405-20-3 |
>98%
|
|
|
2008-12-17
|
66.802795580111
|
2-3-dinor-11-prostaglandin-f2-lipid-maps-ms-standard
|
2,3-dinor-11β-PGF2α
|
2,3-dinor-11.beta.-PGF2.alpha. 2,3-dinor-11beta-PGF2alpha 2,3-dinor-11b-PGF2alpha prostaglandins urine PGD2 asthmatic asthma urinary PGs 2,3-dinor-11β-PGF2α MS mass spectrometry standards |
66.802795580111
|
| 9000462 |
2,3-dinor-6-keto Prostaglandin F1α-d9 (sodium salt)
|
|
- |
≥99% deuterated product
|
|
|
2010-05-07
|
20.833834254144
|
2-3-dinor-6-keto-prostaglandin-f1-d9-sodium-salt
|
2,3-dinor-6-keto PGF1α-d9 (sodium salt)
|
PGI2 metabolites 2,3-dinor-6-keto-PGF1alpha 2,3-dinor-6-keto-PGF1.alpha. prostaglandins PGs MS LC-MS LC/MS GC-MS GC/MS mass spectrometry deuterium deuterated |
20.833834254144
|
| 515121 |
2,3-dinor-6-keto Prostaglandin F1α EIA Kit
|
|
- |
|
|
|
2006-05-23
|
157.716198895028
|
2-3-dinor-6-keto-prostaglandin-f1-eia-kit
|
2,3-dinor-6-keto PGF1α ELISA Kit
|
solid plates enzymes immunoassays Prostaglandins PGI2 prostacyclin vascular myocardial infarction inhibits cyclooxygenases atherosclerosis stroke COX-2 measures kits PGF1a assays |
157.716198895028
|
| 15120 |
2,3-dinor-6-keto Prostaglandin F1α (sodium salt)
|
|
- |
≥95%
|
|
|
|
15.906215469613
|
2-3-dinor-6-keto-prostaglandin-f1-sodium-salt
|
2,3-dinor-6-keto PGF1α (sodium salt)
|
PGI2 metabolites 2,3-dinor-6-keto-PGF1alpha 2,3-dinor-6-keto-PGF1.alpha. prostaglandins |
15.906215469613
|
| 16290 |
2,3-dinor-8-iso Prostaglandin F2α
|
|
221664-05-7 |
>98%
|
|
|
|
35.882523020258
|
2-3-dinor-8-iso-prostaglandin-f2
|
2,3-dinor-iPF2α-III; 2,3-dinor-8-iso PGF2α
|
8-isoprostanes vasoconstriction 2,3-dinor-8-epi-PGF2.alpha. metabolites .beta.-oxidation beta-oxidation b-oxidation 2,3-dinor-8-epi-PGF2alpha 2,3-dinor-8-iso-PGF2.alpha. 2,3-dinor-8-iso-PGF2alpha prostaglandins |
35.882523020258
|
| 16780 |
2,3-dinor Fluprostenol
|
|
- |
≥98%
|
|
|
|
7.430552486188
|
2-3-dinor-fluprostenol
|
|
pgf2.alpha. pgf2alpha 2,3-dinor-fluprostenol prostaglandins FP receptors metabolites analogs |
7.430552486188
|
| 13120 |
2,3-dinor Prostaglandin E1
|
|
7046-40-4 |
>98%
|
|
|
|
31.806685082873
|
2-3-dinor-prostaglandin-e1
|
2,3-dinor PGE1
|
prostaglandins 2,3-dinor-PGE1 erectile dysfunction |
31.806685082873
|
| 10008445 |
3-methoxy Limaprost
|
|
- |
>98%
|
|
|
2006-05-25
|
34.762209944751
|
3-methoxy-limaprost
|
3-methoxy-2,3-dihydro-Limaprost; 3-methoxy-17α,20-dimethyl-Δ2-Prostaglandin E1
|
PGE1 prostaglandins platelets aggregation inhibits inhibitors inhibition analog ADP collagen-induced adhesiveness |
34.762209944751
|
| 15170 |
3-methoxy Prostaglandin F1α
|
|
54432-43-8 |
>95%
|
|
|
|
2.673977900552
|
3-methoxy-prostaglandin-f1
|
3-methoxy PGF1α
|
3-methoxy-PGF1.alpha. analogs 3-methoxy-PGF1alpha |
2.673977900552
|
| 10008588 |
5-cis-15(R)-Iloprost
|
|
- |
≥97%
|
|
|
2006-07-19
|
31.004917127071
|
5-cis-15-r-iloprost
|
5-cis-15(R)-Ciloprost
|
agonists IP receptors vasodilator hypostensive antiduretic hypertension analogs PGI2 prostaglandins carbaprostacyclin selective selectivity C-5 cis-isomers 15-keto-iloprost |
31.004917127071
|
| 18211 |
5-cis Carbaprostacyclin
|
|
69609-77-4 |
>99%
|
|
|
|
3.381539862341
|
5-cis-carbaprostacyclin
|
(5Z)-6a-Carbaprostaglandin I2
|
PGI2 analogs prostaglandins 5(z)-carbaprostacyclin 5z-carbaprostacyclin 5-cis-carbaprostacyclin |
3.381539862341
|
| 10008585 |
5-cis Iloprost
|
|
- |
≥97%
|
|
|
2006-07-17
|
32.266657458563
|
5-cis-iloprost
|
5-cis Ciloprost
|
agonists IP receptors vasodilator hypostensive antiduretic hypertension analogs PGI2 prostaglandins carbaprostacyclin selective selectivity C-5 cis-isomers 15-keto-iloprost |
32.266657458563
|
| 16300 |
5-iPF2α-VI
Exclusive |
|
180469-63-0 |
≥95%
|
|
✓ |
2006-02-06
|
25.938232044199
|
5-ipf2-vi
|
iPF2α-I
|
marker oxidative injury 8-isoprostanes prostaglandins PGs free-radical lipids peroxidations ipf2a arachidonic acids polyunsaturated fatty stereo- regioisomeric oxidative stress Type VI internal lactones facilitates extraction purification pgf2a |
25.938232044199
|
| 10006654 |
5-iPF2α-VI-d11
|
|
- |
≥99% deuterated product
|
|
|
2005-03-17
|
98.054071823204
|
5-ipf2-vi-d11
|
|
isoprostanes peroxidation oxidative injury deuterateds deuteriums isotopes 8,12-isoprostanes iPF2alpha-VI-d11 prostaglandins iPF2a-VI-d11 urine peroxidative damage enantiomers stress |
98.054071823204
|
| 10008132 |
5-trans-17-phenyl trinor Prostaglandin F2α ethyl amide
|
|
- |
≥98%
|
|
|
2009-09-23
|
113.310786480337
|
5-trans-17-phenyl-trinor-prostaglandin-f2-ethyl-amide
|
5-trans Bimatoprost; 5,6-trans-17-phenyl trinor PGF2α ethyl amide
|
isomers impurity intraocular pressure lumigan prostaglandins hypotensive agonists IOPs glaucoma PGF2a PGF2α PGs |
113.310786480337
|
| 10004970 |
(+)-5-trans Cloprostenol
|
|
57968-81-7 |
≥98%
|
|
|
2009-02-27
|
7.083572744015
|
-5-trans-cloprostenol
|
(+)-5-trans-16-m-chlorophenoxy tetranor PGF2α; (+)-5,6-trans Cloprostenol; D-Cloprostenol; (+)-5-trans-16-m-chlorophenoxy tetranor Prostaglandin F2α
|
PGF2.alpha. luteolysis isomer prostaglandins agonists FP receptors PGF2a |
7.083572744015
|
| 16776 |
5-trans Fluprostenol
|
|
57968-83-9 |
≥95%
|
|
|
2004-02-06
|
12.031505524862
|
5-trans-fluprostenol
|
5,6-trans Fluprostenol
|
travoprost intraocular hypotensive cornea glaucoma impurity pressure ophthalmology |
12.031505524862
|
| 16777 |
5-trans Fluprostenol isopropyl ester
|
|
- |
≥95%
|
|
|
|
75.977348066298
|
5-trans-fluprostenol-isopropyl-ester
|
5-trans Travoprost; 5,6-trans Fluprostenol isopropyl ester
|
prostaglandins ocular hypotensive cornea prodrugs 5-trans-fluprostenol esters intraocular ophthalmology glaucoma |
75.977348066298
|
| 16813 |
5-trans Latanoprost
|
|
913258-34-1 |
>98%
|
|
|
|
96.242504604051
|
5-trans-latanoprost
|
5,6-trans Latanoprost
|
eyes ophthalmology ophthalmological intraocular glaucoma isopropyl esters FP receptors agonists 5-trans-17-phenyl-13,14-dihydro-trinor-PGF2.alpha. 5-trans-17-phenyl-13,14-dihydro-trinor-PGF2alpha |
96.242504604051
|
| 10129 |
5-trans Latanoprost (free acid)
|
|
903549-49-5 |
>98%
|
|
|
2009-04-06
|
36.991031307551
|
5-trans-latanoprost-free-acid
|
5,6-trans Latanoprost (free acid)
|
isomers impurity intraocular pressure |
36.991031307551
|
| 12210 |
5-trans Prostaglandin D2
|
|
- |
>98%
|
|
|
|
58.140375690608
|
5-trans-prostaglandin-d2
|
5,6-trans PGD2
|
5-trans-PGD2 vasodilation prostaglandins analytical standards |
58.140375690608
|
| 14210 |
5-trans Prostaglandin E2
|
|
36150-00-2 |
>98%
|
|
|
|
90.734788213628
|
5-trans-prostaglandin-e2
|
trans-Dinoprostone; 5,6-trans PGE2
|
5-trans-PGE2 impurity prostaglandins |
90.734788213628
|
| 16210 |
5-trans Prostaglandin F2α
|
|
36150-01-3 |
>99%
|
|
|
|
21.718342541436
|
5-trans-prostaglandin-f2
|
5,6-trans PGF2α
|
5-trans-PGF2alpha 5-trans-PGF2.alpha. prostaglandins |
21.718342541436
|
| 16220 |
5-trans Prostaglandin F2α (tromethamine salt)
|
|
- |
>99%
|
|
|
|
43.436685082873
|
5-trans-prostaglandin-f2-tromethamine-salt
|
5,6-trans PGF2α (tromethamine salt)
|
5-trans-PGF2alpha 5-trans-PGF2.alpha. prostaglandins THAM salts |
43.436685082873
|
| 16250 |
5-trans Prostaglandin F2β
|
|
36150-02-4 |
>98%
|
|
|
|
1.051381215469
|
5-trans-prostaglandin-f2
|
5-trans-9β-PGF2α; 5,6-trans PGF2β
|
prostaglandins 5-trans-PGF2.beta. 5-trans-PGF2beta 5-trans-9beta-PGF2alpha 5-trans-9.beta.-PGF2.alpha. 5-trans-9b-PGF2alpha |
1.051381215469
|
| 16442 |
5-trans U-44069
|
|
- |
>98%
|
|
|
|
351.977734806630
|
5-trans-u-44069
|
5,6-trans U-44069
|
5-trans-U-44069 isomers endoperoxides PGH2 5-trans-U44069 thromboxanes prostaglandins |
351.977734806630
|
| 16452 |
5-trans U-46619
|
|
- |
>98%
|
|
|
|
101.984299347062
|
5-trans-u-46619
|
5,6-trans U-46619
|
5-trans-U-46619 isomers endoperoxides PGH2 5-trans-U46619 |
101.984299347062
|
| 15270 |
6,15-diketo-13,14-dihydro Prostaglandin F1α
|
|
63983-53-9 |
≥98% (mixture of tautomers)
|
|
|
|
25.136201657458
|
6-15-diketo-13-14-dihydro-prostaglandin-f1
|
6,15-diketo-13,14-dihydro PGF1α
|
6,15-diketo-13,14-dihydro-PGF1α 6,15-diketo-13,14-dihydro-PGF1alpha prostaglandins metabolites |
25.136201657458
|
| 10007220 |
6,15-diketo-13,14-dihydro Prostaglandin F1α Lipid Maps MS Standard
|
|
63983-53-9 |
>98%
|
|
|
2008-12-13
|
33.361620626150
|
6-15-diketo-13-14-dihydro-prostaglandin-f1-lipid-maps-ms-standard
|
6,15-diketo-13,14-dihydro PGF1α
|
MS Mass Spectrometry 6,15-diketo-13,14-dihydro-PGF1α 6,15-diketo-13,14-dihydro-PGF1alpha prostaglandins metabolites |
33.361620626150
|
| 13260 |
6-keto Prostaglandin E1
|
|
67786-53-2 |
>99%
|
|
|
|
75.689309392265
|
6-keto-prostaglandin-e1
|
6-keto PGE1
|
6-keto-PGE1 metabolites prostaglandins |
75.689309392265
|
| 10007210 |
6-keto Prostaglandin E1 Lipid Maps MS Standard
|
|
67786-53-2 |
>99%
|
|
|
2008-11-03
|
50.241491712707
|
6-keto-prostaglandin-e1-lipid-maps-ms-standard
|
6-keto PGE1
|
6-keto-PGE1 metabolites prostaglandins GC LC MS mass spectrometry standards GC/MS LC/MS GC-MS LC-MS |
50.241491712707
|
| 15210 |
6-keto Prostaglandin F1α
|
|
58962-34-8 |
>99%
|
|
|
|
56.309966850828
|
6-keto-prostaglandin-f1
|
6-keto PGF1α
|
PGI2 metabolites prostaglandins 6-keto-PGF1alpha 6-keto-PGF1.alpha. atherosclerosis |
56.309966850828
|
| 315210 |
6-keto Prostaglandin F1α-d4
|
|
- |
≥99% deuterated product
|
|
|
|
16.896099447513
|
6-keto-prostaglandin-f1-d4
|
6-keto PGF1α-d4
|
GC/MS deuterium isotopes 6-keto-PGF1a-d4 6-keto-PGF1alpha-d4 6-keto-PGF1.alpha.-d4 internal standards prostaglandins PGFα deuterated LC/MS GC-MS LC-MS mass spectrometry d4 atherosclerosis |
16.896099447513
|
| 10007274 |
6-keto Prostaglandin F1α-d4 Lipid Maps MS Standard
|
|
- |
≥99% deuterated product
|
|
|
2009-02-26
|
85.894254143646
|
6-keto-prostaglandin-f1-d4-lipid-maps-ms-standard
|
6-keto PGF1α-d4
|
GC/MS deuterium isotopes 6-keto-PGF1a-d4 6-keto-PGF1alpha-d4 6-keto-PGF1.alpha.-d4 internal standards prostaglandins PGFα deuterated LC/MS GC-MS LC-MS mass spectrometry d4 atherosclerosis |
85.894254143646
|
| 515211 |
6-keto Prostaglandin F1α EIA Kit
|
|
- |
|
|
|
|
520.380412318396
|
6-keto-prostaglandin-f1-eia-kit
|
6-keto Prostaglandin F1α ELISA Kit
|
solid plates 6-keto-PGF1alpha 6-keto-PGF1.alpha. prostaglandins measures kits eias atherosclerosis enzyme immunoassays ELISAs 6-keto Prostaglandin F1.alpha. EIA Kit assays |
520.380412318396
|
| 10007219 |
6-keto Prostaglandin F1α Lipid Maps MS Standard
|
|
58962-34-8 |
>99%
|
|
|
2008-12-17
|
37.604464088398
|
6-keto-prostaglandin-f1-lipid-maps-ms-standard
|
6-keto PGF1α
|
PGI2 metabolites prostaglandins 6-keto-PGF1alpha 6-keto-PGF1.alpha. atherosclerosis PGs MS mass spectrometry standards |
37.604464088398
|
| 10006830 |
6-keto Prostaglandin F1α Quant-PAK
|
|
- |
|
|
|
2005-08-08
|
4.201606813996
|
6-keto-prostaglandin-f1-quant-pak
|
|
Quant-PAKs PGI2 metabolites prostaglandins GC/MS deuterium isotopes 6-keto-PGF1a-d4 6-keto-PGF1alpha-d4 6-keto-PGF1.alpha.-d4 internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry d4 packs |
4.201606813996
|
| 18110 |
6α-Prostaglandin I1
|
|
62777-90-6 |
>99%
|
|
|
|
48.628784530386
|
6-prostaglandin-i1
|
5,6α-dihydro PGI2; 6α-PGI1
|
6a-PGI1 analogs prostaglandins 6.alpha.-PGI1 6alpha-PGI1 5,6.alpha.-dihydro-PGI2 5,6alpha-dihydro-PGI2 5,6a-dihydro-PGI2 prostacyclin |
48.628784530386
|
| 18120 |
6β-Prostaglandin I1
|
|
62770-50-7 |
>99%
|
|
|
|
48.628784530386
|
6-prostaglandin-i1
|
5,6β-dihydro PGI2; 6β-PGI1
|
prostacyclin analogs 6.beta.-PGI1 prostaglandins 6beta-PGI1 |
48.628784530386
|
| 10006878 |
8,12-iso-iPF2α-VI-d11
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2005-09-01
|
7.075386740332
|
8-12-iso-ipf2-vi-d11
|
8,12-epi-iPF2α-VI-d11
|
GC/MS deuterium isotopes internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry analogs internal standards isoprostanes prostaglandins free-radical lipid peroxidation stero- regioisomers arachidonic acids 8-isoprostane 8-epi-PGF2.alpha. iPF2.alpha.-III oxidative stress Type VI class internal lactones facilitates extraction and purification neurochemistry neuroscience |
7.075386740332
|
| 16380 |
8-iso-13,14-dihydro-15-keto Prostaglandin F2α
|
|
191919-02-5 |
>98%
|
|
|
|
22.383303867404
|
8-iso-13-14-dihydro-15-keto-prostaglandin-f2
|
8-iso-13,14-dihydro-15-keto PGF2α
|
8-isoprostanes lipid peroxidation metabolites prostaglandins 8-epi-13,14-dihydro-15-keto-PGF2.alpha. 8-epi-13,14-dihydro-15-keto-PGF2alpha 8-iso-13,14-dihydro-15-keto-PGF2.alpha. 8-iso-13,14-dihydro-15-keto-PGF2alpha |
22.383303867404
|
| 14390 |
8-iso-15-keto Prostaglandin E2
|
|
- |
>98%
|
|
|
|
31.394340962904
|
8-iso-15-keto-prostaglandin-e2
|
8-iso-15-keto PGE2
|
8-iso-15-keto-pge2 prostaglandins isoprostanes free radical peroxidative peroxidation 15-hydroxy-pgdh dehydrogenase |
31.394340962904
|
| 16390 |
8-iso-15-keto Prostaglandin F2α
|
|
- |
>95%
|
|
|
|
0.573314917127
|
8-iso-15-keto-prostaglandin-f2
|
8-iso-15-keto PGF2α; 8-epi-15-keto PGF2α
|
8-isoprostanes metabolites prostaglandins 8-epi-15-keto-PGF2.alpha. 8-epi-15-keto-PGF2alpha 8-iso-15-keto-PGF2.alpha. 8-iso-15-keto-PGF2alpha |
0.573314917127
|
| 10008539 |
8-iso-15-keto Prostaglandin F2β
|
|
- |
>95%
|
|
|
2006-06-21
|
0.429815837937
|
8-iso-15-keto-prostaglandin-f2
|
|
prostaglandins PGF2a PGF2.alpha. 15-hydroxy PGDH isomers free radicals peroxidation arachidonic acids contractions umbilical veins artery human canine porcine pulmonary isoprostanes metabolites |
0.429815837937
|
| 16395 |
8-iso-15(R)-Prostaglandin F2α
|
|
214748-65-9 |
>98%
|
|
|
|
24.067040252564
|
8-iso-15-r-prostaglandin-f2
|
8-iso-15-epi PGF2α
|
8-isoprostanes prostaglandins 8-epi-15R-PGF2.alpha. 8-epi-15R-PGF2alpha 8-iso-15R-PGF2.alpha. 8-iso-15R-PGF2alpha 8-epi-15(R)-PGF2.alpha. 8-epi-15(R)-PGF2alpha 8-iso-15(R)-PGF2.alpha. 8-iso-15(R)-PGF2alpha |
24.067040252564
|
| 10008435 |
8-iso-17-phenyl trinor Prostaglandin F2α
|
|
- |
>98%
|
|
|
2006-07-31
|
27.013121546961
|
8-iso-17-phenyl-trinor-prostaglandin-f2
|
|
prostaglandins C-8 epimer bimatprost free acids analogs FP receptors ovine luteal cells CHO inhibits glaucoma intraoccular pressure IOP 8-iso-17-phenyl trinor PGF2.alpha. PGF2a ophthalmology |
27.013121546961
|
| 10008436 |
8-iso-17-phenyl trinor Prostaglandin F2β
|
|
- |
>98%
|
|
|
2006-06-14
|
10.634940805051
|
8-iso-17-phenyl-trinor-prostaglandin-f2
|
|
Bimatoprost analogs prostaglandins PGF2alpha PGF2.alpha. PGF2beta PGF2.beta. agonists 17-phenyl-trinor FP receptors inhibits inibitors inhibition isomers ophthalmology glaucoma IOP intraocular pressure ophthalmology |
10.634940805051
|
| 10047 |
8-iso Misoprostol
Exclusive |
|
- |
>98%
|
|
✓ |
|
7.603093922652
|
8-iso-misoprostol
|
|
cytoprotection PGE1 analogs agonists EP2 EP3 EP4 receptors SC29333 SC-29333 cytotec impurity impurities |
7.603093922652
|
| 10035 |
8-iso Prostaglandin A1
|
|
211186-29-7 |
>97%
|
|
|
|
51.277005524861
|
8-iso-prostaglandin-a1
|
8-iso PGA1; 8-epi PGA1
|
8-iso-pga1 8-epi-pga1 8-isoprostanes prostaglandins prostanoids |
51.277005524861
|
| 10235 |
8-iso Prostaglandin A2
|
|
- |
>98%
|
|
|
2006-08-22
|
6.454287292817
|
8-iso-prostaglandin-a2
|
|
prostaglandins vasodilation 8-iso-pga2 8-epi-pga2 8-isoprostanes prostanoids oxidative stress peroxidation dehydration rat liver |
6.454287292817
|
| 10010500 |
8-iso Prostaglandin A2-biotin
Exclusive |
|
- |
≥95%
|
|
✓ |
2011-03-22
|
1.009171270718
|
8-iso-prostaglandin-a2-biotin
|
8-iso PGA2-biotin
|
Isoprostanes free radicals oxidative stress peroxidation arachidonic acids affinity probes |
1.009171270718
|
| 13360 |
8-iso Prostaglandin E1
|
|
21003-46-3 |
>98%
|
|
|
|
66.538747697974
|
8-iso-prostaglandin-e1
|
Ovinonic acid; 8-iso PGE1; 8-epi PGE1
|
8-iso-PGE1 8-epi-PGE1 8-isoprostanes vasoconstriction prostaglandins |
66.538747697974
|
| 14350 |
8-iso Prostaglandin E2
Exclusive |
|
27415-25-4 |
>99%
|
|
✓ |
|
9.383314917127
|
8-iso-prostaglandin-e2
|
8-iso PGE2; 8-epi PGE2
|
8-isoprostanes 8-epi-PGE2 8-iso-PGE2 renal vasoconstriction prostaglandins |
9.383314917127
|
| 10011321 |
8-iso Prostaglandin E2-d4
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2008-08-14
|
4.518232044199
|
8-iso-prostaglandin-e2-d4
|
8-iso PGE2-d4; 8-epi PGE2-d4
|
8-isoprostanes 8-epi-PGE2 8-iso-PGE2 renal vasoconstriction prostaglandins deuteriums deuterateds |
4.518232044199
|
| 14352 |
8-iso Prostaglandin E2 isopropyl ester
|
|
330589-21-4 |
>98%
|
|
|
|
53.002223756905
|
8-iso-prostaglandin-e2-isopropyl-ester
|
8-iso PGE2 isopropyl ester
|
8-isoprostanes 8-epi-PGE2 8-iso-PGE2 esters prostaglandins vasoconstriction renal |
53.002223756905
|
| 15350 |
8-iso Prostaglandin F1α
|
|
26771-96-0 |
>99%
|
|
|
|
1.764696132596
|
8-iso-prostaglandin-f1
|
8-epi PGF1α
|
8-isoprostanes 8-epi-PGF1.alpha. 8-epi-PGF1alpha 8-iso-PGF1.alpha. 8-iso-PGF1alpha prostaglandins |
1.764696132596
|
| 10008935 |
8-iso Prostaglandin F1α-d9
|
|
- |
≥99% deuterated product
|
|
|
2006-09-15
|
4.381767955801
|
8-iso-prostaglandin-f1-d9
|
8-epi PGF1α-d9
|
GC/MS deuteriums isotopes internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry spectoscopy signalling 8-isoprostanes 8-epi-PGF1.alpha. 8-epi-PGF1alpha 8-iso-PGF1.alpha. 8-iso-PGF1alpha prostaglandins |
4.381767955801
|
| 15370 |
8-iso Prostaglandin F1β
|
|
- |
>99%
|
|
|
|
2.305430149960
|
8-iso-prostaglandin-f1
|
8-iso PGF1β; 8-epi-9β-PGF1α
|
8-isoprostanes 8-epi-PGF1beta 8-epi-PGF1.beta. 8-iso-PGF1beta 8-iso-PGF1.beta. prostaglandins 8-iso-9.beta.-PGF1.alpha. 8-iso-9beta-PGF1alpha 8-iso-9b-PGF1alpha |
2.305430149960
|
| 16350 |
8-iso Prostaglandin F2α
|
|
27415-26-5 |
>99%
|
|
|
|
122.395666052793
|
8-iso-prostaglandin-f2
|
iPF2α-III; 8-epi PGF2α; 8-Isoprostane; 15-F2t-isoprostane
|
8-isoprostanes vasoconstriction 8-epi-PGF2.alpha. 8-epi-PGF2alpha 8-iso-PGF2.alpha. 8-iso-PGF2alpha prostaglandins |
122.395666052793
|
| 316350 |
8-iso Prostaglandin F2α-d4
|
|
211105-40-7 |
≥99% deuterated product
|
|
|
|
50.421588397790
|
8-iso-prostaglandin-f2-d4
|
15-F2t-Isoprostane-d4; iPF2α-III-d4; 8-epi PGF2α-d4; 8-Isoprostane-d4
|
GC/MS deuterium isotopes 8-isoprostanes 8-epi-PGF2.alpha.-d4 8-epi-PGF2alpha-d4 8-iso-PGF2.alpha.-d4 8-iso-PGF2alpha-d4 internal standards prostaglandins mass spectrometry LC/MS GC-MS LC-MS deuterated 8-iso-PGF2a-d4 8-epi-PGF2a-d4 ipf2a neurochemistry 316351 |
50.421588397790
|
| 10005764 |
8-iso Prostaglandin F2α Ethanolamide
|
|
- |
>98%
|
|
|
2004-09-24
|
17.166390423573
|
8-iso-prostaglandin-f2-ethanolamide
|
8-Isoprostane Ethanolamide; 8-epi PGF2α Ethanolamide; 8-iso PGF2α Ethanolamide; iPF2α-III Ethanolamide
|
ethanolamides prostaglandins anandamides AEA COX-2 cox2 cyclooxygenases synthases isoprostanes 8-epi-PGF2alpha 8-iso-PGF2alpha arachidonoyl prostamides congeners decomposition standards non-enzymatic iPF2a-III PGHS2 PGHS-2 ethanolamines 714966-38-8 cannabinoids cbs sythetic |
17.166390423573
|
| 10007652 |
8-iso Prostaglandin F2α Quant-PAK
|
|
- |
|
|
|
2005-10-26
|
10.086749539594
|
8-iso-prostaglandin-f2-quant-pak
|
|
Quant-PAKs Lutalyse vasoconstriction bronchoconstriction endocrinology GC/MS deuterium isotopes 8-iso-PGF2a-d4 8-iso-PGF2alpha-d4 8-iso-PGF2.alpha.-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
10.086749539594
|
| 16370 |
8-iso Prostaglandin F2β
|
|
177020-26-7 |
>98%
|
|
|
|
14.445895816890
|
8-iso-prostaglandin-f2
|
8-iso-9β-PGF2α; 8-iso PGF2β; 8-epi PGF2β
|
8-isoprostanes 8-epi-PGF2beta 8-epi-PGF2.beta. 8-iso-PGF2beta 8-iso-PGF2.beta. prostaglandins 8-iso-9b-PGF2alpha 8-iso-9beta-PGF2alpha 8-iso-9.beta.-PGF2.alpha. 8-epi-9b-PGF2alpha 8-epi-9beta-PGF2alpha 8-epi-9.beta.PGF2.alpha. |
14.445895816890
|
| 16992 |
8-iso Prostaglandin F3α
Exclusive |
|
7045-31-0 |
>98%
|
|
✓ |
|
7.012154696133
|
8-iso-prostaglandin-f3
|
8-iso PGF3α; 8-epi PGF3α
|
8-isoprostanes 8-epi-PGF3.alpha. 8-epi-PGF3alpha 8-iso-PGF3.alpha. 8-iso-PGF3alpha omega-3 prostaglandins .omega.-3 w-3 |
7.012154696133
|
| 516351 |
8-Isoprostane EIA Kit
|
|
- |
|
|
|
|
898.138721844454
|
8-isoprostane-eia-kit
|
iPF2α-III EIA Kit; 8-epi Prostaglandin F2α EIA Kit; 8-iso Prostaglandin F2α EIA Kit; 8-Isoprostane ELISA Kit
|
solid plates oxidative injury stress reactive oxygen species 8-isoprostanes 8-epi-PGF2.alpha. 8-epi-PGF2alpha 8-iso-PGF2.alpha. 8-iso-PGF2alpha prostaglandins free radicals ROS peroxidation lipids measures kits eias enzyme immunoassays ELISAs assays |
898.138721844454
|
| 516360 |
8-Isoprostane Express EIA Kit
|
|
- |
|
|
|
2009-10-26
|
177.831516825716
|
8-isoprostane-express-eia-kit
|
8-epi Prostaglandin F2α Express EIA Kit; iPF2α-III Express EIA Kit; 8-Isoprostane Express ELISA Kit; 8-iso Prostaglandin F2α Express EIA Kit
|
solid plates oxidative injury stress reactive oxygen species 8-isoprostanes 8-epi-PGF2.alpha. 8-epi-PGF2alpha 8-iso-PGF2.alpha. 8-iso-PGF2alpha prostaglandins free radicals ROS peroxidation lipids measures kits eias enzyme immunoassays ELISAs |
177.831516825716
|
| 10007850 |
9,11-methane-epoxy Prostaglandin F1α
|
|
72517-81-8 |
>96%
|
|
|
2006-05-10
|
182.245248618784
|
9-11-methane-epoxy-prostaglandin-f1
|
9,11-Epoxymethano PGH1
|
prostaglandins PGs endoperoxides TXs thromboxanes prostacyclins PGH1 platelets smooth muscles analogs aggregation aorta aortic tracheas histamines coronary perfusion atherosclerosis |
182.245248618784
|
| 14420 |
9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2
Exclusive |
|
61263-35-2 |
>98%
|
|
✓ |
|
65.961988950276
|
9-deoxy-9-methylene-16-16-dimethyl-prostaglandin-e2
|
Meteneprost; 9-deoxy-9-methylene-16,16-dimethyl PGE2
|
9-deoxy-9-methylene-16,16-dimethyl-PGE2 prostaglandins |
65.961988950276
|
| 14430 |
9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2 (potassium salt)
|
|
122576-55-0 |
>98%
|
|
|
|
97.422845303867
|
9-deoxy-9-methylene-16-16-dimethyl-prostaglandin-e2-potassium-salt
|
U-46785b; Metenprost potassium; 9-deoxy-9-methylene-16,16-dimethyl PGE2 (potassium salt)
|
prostaglandins 9-deoxy-9-methylene-16,16-dimethy-PGE2 K+ salts |
97.422845303867
|
| 14410 |
9-deoxy-9-methylene Prostaglandin E2
|
|
61263-32-9 |
>98%
|
|
|
|
67.823499079189
|
9-deoxy-9-methylene-prostaglandin-e2
|
9-deoxy-9-methylene PGE2
|
meteneprosts prostaglandins 9-deoxy-9-methylene-PGE2 |
67.823499079189
|
| 16781 |
9-keto Fluprostenol
|
|
156406-33-6 |
≥95%
|
|
|
|
33.080036832412
|
9-keto-fluprostenol
|
Fluprostenol Prostaglandin E2
|
9-keto-fluprostenol analogs receptors EP1 EP2 EP3 EP4 prostaglandins PGE2 |
33.080036832412
|
| 16782 |
9-keto Fluprostenol isopropyl ester
|
|
1219032-18-4 |
≥98%
|
|
|
|
72.585160220994
|
9-keto-fluprostenol-isopropyl-ester
|
Fluprostenol Prostaglandin E2
|
PGE2 analogs ophthalmological eyes ophthalmology 9-keto-fluprostenol IOP intraocular pressure agonists prostaglandins EP receptors |
72.585160220994
|
| 13619 |
ACS 67
Exclusive |
|
1088434-86-9 |
≥95%
|
|
✓ |
2010-01-19
|
47.753605893186
|
acs-67
|
|
IOPs glaucoma intra ocular pressures latanoprost (free acid) hydrogen sulfide free acids H2Ss hypotensive carboxyl group reduced glutathione cGMP cyclic GMP |
47.753605893186
|
| 14050 |
AH 6809
|
|
33458-93-4 |
>98%
|
|
|
|
72.077886740331
|
ah-6809
|
|
EP1 EP2 receptors antagonists AH6809 DP PGE2 prostaglandins ah-6809 |
72.077886740331
|
| 13620 |
AL 6598
Exclusive |
|
170291-06-2 |
97%
|
|
✓ |
2010-09-16
|
48.491027624309
|
al-6598
|
|
intraocular pressures IOPs glaucoma PGD2 agonists DP receptors eyes hypertension F2 alpha Prostaglandin
Prostaglandin F2 alpha
F2alpha Prostaglandin
Prostaglandin F2alpha
9alpha,11beta-PGF2
9alpha,11beta PGF2
Prostaglandin F2
Enzaprost F alpha, PGF2 PGF2 alpha PGF2alpha Dinoprost Estrofan PGF2 |
48.491027624309
|
| 16735 |
AL 8810
|
|
246246-19-5 |
>98%
|
|
|
|
36.964309392265
|
al-8810
|
|
FP antagonists prostaglandins PGFs receptors AL8810 AL-8810 PGF2alpha PGF2.alpha. analogs |
36.964309392265
|
| 10010470 |
AL 8810 ethyl amide
|
|
- |
>98%
|
|
|
2008-01-18
|
9.571381215469
|
al-8810-ethyl-amide
|
|
FP receptors PGF2.alpha. prostamides ethanolamides IOP glaucoma contraction iris |
9.571381215469
|
| 10113 |
AL 8810 isopropyl ester
|
|
208114-93-6 |
>98%
|
|
|
|
24.470693677102
|
al-8810-isopropyl-ester
|
|
FP antagonists prostaglandins PGFs receptors AL8810 AL-8810 PGF2alpha PGF2.alpha. analogs esters |
24.470693677102
|
| 10008370 |
AL 8810 methyl ester
|
|
- |
>98%
|
|
|
2006-10-05
|
7.332928176795
|
al-8810-methyl-ester
|
|
FP antagonists prostaglandins PGFs receptors AL8810 AL-8810 PGF2alpha PGF2.alpha. analogs esters intraocular |
7.332928176795
|
| 10156 |
BAY-u3405
|
|
116649-85-5 |
>98%
|
|
|
2004-11-17
|
14.526466942299
|
bay-u3405
|
Ramatroban
|
human medications allergic rhinitis antagonists thromboxanes TP receptors DP2/CRTH2 prostaglandins PGD2 7-transmembrane GPCRs G-protein-coupled BAYu3405 |
14.526466942299
|
| 18230 |
Beraprost (sodium salt)
|
|
88475-69-8 |
>98%
|
|
|
|
90.588057793279
|
beraprost-sodium-salt
|
TRK 100; Procyclin; ML 1129
|
prostaglandins inhibitors inhibits PGI2 prostacyclin platelets aggregation pulmonary atherosclerosis hypertension analogs salts ML-1129 ML1129 TRK-100 TRK100 Na+ |
90.588057793279
|
| 13530 |
Bicyclo Prostaglandin E1
|
|
- |
>98%
|
|
|
|
26.406381215469
|
bicyclo-prostaglandin-e1
|
Bicyclo PGE1
|
bicyclo-PGE1 metabolites prostaglandins bicyclo |
26.406381215469
|
| 14530 |
Bicyclo Prostaglandin E2
|
|
74158-09-1 |
>98%
|
|
|
|
7.979171270718
|
bicyclo-prostaglandin-e2
|
Bicyclo PGE2
|
metabolites prostaglandins bicyclo-PGE2 |
7.979171270718
|
| 10007213 |
Bicyclo Prostaglandin E2 Lipid Maps MS Standard
|
|
7415-09-1 |
>98%
|
|
|
2008-11-05
|
4.765386740331
|
bicyclo-prostaglandin-e2-lipid-maps-ms-standard
|
Bicyclo PGE2
|
bicyclo-PGE2 metabolites prostaglandins bicyclo GC LC MS mass spectrometry standards GC/MS LC/MS GC-MS LC-MS |
4.765386740331
|
| 13740 |
Butaprost
Exclusive |
|
69685-22-9 |
>98%
|
|
✓ |
|
88.937265193369
|
butaprost
|
TR 4979; 15-deoxy-16S-hydroxy-17-cyclobutyl PGE1 methyl ester
|
PGE2 prostaglandins R-butaprost PGE1 methyl esters EP2 receptors (R)-butaprost (R)butaprost |
88.937265193369
|
| 13741 |
Butaprost (free acid)
Exclusive |
|
433219-55-7 |
>98%
|
|
✓ |
|
33.499378453039
|
butaprost-free-acid
|
15-deoxy-16S-hydroxy-17-cyclobutyl PGE1; (±)-15-deoxy-16S-hydroxy-17-cyclobutyl PGE1
|
ep2 agonists selectively selectivity receptors |
33.499378453039
|
| 12050 |
BW 245C
|
|
72814-32-5 |
>98%
|
|
|
|
82.064516574585
|
bw-245c
|
|
PGD2 hydantoins agonists BW245C prostaglandins BW-245C |
82.064516574585
|
| 12055 |
BW 246C
|
|
65705-83-1 |
>98%
|
|
|
|
21.284088397790
|
bw-246c
|
8-epi BW 245C
|
PGD2 prostaglandins agonists BW246C BW-246C 8-epi-BW-245C 8-epi-BW245C 8-iso-BW-245C 8-iso-BW245C |
21.284088397790
|
| 12060 |
BW A868C
|
|
118675-50-6 |
>98%
|
|
|
|
66.002306629834
|
bw-a868c
|
|
hydantoin DP receptors antagonists BW245C adenylate cyclase antiaggregatory BWA868C BW-A868C BW-245C prostaglandins PGD2 DP1 |
66.002306629834
|
| 18210 |
Carbaprostacyclin
|
|
69552-46-1 |
>99%
|
|
|
|
113.252704139898
|
carbaprostacyclin
|
Carbacyclin; cPGI
|
analogs vasodilation PPARs peroxisome proliferator-activated receptors PGI2 prostaglandins atherosclerosis cPGI Carbacyclin |
113.252704139898
|
| 18213 |
Carbaprostacyclin-biotin
|
|
- |
>95%
|
|
|
|
28.522610497237
|
carbaprostacyclin-biotin
|
Carbacyclin-biotin; cPGI-biotin
|
receptors binding affinity ligands prostaglandins analogs low biotinylated biotinamides biotins |
28.522610497237
|
| 9000183 |
Carbaprostacyclin methyl ester
Exclusive |
|
69552-55-2 |
≥98%
|
|
✓ |
2010-11-29
|
27.163038674033
|
carbaprostacyclin-methyl-ester
|
|
prostacyclins prostaglandins I2 PGI2 IPs PPARδ stable analog activate activation |
27.163038674033
|
| 13747 |
CAY10408
|
|
212310-16-2 |
>98%
|
|
|
|
17.021560773480
|
cay10408
|
|
PGE2 prostaglandins R-butaprost C-16 epimer EP2 receptors (R)-butaprost (R)butaprost PGE2 |
17.021560773480
|
| 18590 |
CAY10410
|
|
596104-94-8 |
>98% (isomer mixture)
|
|
|
|
103.931657458564
|
cay10410
|
9,10-dihydro-15-deoxy-Δ12,14-Prostaglandin J2; 9,10-dihydro-15-deoxy-Δ12,14-PGJ2
|
PPAR.gamma. PPARgamma prostaglandins 9,10-dihydro-15-deoxy-delta12,14-PGJ2 9,10-dihydro-15-deoxy-d12,14-PGJ2 9,10-dihydro-15-deoxy-.DELTA.12,14-PGJ2 peroxisome proliferator-activated receptors PPARs activators ligands oxidative stress |
103.931657458564
|
| 10005186 |
CAY10441
Exclusive |
|
221529-58-4 |
>98%
|
|
✓ |
2004-09-16
|
119.233397790055
|
cay10441
|
RO1138452
|
receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma cyclic AMP cAMP adenylate cyclase 4,5-dihydro-1H-imidazol-2-yl-4-4-isopropoxy benzyl phenylamine atherosclerosis |
119.233397790055
|
| 10005913 |
CAY10449
Exclusive |
|
- |
>98%
|
|
✓ |
2004-10-26
|
93.114659300184
|
cay10449
|
|
receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma adenylate cyclase cyclic AMP cAMP iloprost athersclerosis CAY 10449 |
93.114659300184
|
| 10006735 |
CAY10471
|
|
627865-18-3 |
≥98%
|
|
|
2005-06-22
|
16.284696132596
|
cay10471
|
|
ramatroban DP2 CRTH2 antagonists TP receptors prostaglandins PGD2 7-transmembranes GPCRs G protein-coupled BAY-u3405 human medications allergic rhinitis analogs |
16.284696132596
|
| 10012553 |
CAY10595
Exclusive |
|
916047-16-0 |
≥97%
|
|
✓ |
2009-07-08
|
9.510211786372
|
cay10595
|
|
DP2 PGD2 CRTH2 chemotaxis inflammation antagonists prostaglandins PGDs |
9.510211786372
|
| 10743 |
CAY10650
Exclusive |
|
1233706-88-1 |
≥98%
|
|
✓ |
2011-06-14
|
23.657458563536
|
cay10650
|
|
cPLA2α cPLA2 inhibitors inflammation anti-inflammatory dermatitis metabolite phospholipase cytosolic prostaglandins PGs leukotrienes synthesis 10662 CAY-10650 CAY10641 CAY-10641 |
23.657458563536
|
| 10012447 |
CG 4305
|
|
- |
≥95%
|
|
|
2010-05-12
|
50.951981057616
|
cg-4305
|
|
antithrombotic PGI2 epoprostenol prostacyclins platelets aggregation 89955-40-8 PGs prostaglandins I2 cartoid artery thrombosis inhibits inhibited inhibition inhibitory Epoprostenol Sodium(5Z,9alpha,11alpha,13E,15S)Isomer
Epoprostenol Sodium
Prostaglandin I(2)
Prostaglandin I2
Prostacyclin Epoprostenol Epoprostanol Flolan PGI2 PGX
|
50.951981057616
|
| 16831 |
Cicaprost
Exclusive |
|
94079-80-8 |
≥98%
|
|
✓ |
2010-09-16
|
53.389462581616
|
cicaprost
|
ZK 96480
|
Prostaglandin I2 PGI2 prostacyclins vasodilators cardiovascular diseases inflammation mitogenesis cancers orally active inflammatory Epoprostenol Sodium(5Z,9alpha,11alpha,13E,15S)-Isomer Epoprostenol Sodium
Prostaglandin I(2) Prostaglandin I2 Prostacyclin Epoprostenol Epoprostanol Flolan PGI2 PGX |
53.389462581616
|
| 18216 |
Ciprostene (calcium salt)
|
|
81703-55-1 |
≥98%
|
|
|
|
51.273157659187
|
ciprostene-calcium-salt
|
U-61431F; Ciprostene calcium
|
PGI2 analogs vasodilation 9.beta.-methyl 9beta-methyl carbaprostacyclin prostaglandins salts cat U61431F atherosclerosis |
51.273157659187
|
| 16765 |
(+)-Cloprostenol
|
|
54276-21-0 |
≥97%
|
|
|
|
75.093954222573
|
-cloprostenol
|
(+)-16-m-chlorophenoxy tetranor Prostaglandin F2α; D-Cloprostenol; (+)-16-m-chlorophenoxy tetranor PGF2α
|
PGF2.alpha. PGF2alpha luteolysis analogs prostaglandins agonists FP receptors enantiomer pharma:6 |
75.093954222573
|
| 10010016 |
(+)-Cloprostenol isopropyl ester
Exclusive |
|
157283-66-4 |
≥98%
|
|
✓ |
2011-04-04
|
483.859288674033
|
-cloprostenol-isopropyl-ester
|
(+)-16-m-chlorophenoxy tetranor Prostaglandin F2α isopropyl ester
|
CAYMAXTM520 PGF2α luteolysis analogs prostaglandins agonists FP receptors enantiomers PGs optically active 15(R) 15R cyclopentenoic esters |
483.859288674033
|
| 10010495 |
(+)-Cloprostenol methyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2010-11-17
|
35.441743784530
|
-cloprostenol-methyl-amide
|
D-Cloprostenol methyl amide; (+)-16-m-Chlorophenoxy tetranor PGF2α methyl amide
|
analogs prosgaglandins PGs F2α PGF2α PGF2a PGF2alpha PGF2.alpha. F2a F2alpha F2.alpha. luteolytic luteolysis pregnancy abortion abortifacient estrus lipophilic synthetic FP agonist potent veterinary medicine vets agents treatments reporductiove disorders lipids free acids prodrugs pro-drugs pro drugs hydrolyzed tissues bioactive |
35.441743784530
|
| 10010115 |
(+)-Cloprostenol methyl ester
Exclusive |
|
56687-85-5 |
≥98%
|
|
✓ |
2010-11-17
|
35.847821132597
|
-cloprostenol-methyl-ester
|
(+)-16-m-Chlorophenoxy tetranor PGF2α methyl ester; D-Cloprostenol methyl ester
|
analogs prosgaglandins PGs F2α PGF2α PGF2a PGF2alpha PGF2.alpha. F2a F2alpha F2.alpha. luteolytic luteolysis pregnancy abortion abortifacient estrus lipophilic synthetic FP agonist potent veterinary medicine vets agents treatments reporductiove disorders lipids |
35.847821132597
|
| 16766 |
(+)-Cloprostenol (sodium salt)
|
|
62561-03-9 |
≥98%
|
|
|
|
75.136574585635
|
-cloprostenol-sodium-salt
|
(+)-16-m-chlorophenoxy tetranor Prostaglandin F2α (sodium salt); (+)-16-m-chlorophenoxy tetranor PGF2α (sodium salt); D-Cloprostenol
|
FP receptors agonists luteolysis analogs PGF2.alpha. PGF2alpha prostaglandins salts Na+ D-Cloprostenol pharma:4 |
75.136574585635
|
| 16764 |
Cloprostenol (sodium salt)
|
|
55028-72-3 |
≥98%
|
|
|
|
66.387845303867
|
cloprostenol-sodium-salt
|
DL-Cloprostenol (sodium salt); (±)-16-m-chlorophenoxy tetranor Prostaglandin F2α (sodium salt); (±)-16-m-chlorophenoxy tetranor PGF2α (sodium salt)
|
PGF2.alpha. PGF2alpha luteolysis analogs prostaglandins agonists FP receptors (+/-)-cloprostenol ±cloprostenol DL-Cloprostenol pharma:3 |
66.387845303867
|
| 70030 |
Corey Lactone Aldehyde Benzoate
|
|
39746-01-5 |
≥90%
|
|
|
|
236.295160220994
|
corey-lactone-aldehyde-benzoate
|
|
intermediates chiral aldehydes benzoates prostaglandins preparation analogs |
236.295160220994
|
| 70035 |
(−)-Corey Lactone Diol
|
|
32233-40-2 |
≥98%
|
|
|
2004-05-12
|
332.658563535911
|
-corey-lactone-diol
|
|
prostaglandins diols intermediates analogs hydroxy lactones pharma:17 |
332.658563535911
|
| 70036 |
Corey PG-Lactone Diol
|
|
- |
≥95%
|
|
|
|
1065.785635359115
|
corey-pg-lactone-diol
|
|
chiral intermediate |
1065.785635359115
|
| 60100 |
COX-1 (ovine)
|
|
- |
>95%
|
|
|
|
132.372501255650
|
cox-1-ovine
|
Prostaglandin H Synthase 1; Prostaglandin Endoperoxide Synthase; Cyclooxygenase 1
|
cyclooxygenases COX-1 enzymes PGHS1 PGHS-1 constitutive prostaglandins synthases 1 sheep 760110 tween 20 |
132.372501255650
|
| 360100 |
COX-1 (ovine) Electrophoresis Standard
|
|
- |
>95%
|
|
|
|
9.809944751381
|
cox-1-ovine-electrophoresis-standard
|
Prostaglandin H Synthase 1; Cyclooxygenase 1; PGHS-1
|
PGHS-1 sheep COX1 Western blots immunoblotting cyclooxygenases pghs1 synthases standards prostaglandins antibodies |
9.809944751381
|
| 60122 |
COX-2 (human recombinant)
|
|
- |
>70%
|
|
|
|
134.936866175567
|
cox-2-human-recombinant
|
Prostaglandin H Synthase 2; Cyclooxygenase 2
|
cyclooxygenases COX2 PGHS-2 PGHS2 inducible synthases synthase-2 prostaglandins enzymes |
134.936866175567
|
| 10009624 |
COX-2 (human) Western Ready Control
|
|
- |
Whole cell lysate
|
|
|
2007-04-30
|
52.972715074979
|
cox-2-human-western-ready-control
|
Cyclooxygenase-2; Prostaglandin H Synthase 2
|
western blots WB PGHS-2 Prostaglandin H Synthase 2 cyclooxygenase 2 |
52.972715074979
|
| 60120 |
COX-2 (ovine)
|
|
- |
~70%
|
|
|
|
110.270283609576
|
cox-2-ovine
|
Prostaglandin H Synthase 2; Inducible cyclooxygenase (ovine); Cyclooxygenase 2
|
cyclooxygenases COX2 PGHS-2 PGHS2 inducible sheep synthases synthase-2 enzymes 760112 |
110.270283609576
|
| 360120 |
COX-2 (ovine) Electrophoresis Standard
|
|
- |
>95%
|
|
|
|
40.503370165746
|
cox-2-ovine-electrophoresis-standard
|
Prostaglandin H Synthase 2; Cyclooxygenase 2; PGHS-2
|
standards prostaglandins PGHS-2 sheep COX2 pghs2 synthases western blots immunoblotting cyclooxygenases antibodies |
40.503370165746
|
| 10000 |
Cyclopentenone Prostaglandin HPLC Mixture
|
|
- |
≥98% for each compound
|
|
|
|
53.222397790054
|
cyclopentenone-prostaglandin-hplc-mixture
|
Cyclopentenone PG HPLC Mixture
|
PGA2 PGB2 PGD2 PGE2 15-deoxy-.DELTA.12,14-PGJ2 prostaglandins mixtures chromatography 15-deoxy-delta12,14-PGJ2 cyclopentenones UV-absorbing 15-deoxy-d12,14-PGJ2 |
53.222397790054
|
| 10010380 |
ent-8-iso-15(S)-Prostaglandin F2α
|
|
- |
≥98%
|
|
|
2008-04-24
|
10.323038674033
|
ent-8-iso-15-s-prostaglandin-f2
|
ent-8-iso-15-epi-PGF2α; ent-15-epi-F2t-Isoprostane
|
inhibitors inhibits inhibition 8-iso-PGF2.alpha. vasoconstriction platelet aggregation oxidative stress isoprostanes 15-F2t-isoprostane prostaglandins |
10.323038674033
|
| 10011545 |
ent-8-iso Prostaglandin F2α
|
|
- |
>98%
|
|
|
2008-05-28
|
9.871736385161
|
ent-8-iso-prostaglandin-f2
|
ent-8-epi PGF2α; ent-15-F2t-Isoprostane; ent-8-iso PGF2α
|
vasoconstrictor oxidative stress isoprostanes prostaglandins iPs PGF2a PGF2.alpha. |
9.871736385161
|
| 10011721 |
ent-8-iso Prostaglandin F2α-d9
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2008-08-11
|
9.991418047881
|
ent-8-iso-prostaglandin-f2-d9
|
ent-8-epi PGF2α-d9; ent-15-F2t-Isoprostane-d9; ent-8-iso PGF2α-d9
|
deuterated deuterium inhibitors inhibits inhibition 8-iso-PGF2.alpha. vasoconstriction platelet aggregation oxidative stress isoprostanes 15-F2t-isoprostane GC/MS GC-MS LC/MS LC-MS mass spectrometry |
9.991418047881
|
| 10653 |
ent-Corey PG-Lactone Diol
Exclusive |
|
- |
≥98%
|
|
✓ |
2011-01-18
|
375.377311233885
|
ent-corey-pg-lactone-diol
|
|
chiral intermediate prostaglandins PGs synthesis |
375.377311233885
|
| 10008294 |
ent-Prostaglandin E2
|
|
65085-69-0 |
>98%
|
|
|
2006-03-30
|
68.662872928177
|
ent-prostaglandin-e2
|
ent-PGE2
|
prostaglandins enantiomers enzymatically-derived optically free radical-catalyzed peroxidation arachidonates racemic in vitro in vivo oxidative stress isoprostanes 15-E2t-IsoP 8-iso endoperoxides |
68.662872928177
|
| 10008122 |
ent-Prostaglandin F2α
|
|
54483-31-7 |
>98%
|
|
|
2006-03-30
|
15.127219152855
|
ent-prostaglandin-f2
|
(-)-Prostaglandin F2α; ent-PGF2α
|
prostaglandins enantiomers optically free radical-catalyzed peroxidation racemic isoprostanes lipids oxidative stress human urine cigarette smokers hpercholesterolemia COX cyclooxygenase oxidative stress |
15.127219152855
|
| 10010382 |
ent-Prostaglandin F2α EIA Kit
|
|
- |
|
|
|
2008-04-08
|
172.767099447513
|
ent-prostaglandin-f2-eia-kit
|
ent-PGF2α EIA Kit
|
prostaglandins PGH2 PGs COX cyclooxygenases reproduction smooth muscles contractions urine enantiomers quantification measures kits eias enzyme immunoassays ELISAs assays |
172.767099447513
|
| 600340 |
EP2 Receptor (rat) STEP Reporter Assay Kit (Luminescence)
Exclusive |
|
- |
|
|
✓ |
2010-09-20
|
23.550653775322
|
ep2-receptor-rat-step-reporter-assay-kit-luminescence
|
Prostaglandin E2 Receptor 2; PGE2 Receptor 2
|
prostaglandins E2 PGE2 prostanoids G protein-coupled receptors GPCRs EP1 EP3 EP4 signal transduction tissues regulation cells mediates cAMP cyclic messenger pathways mucosal protection gastrointestinal secretions motility immunity inflammation mice mouse murine tumors cancers cancer-associated immunodeficiency dendritic-cell differentiation in vitro neuroprotective NMDA toxicity oxygen glucose deprivation agonists antagonists therapeutics Surface transfection and expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated endocytosis solution-phase co-transfection plasmids secretory alkalines phosphatases substrates SEAP proteins lipids signal transduction luminescence-based cell-based assays kits CBAs high-throughput screening |
23.550653775322
|
| 600350 |
EP4 Receptor (rat) STEP Reporter Assay Kit (Luminescence)
|
|
- |
|
|
|
2010-11-04
|
21.126413443830
|
ep4-receptor-rat-step-reporter-assay-kit-luminescence
|
PGE2 Receptor 4; Prostaglandin E2 Receptor 4
|
prostaglandins E2 PGE2 prostanoids G protein-coupled receptors GPCRs EP1 EP2 EP3 signal transduction tissues regulation cells intestines lungs kidneys thymus brains uterus mediates cAMP cyclic messenger pathways PtdIns phosphatidylinositols 3-kinases Gi mediates relaxation smooth muscles gastric acid secretions intestinal epithelial transportation adrenal aldosterone uterine immunity inflammation mice mouse murine colon tumors cancers cancer-associated carcinogenesis in vivo neuroprotective NMDA neuroprotective excitotoxic brain injury agonists antagonists therapeutics Surface transfection and expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated endocytosis solution-phase co-transfection plasmids secretory alkalines phosphatases substrates SEAP proteins lipids signal transduction luminescence-based cell-based assays kits CBAs high-throughput screening |
21.126413443830
|
| 16768 |
Fluprostenol
Exclusive |
|
54276-17-4 |
≥95%
|
|
✓ |
|
93.030672191528
|
fluprostenol
|
16-m-trifluoromethylphenoxy tetranor PGF2α
|
16767 PGF2alpha PGF2.alpha. analogs FP agonists luteolysis prostaglandins receptors (+)-Fluprostenol |
93.030672191528
|
| 316767 |
Fluprostenol-d4
|
|
- |
≥99% deuterated product
|
|
|
|
1.723756906078
|
fluprostenol-d4
|
16-m-trifluoromethylphenoxy tetranor Prostaglandin F2α-d4
|
GC/MS deuterium isotopes internal standards GC-MS LC/MS LC-MS mass spectrometry (+)-fluprostenol prostaglandins deuterated |
1.723756906078
|
| 516761 |
Fluprostenol EIA Kit
|
|
- |
|
|
|
|
52.382971147943
|
fluprostenol-eia-kit
|
16-m-trifluoromethylphenoxy tetranor Prostaglandin F2α; Fluprostenol ELISA Kit
|
solid plates prostaglandins measures kits eias enzyme immunoassays ELISAs eyes ophthalmology ophthalmological intraocular glaucoma esters assays (+)-Fluprostenols 16-meta-trifluoromethylphenoxy |
52.382971147943
|
| 16769 |
Fluprostenol isopropyl ester
|
|
157283-68-6 |
≥98%
|
|
|
|
41.575451197053
|
fluprostenol-isopropyl-ester
|
Flu-Ipr; Travoprost; 16-m-trifluoromethylphenoxy tetranor PGF2α isopropyl ester
|
esters prodrug FP receptors agonists intraocular hypotensive IOP glaucoma analogs prostaglandins travatan ophthalmology |
41.575451197053
|
| 70037 |
Fluprostenol Lactone Diol
|
|
- |
≥98%
|
|
|
|
535.398895027624
|
fluprostenol-lactone-diol
|
|
lactones diols intermediates synthesis |
535.398895027624
|
| 10010406 |
Fluprostenol methyl amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2009-04-17
|
5.287874553136
|
fluprostenol-methyl-amide
|
|
FPs PGF2α glaucoma ocular hypertension fluprostenol luteolysis |
5.287874553136
|
| 10010151 |
Fluprostenol methyl ester
|
|
73275-76-0 |
≥98%
|
|
|
2009-03-16
|
5.978523020257
|
fluprostenol-methyl-ester
|
|
FP PGF2.alpha. glaucoma ocular hypertension fluprostenol luteolysis hair growth |
5.978523020257
|
| 10004236 |
Fluprostenol serinol amide
|
|
- |
≥98%
|
|
|
2004-09-23
|
25.495878453039
|
fluprostenol-serinol-amide
|
Flu-SA
|
PGF2.alpha. PGF2alpha analogs agonists prostaglandins receptors amides cannabinoids CB1 CBs synthetic |
25.495878453039
|
| 10009162 |
GW 627368X
Exclusive |
|
439288-66-1 |
≥96%
|
|
✓ |
2007-05-14
|
22.181139502762
|
gw-627368x
|
|
EP4 receptor antagonist TP prostanoid prostaglandin platelets U-46619 aggregation PGE2 EP1 EP2 EP3 GW627368X GW-627368X |
22.181139502762
|
| 18215 |
Iloprost
|
|
78919-13-8 |
≥97%
|
|
|
|
134.543953345610
|
iloprost
|
Ciloprost
|
agonists IP receptors vasodilator hypostensive atherosclerosis antiduretic hypertension analogs PGI2 prostaglandins prostacyclin selective selectivity pharma:21 |
134.543953345610
|
| 16230 |
iPF2α-IV
|
|
331962-00-6 |
≥98%
|
|
|
2006-07-27
|
16.945303867403
|
ipf2-iv
|
|
isoprostanes prostaglandins lipids peroxidation arachidonic acids PUFAs polyunsaturated fatty oxidative stress injury |
16.945303867403
|
| 316300 |
iPF2α-VI-d4
|
|
214977-79-4 |
≥99% deuterated product
|
|
|
|
25.528738489871
|
ipf2-vi-d4
|
8-iso-5(R),6E,14Z-Prostaglandin F2α-d4
|
deuteriums isotopes 8-isoprostanes iPF2.alpha.-VI-d4 iPF2alpha-VI-d4 lipid peroxidation oxidative ipf2a injury stress prostaglandins deuterated iPF2a-VI-d4 pgf2a deuterium GC/MS GC-MS LC/MS LC-MS mass specrometry |
25.528738489871
|
| 516301 |
iPF2α-VI EIA Kit
|
|
- |
|
|
|
|
148.788477209944
|
ipf2-vi-eia-kit
|
iPF2α-VI ELISA Kit
|
solid plates prostaglandins measures kits eias enzyme immunoassays ELISAs ipf2a-VI ipf2aVI isoprostanes assays |
148.788477209944
|
| 10007712 |
L-902,688
Exclusive |
|
634193-54-7 |
≥98%
|
|
✓ |
2010-05-07
|
44.592225730070
|
l-902-688
|
|
PGE2 bones growth EP4 agonists hyperalgesia vasodialation |
44.592225730070
|
| 16812 |
Latanoprost
|
|
130209-82-4 |
>98%
|
|
|
|
55.231197053406
|
latanoprost
|
CAY530500; 17-phenyl-13,14-dihydro trinor Prostaglandin F2α isopropyl ester; 17-phenyl-13,14-dihydro trinor PGF2α isopropyl ester
|
eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists IOP pressure prostaglandins 17-phenyl-13,14-dihydro-trinor-PGF2.alpha. 17-phenyl-13,14-dihydro-trinor-PGF2alpha |
55.231197053406
|
| 10006556 |
Latanoprost-d4
|
|
- |
≥99% deuterated product
|
|
|
2005-11-30
|
21.322550644567
|
latanoprost-d4
|
17-phenyl-13,14-dihydro trinor Prostaglandin F2α-d4 isopropyl ester
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids GC/MS deuterium isotopes internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry 17-phenyl-13,14-dihydro-trinor-PGF2.alpha.-d4 17-phenyl-13,14-dihydro-trinor-PGF2alpha-d5 17-phenyl-13,14-dihydro trinor-PGF2a-d4 PGs |
21.322550644567
|
| 516811 |
Latanoprost EIA Kit
|
|
- |
|
|
|
|
121.156949048495
|
latanoprost-eia-kit
|
Latanoprost ELISA Kit; PhXA 85 EIA Kit; 17-phenyl-13,14-dihydro trinor Prostaglandin F2α isopropyl ester EIA Kit; 17-phenyl-13,14-dihydro trinor Prostaglandin F2α EIA Kit
|
solid plates prostaglandins measures kits eias enzyme immunoassays ELISAs eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists phxa85 17-phenyl-13,14-dihydro-trinor-PGF2alpha 17-phenyl-13,14-dihydro-trinor-PGF2.alpha. assays |
121.156949048495
|
| 16822 |
Latanoprost ethyl amide
|
|
- |
>98%
|
|
|
|
26.177384898710
|
latanoprost-ethyl-amide
|
Lat-NEt
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids |
26.177384898710
|
| 316822 |
Latanoprost ethyl amide-d4
|
|
- |
≥99% deuterated product
|
|
|
2006-03-16
|
29.224337016574
|
latanoprost-ethyl-amide-d4
|
Lat-NEt-d4
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids GC/MS deuterium isotopes internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry |
29.224337016574
|
| 16811 |
Latanoprost (free acid)
|
|
41639-83-2 |
≥98%
|
|
|
|
88.343117600631
|
latanoprost-free-acid
|
PhXA-85; Lat-FA; 17-phenyl-13,14-dihydro trinor PGF2α
|
eyes glaucoma prostaglandins agonists FP receptors phxa85 ophthalmology ophthalmological intraocular acids 17-phenyl-13,14-dihydro-trinor-PGF2.alpha. PhXA85 17-phenyl-13,14-dihydro-trinor-PGF2alpha IOP |
88.343117600631
|
| 316811 |
Latanoprost (free acid)-d4
|
|
- |
≥99% deuterated product
|
|
|
|
38.763618784530
|
latanoprost-free-acid-d4
|
PhXA 85-d4; 17-phenyl-13,14-dihydro trinor Prostaglandin F2α-d4; Lat-FA-d4
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids GC/MS deuterium isotopes internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry 17-phenyl-13,14-dihydro-trinor-PGF2.alpha.-d4 PhXA85-d4 17-phenyl-13,14-dihydro-trinor-PGF2alpha-d5 LatFA-d4 17-phenyl-13,14-dihydro trinor-PGF2a-d4 |
38.763618784530
|
| 70049 |
Latanoprost Lactol
|
|
352276-28-9 |
>98%
|
|
|
|
28.777030386740
|
latanoprost-lactol
|
|
eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists IOP pressure prostaglandins |
28.777030386740
|
| 70039 |
Latanoprost Lactone Diol
|
|
145667-75-0 |
>98%
|
|
|
2004-01-02
|
38.369373848987
|
latanoprost-lactone-diol
|
|
eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists IOP pressure prostaglandins |
38.369373848987
|
| 13810 |
Limaprost
|
|
74397-12-9 |
>98%
|
|
|
|
43.118038674033
|
limaprost
|
17α,20-dimethyl-Δ2-Prostaglandin E1; 17α,20-dimethyl-Δ2-PGE1
|
PGE1 analogs inhibitors platelets aggregation prostaglandins |
43.118038674033
|
| 10009597 |
Luminex® Prostaglandin E2/Interleukin-1β Duplex Kit
|
|
- |
|
|
|
2008-03-26
|
310.739116022099
|
luminex-prostaglandin-e2-interleukin-1-duplex-kit
|
|
ILs prostaglandins PGE2-phycoerytherin conjugates tracer xMAP beads microspheres monoclonal interleukins measures kits eias enzyme immunoassays ELISAs interleukin-1.beta. interleukin-1beta luminex 100TM 200TM analyzer cyslt cys-LTs LTC4 LTD4 LTE4 measures kits asthma peptido-lts peptido-leukotrienes cysteinyl-leukotrienes allergy cysteinyl-LTs in vivo in vitro inflammation pro-inflammatory mediators cytokines sandwich-type competitive assays |
310.739116022099
|
| 10007501 |
Luminex® Prostaglandin E2 Kit
|
|
- |
|
|
|
2006-02-06
|
270.004972375691
|
luminex-prostaglandin-e2-kit
|
|
prostaglandins PGE2-phycoerytherin conjugates tracer xMAP beads microspheres measures kits asthma monoclonal luminex 100TM 200TM analyzer assays |
270.004972375691
|
| 16685 |
Lumula
|
|
- |
>98%
|
|
|
|
25.729419889502
|
lumula
|
Unoprostone N-ethyl amide; Maxeyprost
|
prostaglandins PGF2alpha PGF2.alpha. analogs hypotensive hypotension intraocular pressure ophthalmological eyes ophthalmology iop glaucoma prostamide docosanoid docosaprostamide |
25.729419889502
|
| 13820 |
Misoprostol
|
|
59122-46-2 |
>98%
|
|
|
|
30.865580110496
|
misoprostol
|
SC-29333; Cytotec
|
cytoprotection PGE1 analogs agonists EP2 EP3 EP4 receptors SC29333 RU-486 RU486 |
30.865580110496
|
| 13821 |
Misoprostol (free acid)
|
|
112137-89-0 |
>97%
|
|
|
|
47.279292817679
|
misoprostol-free-acid
|
|
PGE1 analogs agonists EP2 EP3 EP4 cytotec cytoprotection SC-29333 SC29333 receptors RU486 RU-486 |
47.279292817679
|
| 10010333 |
Misoprostol (free acid)-d5
|
|
- |
≥99% deuterated product
|
|
|
2008-01-16
|
20.789350828729
|
misoprostol-free-acid-d5
|
|
PGE1 analogs agonists EP2 EP3 EP4 cytotec cytoprotection SC-29333 SC29333 receptors RU486 RU-486 deuterated deuteriums GC/MS GC-MS LC/MS LC-MS mass spectrometry |
20.789350828729
|
| 10010411 |
NS-304
|
|
475086-01-2 |
>98%
|
|
|
2008-04-09
|
41.397650158956
|
ns-304
|
ACT-293987; Selexipag
|
prostaglandins PGI2 IP receptors inflammation MRE-269 agonists vasodilator hypotensive vascular diseases atherosclerosis hypertension analogs potent selective PGs |
41.397650158956
|
| 14070 |
ONO-8711
|
|
216158-34-8 |
≥98%
|
|
|
2011-06-15
|
21.005331491712
|
ono-8711
|
|
ONO 8711 ONO8711 prostaglandins EPs EP1 receptors potent PGs antagonists AH-6809 AH 6809 AH6809 14060 14050 SC-19220 SC19220 SC 19220 |
21.005331491712
|
| 13454 |
PGDM
New |
|
133161-96-3 |
≥90% (mixture)
|
|
|
2012-02-02
|
150.276255180749
|
pgdm
|
Prostaglandin D Metabolite
|
PGD-M urine PGD2 prostaglandins D2 PGs metabolites urinary side chains cyclization biomarkers endogenous allergic asthmatic sleep body temperatures |
150.276255180749
|
| 11344 |
PGDM-d4
New |
|
- |
≥99% deuterated forms (d1-d4)
|
|
|
2012-02-02
|
150.276255180749
|
pgdm-d4
|
Prostaglandin D Metabolite-d4
|
PGD-M deuterated deuterium GC/MS GC-MS LC/MS LC-MS mass spectrometry urine PGD2 prostaglandins D2 PGs metabolites urinary side chains cyclization biomarkers endogenous allergic asthmatic sleep body temperatures |
150.276255180749
|
| 18228 |
Piriprost (potassium salt)
|
|
88851-62-1 |
>98%
|
|
|
|
16.263898973954
|
piriprost-potassium-salt
|
U-60257B
|
inhibitors 5-lipoxygenases 5-LOs selective allergy inflammation analogs inhibits prostaglandins salts K+ |
16.263898973954
|
| 10001 |
Primary Eicosanoid HPLC Mixture
|
|
- |
>98% for each compound
|
|
|
|
52.340570902394
|
primary-eicosanoid-hplc-mixture
|
|
PGD2 PGE2 6-keto-PGF1alpha 6-keto-PGF1.alpha. PGF2alpha PGF2.alpha. TXB2 prostaglandins eicosanoids mixtures chromatography cyclooxygenases metabolites PGHS2 PGHS-2 COX-2 COX2 COX1 COX-1 PGHS-1 PGHS1 synthases |
52.340570902394
|
| 10010 |
Prostaglandin A1
|
|
14152-28-4 |
>98%
|
|
|
|
139.226084254143
|
prostaglandin-a1
|
PGA1
|
prostaglandins renal vasodilation pge1 dehydration semen antimitotic antiproliferative |
139.226084254143
|
| 10013 |
Prostaglandin A1-biotin
|
|
- |
>95%
|
|
|
|
29.195893186003
|
prostaglandin-a1-biotin
|
PGA1-biotin
|
antimitotic antiproliferative probes ligands prostaglandins pga1-biotinimides detection affinity complexes DNA nucleic acid protein binding partners mechanism biotins PGA1-biotins PGA1-biotinylated PGA1-biotinamides biotinylated biotinamides |
29.195893186003
|
| 10020 |
Prostaglandin A1 ethyl ester
|
|
93464-24-5 |
>98%
|
|
|
|
68.835801104972
|
prostaglandin-a1-ethyl-ester
|
PGA1 ethyl ester
|
PGA1 renal vasodilation prostaglandins esters prodrugs lipid-soluble |
68.835801104972
|
| 9000184 |
Prostaglandin A1 methyl ester
Exclusive |
|
26771-94-8 |
≥98%
|
|
✓ |
2010-11-08
|
18.494516574585
|
prostaglandin-a1-methyl-ester
|
PGA1 methyl ester
|
hypertension cancers lipophilic analogs PGA1 prostaglandins |
18.494516574585
|
| 10210 |
Prostaglandin A2
|
|
13345-50-1 |
>98%
|
|
|
|
23.069736506587
|
prostaglandin-a2
|
Medullin; PGA2
|
PGA2 prostaglandins vasodilation |
23.069736506587
|
| 10010499 |
Prostaglandin A2-biotin
Exclusive |
|
- |
≥95%
|
|
✓ |
2011-03-07
|
3.310455801104
|
prostaglandin-a2-biotin
|
PGA2-biotin
|
affinity probes cancer apoptosis cells cycles biotins biotinamides biotinimides biotinylateds ligands receptors thromboxanes A2 prostaglandins H2 EP4 subtypes EP3 EP2 EP1 E2 PGE prostanoids TXA2-PGH2 TXA2 PGH2 PGE2 PGs |
3.310455801104
|
| 310210 |
Prostaglandin A2-d4
|
|
- |
≥99% deuterated product
|
|
|
|
2.975046040515
|
prostaglandin-a2-d4
|
Medullin-d4; PGA2-d4
|
GC/MS deuterium isotopes PGA2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry neuroscience |
2.975046040515
|
| 10007199 |
Prostaglandin A2 Lipid Maps MS Standard
|
|
- |
≥98%
|
|
|
2008-07-01
|
3.448539857932
|
prostaglandin-a2-lipid-maps-ms-standard
|
Medullin; PGA2
|
PGA2 prostaglandins vasodilation mass spectrometry |
3.448539857932
|
| 9000185 |
Prostaglandin A2 methyl ester
Exclusive |
|
31753-19-2 |
≥98%
|
|
✓ |
2010-11-08
|
1.213419275629
|
prostaglandin-a2-methyl-ester
|
PGA2 methyl ester; Medullin methyl ester
|
hypertension cancers lipophilic analogs PGA2 prostaglandins |
1.213419275629
|
| 10006840 |
Prostaglandin A2 Quant-PAK
|
|
- |
|
|
|
2005-08-08
|
1.010041436464
|
prostaglandin-a2-quant-pak
|
|
Quant-Paks vasodilation GC/MS deuterium isotopes PGA2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
1.010041436464
|
| 10310 |
Prostaglandin A3
Exclusive |
|
36614-31-0 |
>98%
|
|
✓ |
|
20.453314917127
|
prostaglandin-a3
|
PGA3
|
PGA3 omega-3 prostaglandins .omega.-3 w-3 |
20.453314917127
|
| 11110 |
Prostaglandin B1
|
|
13345-51-2 |
>98%
|
|
|
|
36.189751381215
|
prostaglandin-b1
|
PGB1
|
PGB1 prostaglandins |
36.189751381215
|
| 11210 |
Prostaglandin B2
|
|
13367-85-6 |
>99%
|
|
|
|
47.998784530386
|
prostaglandin-b2
|
PGB2
|
PGB2 prostaglandins |
47.998784530386
|
| 311210 |
Prostaglandin B2-d4
|
|
- |
≥99% deuterated product
|
|
|
|
17.886243093922
|
prostaglandin-b2-d4
|
PGB2-d4
|
GC/MS deuterium isotopes PGB2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry |
17.886243093922
|
| 10007201 |
Prostaglandin B2 Lipid Maps MS Standard
|
|
13367-85-6 |
>99%
|
|
|
2008-10-24
|
38.601289134438
|
prostaglandin-b2-lipid-maps-ms-standard
|
PGB2
|
PGB2 prostaglandins vasodilation mass spectrometry GC LC MS standards |
38.601289134438
|
| 10006841 |
Prostaglandin B2 Quant-PAK
|
|
- |
|
|
|
2005-08-08
|
2.097228360957
|
prostaglandin-b2-quant-pak
|
|
Quant-PAKs GC/MS deuterium isotopes PGB2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
2.097228360957
|
| 11990 |
Prostaglandin B3
Exclusive |
|
36614-32-1 |
>97%
|
|
✓ |
|
17.887458563536
|
prostaglandin-b3
|
PGB3
|
PGB3 omega-3 prostaglandins .omega.-3 PGE3 w-3 |
17.887458563536
|
| 11510 |
Prostaglandin Bx
Exclusive |
|
39306-29-1 |
Mixture of oligomers
|
|
✓ |
|
30.350552486188
|
prostaglandin-bx
|
PGBx
|
PGBx free radicals antioxidants prostaglandins |
30.350552486188
|
| 12000 |
Prostaglandin D1
|
|
17968-82-0 |
>98%
|
|
|
|
30.389686924493
|
prostaglandin-d1
|
PGD1
|
PGD1 prostaglandins metabolites DGLA dihomo-gamma-linoleic dihomo-g-linoleic dihomo-.gamma.-linoleic acids |
30.389686924493
|
| 12002 |
Prostaglandin D1 Alcohol
|
|
1176470-37-3 |
>99%
|
|
|
|
1.097900552486
|
prostaglandin-d1-alcohol
|
PGD1 Alcohol
|
PGD1 alcohols prostaglandins |
1.097900552486
|
| 312000 |
Prostaglandin D1-d4
|
|
- |
≥99% deuterated product
|
|
|
|
0.587918968692
|
prostaglandin-d1-d4
|
PGD1-d4
|
GC/MS deuterium isotopes PGD1-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry |
0.587918968692
|
| 10006842 |
Prostaglandin D1 Quant-PAK
|
|
- |
|
|
|
2005-08-08
|
0.469868253293
|
prostaglandin-d1-quant-pak
|
|
Quant-PAKs metabolites DGLA dihomo-gamma-linoleic dihomo-g-linoleic dihomo-.gamma.-linoleic acids GC/MS deuterium isotopes PGD1-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
0.469868253293
|
| 12010 |
Prostaglandin D2
|
|
41598-07-6 |
>99%
|
|
|
|
180.514980639373
|
prostaglandin-d2
|
PGD2
|
Vasodilation prostaglandins brain sleep platelets aggregation. H-PGDS synthases mast cells hematopoietic allergic allergy asthmatic anaphylaxis hypotension inhibits inhibitors inhibition beta-trace .beta.-trace b-trace neurochemistry |
180.514980639373
|
| 12015 |
Prostaglandin D2-1-glyceryl ester
|
|
309260-52-4 |
>95% (as a 9:1 mixture of the 1- and 2-glyceryl esters)
|
|
|
2004-08-05
|
35.607513812154
|
prostaglandin-d2-1-glyceryl-ester
|
PGD2-1-glyceryl ester
|
endocannabinoids anandamides 2AG fatty acids porcine brain isomerase moiety cannabinoids cbs synthetic |
35.607513812154
|
| 312010 |
Prostaglandin D2-d4
|
|
- |
≥99% deuterated product
|
|
|
|
55.610165745856
|
prostaglandin-d2-d4
|
PGD2-d4
|
GC/MS deuterium isotopes PGD2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry neurochemistry neuroscience |
55.610165745856
|
| 10007272 |
Prostaglandin D2-d4 Lipid Maps MS Standard
|
|
- |
≥99% deuterated compound
|
|
|
2009-02-26
|
47.598011049723
|
prostaglandin-d2-d4-lipid-maps-ms-standard
|
PGD2-d4
|
GC/MS deuterium isotopes PGD2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry neurochemistry neuroscience MS mass spectrometry standards |
47.598011049723
|
| 10010123 |
Prostaglandin D2-d9
|
|
- |
≥99% deuterated product
|
|
|
2007-10-25
|
93.132005831798
|
prostaglandin-d2-d9
|
PGD2-d9
|
GC/MS deuterium isotopes internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry neurochemistry neuroscience allergy asthma |
93.132005831798
|
| 512031 |
Prostaglandin D2 EIA Kit
|
|
- |
|
|
|
2010-07-19
|
268.101938305709
|
prostaglandin-d2-eia-kit
|
PGD2 ELISA Kit
|
PGD2 prostaglandins measures kits eias enzyme immunoassays ELISAs measurements brains glutathione-independent lipocalin-type synthases L-PGDS cerebrospinal fluid CSF physiologic sleep rats humans mast cells leukocytes intracellular myeloid-type glutathione-dependent vascular 11β-PGF2α eicosanoids cultures lysates biosynthesis serum proteins albumin media medium methoximine derivatives PGD2-MOX competitive enzymatic reactions |
268.101938305709
|
| 12012 |
Prostaglandin D2 Ethanolamide
|
|
398138-28-8 |
>96%
|
|
|
|
29.102312549329
|
prostaglandin-d2-ethanolamide
|
PGD2-EA
|
anandamides ethanolamides cannabinoids PGD2 prostaglandins AEA neurochemistry neuroscience ethanolamines prostamides |
29.102312549329
|
| 10007203 |
Prostaglandin D2 Ethanolamide Lipid Maps MS Standard
|
|
398138-28-8 |
>96%
|
|
|
2008-10-29
|
28.541617995264
|
prostaglandin-d2-ethanolamide-lipid-maps-ms-standard
|
PGD2-EA
|
anandamides ethanolamides cannabinoids PGD2 prostaglandins AEA neurochemistry neuroscience ethanolamines prostamides GC LC mass spectrometry MS standards |
28.541617995264
|
| 512041 |
Prostaglandin D2 Express EIA Kit
|
|
- |
|
|
|
2010-07-19
|
125.652167445813
|
prostaglandin-d2-express-eia-kit
|
PGD2 Express ELISA Kit
|
PGD2 prostaglandins measures kits eias enzyme immunoassays ELISAs measurements brains glutathione-independent lipocalin-type synthases L-PGDS cerebrospinal fluid CSF physiologic sleep rats humans mast cells leukocytes intracellular myeloid-type glutathione-dependent vascular 11β-PGF2α eicosanoids cultures lysates biosynthesis serum proteins albumin media medium methoximine derivatives PGD2-MOX competitive enzymatic reactions |
125.652167445813
|
| 500581 |
Prostaglandin D2 FPIA Kit - Green
|
|
- |
|
|
|
2004-11-16
|
49.297600138121
|
prostaglandin-d2-fpia-kit-green
|
PGD2 Fluorescence Polarization Immunoassay - Green
|
PGD2 metabolites prostaglandins immunoassays HTS high-throughput kits screenings rapid measurements assays |
49.297600138121
|
| 512051 |
Prostaglandin D2 FPIA Kit - Red
|
|
- |
|
|
|
2011-04-11
|
73.091519337016
|
prostaglandin-d2-fpia-kit-red
|
PGD2 Fluorescence Polarization Immunoassay - Red
|
PGD2 Fluorescence Polarization Immunoassays metabolites prostaglandins D2 immunoassays HTS high-throughput kits screenings rapid measurements assays brains glutathione-independent lipocalin-type synthases L-PGDS cerebral spinal fluids CSF physiologic sleep rats humans mast cells leukocytes cellular myeloid-type glutathione-dependent hematopoietic H-PGDS intracellular vascular 11.beta.-PGF2.alpha. 11beta-PGF2alpha 11β-PGF2α β-oxidations beta-oxidations .beta.-oxidations tetranor-PGDM metabolites eicosanoids supernatants cultures enzymes preparations biosynthesis serum proteins albumin |
73.091519337016
|
| 10007202 |
Prostaglandin D2 Lipid Maps MS Standard
|
|
41598-07-6 |
>99%
|
|
|
2008-10-27
|
18.350641733956
|
prostaglandin-d2-lipid-maps-ms-standard
|
PGD2
|
Vasodilation prostaglandins brain sleep platelets aggregation. H-PGDS synthases mast cells hematopoietic allergic allergy asthmatic anaphylaxis hypotension inhibits inhibitors inhibition beta-trace .beta.-trace b-trace neurochemistry mass spectrometry standards GC LC MS |
18.350641733956
|
| 10008385 |
Prostaglandin D2 methyl ester
Exclusive |
|
49852-81-5 |
>97%
|
|
✓ |
2006-05-01
|
162.530276243094
|
prostaglandin-d2-methyl-ester
|
PGD2 methyl ester
|
esters prodrug H-PGDS synthases platelets aggregation mast cells hematopoietic allergic allergy asthmatic anaphylaxis vasodilation hypotension inhibits inhibitors inhibition brain b-trace .beta.-trace betatrace sleep prostaglandins |
162.530276243094
|
| 512011 |
Prostaglandin D2-MOX EIA Kit
|
|
- |
|
|
|
|
214.764715864246
|
prostaglandin-d2-mox-eia-kit
|
PGD2-MOX EIA Kit; Prostaglandin D2-MOX ELISA Kit
|
solid plates PGD2-MOX prostaglandins measures kits eias enzyme immunoassays ELISAs assays |
214.764715864246
|
| 500151 |
Prostaglandin D2-MOX Express EIA Kit
|
|
- |
|
|
|
|
63.122967640094
|
prostaglandin-d2-mox-express-eia-kit
|
PGD2-MOX EIA Express Kit; Prostaglandin D2-MOX Express ELISA Kit
|
solid plates PGD2-MOX-hcl prostaglandins measures kits eias enzyme immunoassays ELISAs methoxime methoxylamine hydrochloride same-day assays |
63.122967640094
|
| 10006843 |
Prostaglandin D2 Quant-PAK
|
|
- |
|
|
|
2005-08-08
|
15.005151933701
|
prostaglandin-d2-quant-pak
|
|
Quant-PAKs vasodilation prostaglandins brain sleep platelets aggregation GC/MS deuterium isotopes PGD2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
15.005151933701
|
| 10192 |
Prostaglandin D2 serinol amide
|
|
- |
>98%
|
|
|
2004-05-13
|
39.763292817680
|
prostaglandin-d2-serinol-amide
|
PGD2-SA
|
PGD2 vasodilation prostaglandins brain sleep platelets aggregation anandamides serinols amides cannabinoids AEA |
39.763292817680
|
| 12990 |
Prostaglandin D3
Exclusive |
|
71902-47-1 |
>98%
|
|
✓ |
|
74.783775322283
|
prostaglandin-d3
|
PGD3
|
PGD3 omega-3 w-3 .omega.-3 metabolites EPA eicoaspentaenoic acid prostaglandins |
74.783775322283
|
| 10006593 |
Prostaglandin D Synthase (hematopoietic-type; human recombinant)
|
|
- |
≥95%
|
|
|
2005-02-16
|
34.087328334649
|
prostaglandin-d-synthase-hematopoietic-type-human-recombinant
|
Hematopoietic-PGDS; H-PGDS; PGD Synthase (hematopoietic-type; human recombinant)
|
prostaglandins synthases PGDs PGD2 HPGDS H-PGDS enzymes peripheral tissues antigen-presenting cells mast megakaryocytes glutathiones glutathione-S-transferases allergen allergy allergic mediators |
34.087328334649
|
| 10009625 |
Prostaglandin D Synthase (hematopoietic-type; human recombinant) Western Ready Control
|
|
- |
|
|
|
2007-07-19
|
24.699454419889
|
prostaglandin-d-synthase-hematopoietic-type-human-recombinant-western-ready-control
|
Hematopoietic-PGDS; H-PGDS
|
western blot WB PGH2 lipocalin-type hematopoietic peripheral tisses antigen-presenting cells mast megakaryocytes allergic HPGDS H-PGDS inflammatory diseases inhibits inhibitor inhibition E. coli |
24.699454419889
|
| 10004347 |
Prostaglandin D Synthase (hematopoietic-type; mouse recombinant)
Exclusive |
|
- |
≥85%
|
|
✓ |
2008-06-05
|
33.098225905463
|
prostaglandin-d-synthase-hematopoietic-type-mouse-recombinant
|
H-PGDS; Hematopoietic-PGDS
|
PGH2 lipocalin-type .beta.-trace prostaglandins hematopoietic enzymes PGD2 proteins recombinant inflammation activity high throughput screening inhibitors inhibits inhibition assays HPGDS H-PGDS |
33.098225905463
|
| 10006595 |
Prostaglandin D Synthase Inhibitor Screening Assay Kit
|
|
- |
|
|
|
2005-08-31
|
47.598204419889
|
prostaglandin-d-synthase-inhibitor-screening-assay-kit
|
PGDS Inhibitor Screening Assay Kit
|
prostaglandins synthases inhibitors PGDS assays hematopoietic-types lipocalin-types pro-inflammatory mediators allergic allergy allergies allergens activity inhibitors inhibition inhibits H-PGDS L-PGDS |
47.598204419889
|
| 10006788 |
Prostaglandin D Synthase (lipocalin-type; human recombinant)
|
|
- |
≥95%
|
|
|
2005-03-23
|
39.367700605103
|
prostaglandin-d-synthase-lipocalin-type-human-recombinant
|
L-PGDS; Lipocalin-PGDS
|
prostaglandins synthases PGDs PGD2 H-PGDS enzymes peripheral tissues antigen-presenting cells mast megakaryocytes glutathiones glutathione-S-transferases allergen allergy allergic mediators neurochemistry lpgds l-pgds |
39.367700605103
|
| 10009741 |
Prostaglandin D Synthase (lipocalin type; human) Western Ready Control
|
|
- |
|
|
|
2007-04-30
|
6.126104972375
|
prostaglandin-d-synthase-lipocalin-type-human-western-ready-control
|
L-PGDS; Lipocalin-PGDS
|
GST lpgds l-pgds western blot WB neurochemistry hL-PGDS hLPGDS |
6.126104972375
|
| 10006787 |
Prostaglandin D Synthase (lipocalin-type; mouse recombinant)
|
|
- |
≥95%
|
|
|
2005-03-23
|
41.216685082873
|
prostaglandin-d-synthase-lipocalin-type-mouse-recombinant
|
L-PGDS; Lipocalin-PGDS
|
prostaglandins synthases PGDs PGD2 H-PGDS enzymes peripheral tissues antigen-presenting cells mast megakaryocytes glutathiones glutathione-S-transferases allergen allergy allergic mediators neurochemistry lpgds l-pgds |
41.216685082873
|
| 10010548 |
Prostaglandin D Synthase (lipocalin-type; rat recombinant)
Exclusive |
|
- |
≥95%
|
|
✓ |
2008-07-01
|
38.236034849129
|
prostaglandin-d-synthase-lipocalin-type-rat-recombinant
|
L-PGDS; Lipocalin-PGDS
|
prostaglandins PGH2 beta-trace b-trace proteins assays neurochemistry rL-PGDS rlPGDS .beta.-trace beta-trace b-trace recombinant human cerebrospinal fluid PGs CSF GST-tags GST-tagged N-terminal lpgds l-pgds |
38.236034849129
|
| 13010 |
Prostaglandin E1
|
|
745-65-3 |
>98%
|
|
|
|
56.894554941681
|
prostaglandin-e1
|
Alprostadil; PGE1
|
PGE1 vasodilation atherosclerosis erectile dysfunction prostaglandins pharma:1 |
56.894554941681
|
| 13020 |
Prostaglandin E1 Alcohol
Exclusive |
|
21562-57-2 |
>99%
|
|
✓ |
|
25.100883977901
|
prostaglandin-e1-alcohol
|
1-hydroxy Prostaglandin E1; PGE1 Alcohol
|
PGE1 alcohols agonists prostaglandins EP2 EP4 receptors |
25.100883977901
|
| 13010.1 |
Prostaglandin E1 Analytical Reference Standard
|
|
745-65-3 |
>99%
|
|
|
|
31.944162062615
|
prostaglandin-e1-analytical-reference-standard
|
Alprostadil; PGE1
|
PGE1 vasodilation USP erectile dysfunction prostaglandins |
31.944162062615
|
| 313010 |
Prostaglandin E1-d4
|
|
- |
≥99% deuterated product
|
|
|
|
24.456611418048
|
prostaglandin-e1-d4
|
Alprostadil-d4; PGE1-d4
|
GC/MS deuterium isotopes PGE1-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry atherosclerosis |
24.456611418048
|
| 13012 |
Prostaglandin E1 Ethanolamide
|
|
210976-81-1 |
>98%
|
|
|
|
37.707145488030
|
prostaglandin-e1-ethanolamide
|
PGE1-EA; Alprostadil Ethanolamide
|
anandamides ethanolamides cannabinoids PGE1 prostaglandins AEA neurochemistry neuroscience ethanolamines prostamides |
37.707145488030
|
| 10006844 |
Prostaglandin E1 Quant-PAK
|
|
- |
|
|
|
2005-08-10
|
5.034120626151
|
prostaglandin-e1-quant-pak
|
|
Quant-PAKs vasodilation erectile dysfunction prostaglandins GC/MS deuterium isotopes PGE1-d4 internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
5.034120626151
|
| 14010 |
Prostaglandin E2
|
|
363-24-6 |
≥99%
|
|
|
|
256.004151789883
|
prostaglandin-e2
|
PGE2; Dinoprostone
|
PGE2 metabolites EP1 EP2 EP3 EP4 prostaglandins pharma:2 |
256.004151789883
|
| 10140 |
Prostaglandin E2-1-glyceryl ester
|
|
37497-47-5 |
>98% (as a 85:15 mixture of the 1- and 2-glyceryl esters)
|
|
|
|
48.040865561694
|
prostaglandin-e2-1-glyceryl-ester
|
PGE2-1-glyceryl ester
|
Prostaglandins PGE2-1-GE esters 2-AG 2-arachidonyl-glycerol metabolites COX-2 PGHS-2 cycloxygenases synthases PGE2-2-GE COX2 PGHS2 cannabinoids cbs synthetic |
48.040865561694
|
| 514018 |
Prostaglandin E2 Affinity Purification Kit (20 ml)
|
|
- |
|
|
|
|
243.960254143646
|
prostaglandin-e2-affinity-purification-kit-20-ml
|
PGE2 Affinity Purification Kit
|
PGE2 samples purifications sorbents resins prostaglandins kits eias enzyme immunoassays reagents purify matrix antibodies |
243.960254143646
|
| 500450 |
Prostaglandin E2 Affinity Purification Kit (4 ml)
|
|
- |
|
|
|
2010-07-28
|
191.640753749013
|
prostaglandin-e2-affinity-purification-kit-4-ml
|
PGE2
|
PGE2 samples purifications sorbents resins prostaglandins kits eias enzyme immunoassays reagents purify matrix antibodies |
191.640753749013
|
| 314010 |
Prostaglandin E2-d4
|
|
- |
≥99% deuterated product
|
|
|
|
75.793270718232
|
prostaglandin-e2-d4
|
Dinoprostone-d4; PGE2-d4
|
GC/MS deuterium isotopes PGE2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry |
75.793270718232
|
| 10007273 |
Prostaglandin E2-d4 Lipid Maps MS Standard
|
|
- |
≥99% deuterated product
|
|
|
2009-02-26
|
51.720033149171
|
prostaglandin-e2-d4-lipid-maps-ms-standard
|
Dinoprostone-d4; PGE2-d4
|
GC/MS deuterium isotopes PGE2-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry MS mass spectrometry standards |
51.720033149171
|
| 10581 |
Prostaglandin E2-d9
|
|
- |
≥99% deuterated product
|
|
|
2010-09-16
|
95.288941068139
|
prostaglandin-e2-d9
|
PGE2-d9; Dinoprostone-d9
|
PGE2 metabolites EP1 EP2 EP3 EP4 prostaglandins pharma:2 deuterateds deuteriums LC-MS LC/MS GC-MS GC/MS mass spectrometry MS standards |
95.288941068139
|
| 514010 |
Prostaglandin E2 EIA Kit - Monoclonal
|
|
- |
|
|
|
|
1746.832549807466
|
prostaglandin-e2-eia-kit-monoclonal
|
PGE2 EIA Kit - Monoclonal; Prostaglandin E2 ELISA Kit - Monoclonal
|
solid plates kitrecommendation:pge2 prostaglandins measures kits eias enzyme immunoassays ELISAs assays PGE2 |
1746.832549807466
|
| 14012 |
Prostaglandin E2 Ethanolamide
Exclusive |
|
194935-38-1 |
>98%
|
|
✓ |
|
40.204841160221
|
prostaglandin-e2-ethanolamide
|
PGE2-EA; Dinoprostone Ethanolamide; Prostamide E2
|
anandamides ethanolamides cannabinoids PGE2 prostaglandins AEA analogs neurochemistry neuroscience ethanolamines prostamides |
40.204841160221
|
| 10007212 |
Prostaglandin E2 Ethanolamide Lipid Maps MS Standard
|
|
194935-38-1 |
>98%
|
|
|
2008-11-05
|
31.647041129527
|
prostaglandin-e2-ethanolamide-lipid-maps-ms-standard
|
Dinoprostone Ethanolamide; Prostamide E2; PGE2-EA
|
anandamides ethanolamides cannabinoids PGE2 prostaglandins AEA analogs neurochemistry neuroscience ethanolamines prostamides GC-MS GC/MS LC-MS LC/MS mass spectromatory standards |
31.647041129527
|
| 500141 |
Prostaglandin E2 Express EIA Kit
|
|
- |
|
|
|
|
491.032168508287
|
prostaglandin-e2-express-eia-kit
|
PGE2 Express EIA Kit; Prostaglandin E2 Express ELISA Kit
|
solid plates kitrecommendation:pge2 prostaglandins measures kits eias enzyme immunoassays ELISAs same-day assays |
491.032168508287
|
| 500501 |
Prostaglandin E2 FPIA Kit - Green
|
|
- |
|
|
|
|
142.502231430325
|
prostaglandin-e2-fpia-kit-green
|
PGE2 Fluorescence Polarization Immunoassay - Green
|
kitrecommendation:pge2 metabolites EP1 EP2 EP3 EP4 prostaglandins immunoassays HTS fluorescent high-throughput kits screenings fluorescence fluorometric assays |
142.502231430325
|
| 10004517 |
Prostaglandin E2 FPIA Kit - Red
|
|
- |
|
|
|
2004-06-18
|
183.669972375690
|
prostaglandin-e2-fpia-kit-red
|
PGE2 Fluorescence Polarization Immunoassay - Red
|
kitrecommendation:pge2 metabolites EP1 EP2 EP3 EP4 prostaglandins immunoassays HTS fluorescent high-throughput kits screenings rhodamine rhodamine red-shifted fluorescence fluorometric assays |
183.669972375690
|
| 10384 |
Prostaglandin E2 isopropyl ester
Exclusive |
|
71845-66-4 |
≥98%
|
|
✓ |
2010-06-07
|
324.828397790054
|
prostaglandin-e2-isopropyl-ester
|
|
PGE2 inflammation fertility parturition immunology reproductive biology pain prostaglandins E2 lipophilic |
324.828397790054
|
| 10007211 |
Prostaglandin E2 Lipid Maps MS Standard
|
|
363-24-6 |
>99%
|
|
|
2008-11-05
|
16.598158379374
|
prostaglandin-e2-lipid-maps-ms-standard
|
Dinoprostone; PGE2
|
PGE2 metabolites EP1 EP2 EP3 EP4 prostaglandins GC LC MS mass spectrometry standards GC/MS LC/MS GC-MS LC-MS |
16.598158379374
|
| 14011 |
Prostaglandin E2 methyl ester
Exclusive |
|
31753-17-0 |
>98%
|
|
✓ |
|
70.223591160220
|
prostaglandin-e2-methyl-ester
|
Dinoprostone methyl ester; PGE2 methyl ester
|
PGE2-OMe methyl esters prostaglandins |
70.223591160220
|
| 14053 |
Prostaglandin E2 p-acetamidophenyl ester
|
|
57790-52-0 |
>98%
|
|
|
|
97.422845303867
|
prostaglandin-e2-p-acetamidophenyl-ester
|
PGE2 p-acetamidophenyl ester
|
derivatives prostaglandins PGE2-p-acetamidophenyl esters PGE2-para-acetamidophenyl |
97.422845303867
|
| 14054 |
Prostaglandin E2 p-benzamidophenyl ester
|
|
57790-53-1 |
>98%
|
|
|
|
97.422845303867
|
prostaglandin-e2-p-benzamidophenyl-ester
|
PGE2 p-benzamidophenyl ester
|
derivatives prostaglandins PGE2-p-benzamidophenyl esters PGE2-para-benzamidophenyl |
97.422845303867
|
| 9000376 |
Prostaglandin E2-PEG11-biotin
Exclusive |
|
- |
≥98%
|
|
✓ |
2009-05-13
|
69.399373848986
|
prostaglandin-e2-peg11-biotin
|
PGE2-PEG11-biotin
|
prostaglandins E2 PGE2 linker spacer biotins biotinamides receptors ligands fatty acids binding proteins avidin PEGlycated PGE2-biotin PGs biotinylated |
69.399373848986
|
| 10006846 |
Prostaglandin E2 Quant-PAK
|
|
- |
|
|
|
2005-08-10
|
19.369524011899
|
prostaglandin-e2-quant-pak
|
|
Quant-PAKs GC/MS deuterium isotopes PGE2-d4 internal standards deuterated LC/MS GC-MS LC-MS mass spectrometry metabolites EP1 EP2 EP3 EP4 prostaglandins packs |
19.369524011899
|
| 10193 |
Prostaglandin E2 serinol amide
Exclusive |
|
- |
≥98%
|
|
✓ |
2004-03-03
|
36.258397790055
|
prostaglandin-e2-serinol-amide
|
PGE2-SA
|
PGE2SA cannabinoids agonists CB1 receptors analogs 2-glyceryl neurochemistry neuroscience |
36.258397790055
|
| 14990 |
Prostaglandin E3
Exclusive |
|
802-31-3 |
>98%
|
|
✓ |
|
17.887458563536
|
prostaglandin-e3
|
PGE3
|
PGE3 omega-3 metabolites prostaglandins .omega.-3 w-3 intraocular pressure IOP COX cyclooxygenaes eyes |
17.887458563536
|
| 514531 |
Prostaglandin E Metabolite EIA Kit
|
|
- |
|
|
|
|
367.839143646408
|
prostaglandin-e-metabolite-eia-kit
|
Prostaglandin E Metabolite ELISA Kit; PGEM EIA Kit; PGE Metabolite EIA Kit
|
solid plates kitrecommendation:pge2 bicyclo-PGE2 metabolites 13,14-dihydro-15-keto-PGE2 prostaglandins measures kits eias enzyme immunoassays ELISAs assays |
367.839143646408
|
| 10007939 |
Prostaglandin E Synthase-1 (microsomal) (human recombinant)
|
|
- |
16,000 x g supernatant
|
|
|
2009-03-15
|
25.421565377532
|
prostaglandin-e-synthase-1-microsomal-human-recombinant
|
Membrane-Associated PGES-1; Prostaglandin H/E Isomerase; PIG12; mPGE Synthase-1; MGST1-L1
|
enzymes proteins PGs prostaglandins catalyzes conversion PGH2 PGE2 membrane-associated eicosanoids glutathiones metabolisms MAPEG expression proinflammatory stimuli stimulus IL-1.beta. IL-1b interleukins glucocorticoids synovial tissues primary synoviocytes rheumatiod arthritis fever onset drugs anti-inflammatory therapy therapies E. coli mPGES mPGES-1 mPGES1 |
25.421565377532
|
| 10009734 |
Prostaglandin E Synthase-1 (microsomal) Western Ready Control
|
|
- |
|
|
|
2007-05-01
|
8.713128453038
|
prostaglandin-e-synthase-1-microsomal-western-ready-control
|
mPGE Synthase-1; PIG12; Memebrane-Associated PGES-1; Prostaglandin H/E Isomerase; MGST-L1
|
western blot WB prostaglandins renal failure synthase inhibitors mPGES mPGES-1 mPGES1 |
8.713128453038
|
| 10010498 |
Prostaglandin E Synthase (cytosolic) (human recombinant, inactive protein)
|
|
- |
22.3 kDa (His-tagged); 18 kDa (native)
|
|
|
2008-01-22
|
3.946563535911
|
prostaglandin-e-synthase-cytosolic-human-recombinant-inactive-protein
|
Hsp90 Co-chaperone; p23; Telomerase-binding protein p23; cPGE Synthanse; cPGES
|
cPGES cPGE synthases telomerase-binding proteins p23 Hsp90 cochaperone PGES cytosolic enzymes |
3.946563535911
|
| 10009735 |
Prostaglandin E Synthase (cytosolic) Western Ready Control
|
|
- |
|
|
|
2007-04-02
|
10.446961325966
|
prostaglandin-e-synthase-cytosolic-western-ready-control
|
Hsp 90 Co-chaperone; p23; cPGE Synthase; cPGES; Telomerase-binding protein p23
|
telomerase-binding protein p23 blotting blots western WB glutathione dependent enzymes pges |
10.446961325966
|
| 15010 |
Prostaglandin F1α
|
|
745-62-0 |
>98%
|
|
|
|
3.522523020257
|
prostaglandin-f1
|
PGF1α
|
PGF1alpha PGF1.alpha. metabolites prostaglandins DGLA dihomo-.gamma.-linolenic acid dihomo-g-linolenic dihomo-gamma-linolenic COX cyclooxygenases endocrinology |
3.522523020257
|
| 15020 |
Prostaglandin F1α Alcohol
|
|
13487-47-3 |
>99%
|
|
|
|
2.743176795580
|
prostaglandin-f1-alcohol
|
PGF1α Alcohol
|
PGF1alpha PGF1.alpha. alcohols prostaglandins |
2.743176795580
|
| 10008665 |
Prostaglandin F1α-d9
|
|
- |
≥99% deuterated product
|
|
|
2006-08-04
|
7.724198895027
|
prostaglandin-f1-d9
|
PGF1α-d9
|
GC/MS deuterium isotopes PGF1a-d4 PGF1alpha-d4 PGF1.alpha.-d9 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry |
7.724198895027
|
| 15410 |
Prostaglandin F1β
|
|
10164-73-5 |
>98%
|
|
|
|
1.145469613259
|
prostaglandin-f1
|
PGF1β; 9β-PGF1α
|
prostaglandins PGF1.beta. PGF1beta 9.beta.-PGF1.alpha. 9beta-PGF1alpha 9b-PGF1alpha C-9 epimers |
1.145469613259
|
| 16010 |
Prostaglandin F2α
|
|
551-11-1 |
>99%
|
|
|
|
61.501929986107
|
prostaglandin-f2
|
PGF2α; Dinoprost
|
PGF2alpha PGF2.alpha. Lutalyse vasoconstriction bronchoconstriction prostaglandins endocrinology prostaglandin f2alpha f2 alpha prostaglandin f2 alpha |
61.501929986107
|
| 16110 |
Prostaglandin F2α 1,11-lactone
|
|
62410-84-8 |
>98%
|
|
|
|
14.478895027624
|
prostaglandin-f2-1-11-lactone
|
PGF2α 1,11-lactone
|
1,11-lactone-PGF2alpha 1,11-lactone-PGF2.alpha. prostaglandins 1,11-lactones internal esters |
14.478895027624
|
| 16120 |
Prostaglandin F2α 1,15-lactone
|
|
55314-49-3 |
>99%
|
|
|
|
0E-12
|
prostaglandin-f2-1-15-lactone
|
PGF2α 1,15-lactone
|
1,15-lactone-PGF2alpha 1,15-lactone-PGF2.alpha. prostaglandins 1,15-lactones internal esters |
0E-12
|
| 16130 |
Prostaglandin F2α 1,9-lactone
|
|
55314-48-2 |
>99%
|
|
|
|
14.478895027624
|
prostaglandin-f2-1-9-lactone
|
PGF2α 1,9-lactone
|
1,9-lactone-PGF2alpha 1,9-lactone-PGF2.alpha. 1,9-lactones prostaglandins internal esters |
14.478895027624
|
| 10139 |
Prostaglandin F2α-1-glyceryl ester
|
|
43042-79-1 |
>98% (as a 9:1 mixture of the 2- and 1-glyceryl esters)
|
|
|
|
16.060359116022
|
prostaglandin-f2-1-glyceryl-ester
|
PGF2α-1-glyceryl ester
|
Prostaglandins PGF2alpha-1-GE PGF2.alpha.-1-GE esters 2-AG 2-arachidonoyl-glycerol COX-2 metabolites cyclooxygenases PGHS-2 synthases PGHS2 COX2 PGF2alpha-2-GE PGF2.alpha.-2-GE PGFa-2-GE PGF2a-1-GE cannabinoids cbs synthetic |
16.060359116022
|
| 16012 |
Prostaglandin F2α Alcohol
|
|
13261-27-3 |
>98%
|
|
|
|
24.165011838989
|
prostaglandin-f2-alcohol
|
ZK 62717; PGF2α-OH; AGN190190
|
prostaglandins PGF2.alpha. PGF2alpha alcohols analogs glaucoma IOP hypotensive hypotension eyes intraocular pressure ophthamology ophthalmological neuroscience ophthalmology |
24.165011838989
|
| 16014 |
Prostaglandin F2α Alcohol methyl ether
|
|
143656-18-2 |
>98%
|
|
|
|
24.165011838989
|
prostaglandin-f2-alcohol-methyl-ether
|
PGF2α-OMe; AGN191129
|
prostaglandins PGF2.alpha. PGF2alpha alcohols analogs glaucoma IOP hypotensive hypotension eyes intraocular pressure ethers opthamology opthamological |
24.165011838989
|
| 316010 |
Prostaglandin F2α-d4
|
|
34210-11-2 |
≥99% deuterated product
|
|
|
|
30.461259668508
|
prostaglandin-f2-d4
|
Dinoprost-d4; PGF2α-d4
|
GC/MS deuterium isotopes PGF2a-d4 PGF2alpha-d4 PGF2.alpha.-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry prostaglandin f2a d4 |
30.461259668508
|
| 10007275 |
Prostaglandin F2α-d4 Lipid Maps MS Standard
|
|
34210-11-2 |
≥99% deuterated product
|
|
|
2009-02-26
|
14.511204419889
|
prostaglandin-f2-d4-lipid-maps-ms-standard
|
Dinoprost-d4; PGF2α-d4
|
GC/MS deuterium isotopes PGF2a-d4 PGF2alpha-d4 PGF2.alpha.-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry |
14.511204419889
|
| 10008643 |
Prostaglandin F2α-d9
|
|
- |
≥99% deuterated product
|
|
|
2006-08-04
|
37.177872314303
|
prostaglandin-f2-d9
|
Dinoprost-d9
|
GC/MS deuterium PGF2.alpha.-d9 PGF2alpha-d9 internal standards prostaglandins mass spectrometry LC/MS GC-MS LC-MS deuterated PGF2a-d9 |
37.177872314303
|
| 16023 |
Prostaglandin F2α diethyl amide
|
|
- |
>98%
|
|
|
|
63.940564763658
|
prostaglandin-f2-diethyl-amide
|
Dinoprost diethyl amide; PGF2α-NEt2
|
PGF2alpha PGF2.alpha. amides prostaglandins intraocular pressure hypotensive IOP corneal amidase ophthalmology glaucoma |
63.940564763658
|
| 16032 |
Prostaglandin F2α dimethyl amide
|
|
68192-15-4 |
>98%
|
|
|
|
32.006497851442
|
prostaglandin-f2-dimethyl-amide
|
PGF2α dimethyl amide; Dinoprost dimethyl amide
|
PGF2alpha PGF2.alpha. amides prostaglandins FP receptors antagonists |
32.006497851442
|
| 16033 |
Prostaglandin F2α dimethyl amine
|
|
- |
>98%
|
|
|
|
42.771905054225
|
prostaglandin-f2-dimethyl-amine
|
PGF2α dimethyl amine; Dinoprost dimethyl amine
|
PGF2alpha PGF2.alpha. amines prostaglandins FP receptors antagonists |
42.771905054225
|
| 516011 |
Prostaglandin F2α EIA Kit
|
|
- |
|
|
|
|
387.494414364641
|
prostaglandin-f2-eia-kit
|
Prostaglandin F2α ELISA Kit; PGF2α EIA Kit
|
solid plates PGF2alpha prostaglandins PGF2.alpha. measures kits eias enzyme immunoassays ELISAs endocrinology assays PGF2α Kit PGF2a PGs Kit |
387.494414364641
|
| 16013 |
Prostaglandin F2α Ethanolamide
|
|
353787-70-9 |
>98%
|
|
|
|
10.537682286338
|
prostaglandin-f2-ethanolamide
|
PGF2α-EA; Dinoprost Ethanolamide
|
ethanolamides cannabinoids prostaglandins PGF2.alpha. PGF2alpha anandamides AEA COX-2 cox2 cyclooxygenases pghs2 pghs-2 synthases synthase-2 neuroscience ethanolamines prostamides |
10.537682286338
|
| 316013 |
Prostaglandin F2α Ethanolamide-d4
|
|
- |
≥99% deuterated product
|
|
|
|
10.959005524862
|
prostaglandin-f2-ethanolamide-d4
|
PGF2α-EA-d4
|
ethanolamides cannabinoids prostaglandins PGF2.alpha. PGF2alpha anandamides AEA COX-2 cox2 cyclooxygenases pghs2 pghs-2 synthases synthase-2 deuterium deuterated neuroscience ethanolamines prostamides GC/MS GC-MS LC/MS LC-MS mass spectrometry |
10.959005524862
|
| 10007222 |
Prostaglandin F2α Ethanolamide Lipid Maps MS Standard
|
|
353787-70-9 |
>99%
|
|
|
2008-12-08
|
16.623425414364
|
prostaglandin-f2-ethanolamide-lipid-maps-ms-standard
|
PGF2α-EA; Dinoprost Ethanolamide
|
ethanolamides cannabinoids prostaglandins PGF2.alpha. PGF2alpha anandamides AEA COX-2 cox2 cyclooxygenases pghs2 pghs-2 synthases synthase-2 neuroscience ethanolamines prostamides MS mass spectrometry |
16.623425414364
|
| 16016 |
Prostaglandin F2α ethyl amide
|
|
54130-36-8 |
>98%
|
|
|
|
24.151679967260
|
prostaglandin-f2-ethyl-amide
|
Dinoprost ethyl amide; PGF2α-NEt
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids amides N-ethyl amides PGF2alpha PGF2.alpha. neuroscience |
24.151679967260
|
| 16030 |
Prostaglandin F2α isopropyl ester
|
|
53764-90-2 |
>98%
|
|
|
|
15.227569060773
|
prostaglandin-f2-isopropyl-ester
|
PGF2α isopropyl ester; Dinoprost isopropyl ester
|
PGF2alpha PGF2.alpha. esters prostaglandins eyes ophthalmology ophthalmological intraocular hypotensive hypotension glaucoma IOP pressure |
15.227569060773
|
| 10007221 |
Prostaglandin F2α Lipid Maps MS Standard
|
|
551-11-1 |
>99%
|
|
|
2008-12-13
|
42.374834254143
|
prostaglandin-f2-lipid-maps-ms-standard
|
PGF2α; Dinoprost
|
PGF2alpha PGF2.alpha. Lutalyse vasoconstriction bronchoconstriction prostaglandins endocrinology prostaglandin f2alpha f2 alpha MS Mass Spectrometry |
42.374834254143
|
| 16011 |
Prostaglandin F2α methyl ester
|
|
33854-16-9 |
>98%
|
|
|
|
28.777963781461
|
prostaglandin-f2-methyl-ester
|
PGF2α methyl ester
|
PGF2alpha-OMe PGF2.alpha.-OMe esters prostaglandins eyes ophthalmology ophthalmological intraocular hypotensive hypotension glaucoma IOP pressure ocular |
28.777963781461
|
| 10006848 |
Prostaglandin F2α Quant-PAK
|
|
- |
|
|
|
2005-08-10
|
5.732734806629
|
prostaglandin-f2-quant-pak
|
|
Quant-PAKs Lutalyse vasoconstriction bronchoconstriction endocrinology GC/MS deuterium isotopes PGF2a-d4 PGF2alpha-d4 PGF2.alpha.-d4 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry packs |
5.732734806629
|
| 10194 |
Prostaglandin F2α serinol amide
|
|
- |
>98%
|
|
|
2004-02-23
|
13.622338858195
|
prostaglandin-f2-serinol-amide
|
PGF2α-SA
|
PGF2alphaSA PGF2.alpha.SA PGF2alpha-SA PGF2.alpha.-SA cannabinoids agonists CB1 recptors analogs 2-glyceryl esters amides neuroscience |
13.622338858195
|
| 16020 |
Prostaglandin F2α (tromethamine salt)
|
|
38562-01-5 |
>99%
|
|
|
|
59.654364640884
|
prostaglandin-f2-tromethamine-salt
|
PGF2α (tromethamine salt); Dinoprost (tromethamine salt)
|
PGF.alpha. PGF2alpha prostaglandins salts THAM |
59.654364640884
|
| 16410 |
Prostaglandin F2β
|
|
4510-16-1 |
≥99%
|
|
|
|
6.316197890507
|
prostaglandin-f2
|
9β-PGF2α; PGF2β
|
PGF2beta PGF2.beta. prostaglandins |
6.316197890507
|
| 10007232 |
Prostaglandin F2β Lipid Maps MS Standard
|
|
4510-16-1 |
≥99%
|
|
|
2009-02-03
|
4.664060773480
|
prostaglandin-f2-lipid-maps-ms-standard
|
9β-PGF2α; PGF2β
|
prostaglandins MS mass spectrometry standards PGs inactive PGF2beta PGF2.beta. |
4.664060773480
|
| 16420 |
Prostaglandin F2β (tromethamine salt)
|
|
89847-02-9 |
>99%
|
|
|
|
43.436685082873
|
prostaglandin-f2-tromethamine-salt
|
9β-PGF2α (tromethamine salt); PGF2β (tromethamine salt)
|
PGF2beta PGF2.beta. prostaglandins salts 9.beta.-PGF2.alpha. 9beta-PGF2alpha 9b-PGF2alpha THAM |
43.436685082873
|
| 16990 |
Prostaglandin F3α
Exclusive |
|
745-64-2 |
>98%
|
|
✓ |
|
4.778784530387
|
prostaglandin-f3
|
PGF3α
|
prostaglandins PGF3alpha PGF3.alpha. |
4.778784530387
|
| 10007940 |
Prostaglandin F Synthase (human recombinant)
|
|
- |
≥90%
|
|
|
2006-06-14
|
65.122108655617
|
prostaglandin-f-synthase-human-recombinant
|
AKR1C3; PGFS
|
11.beta.-PGF2.alpha. 11b-PGF2alpha 9,11-endoperoxides 11-ketoreductases aldo-keto reductases human monomeric proteins catalyzing catalyzes isomerization PGH2 PGD2 NADPH nicotinamide adenine dinucleotide phosphates enzymes carbonyls nitroacetophenones nitrobenzaldehydes 9,10-phenanthrene quinine PQ E. coli gel electrophoresis commassie staining |
65.122108655617
|
| 17010 |
Prostaglandin G2
|
|
51982-36-6 |
>95%
|
|
|
|
79.657596685083
|
prostaglandin-g2
|
PGG2
|
endoperoxides cyclooxygenases prostaglandins PGG2 cox-2 PGHS-1 PGHS-2 cox1 cox2 cox-1 synthases PGHS1 PGHS2 |
79.657596685083
|
| 10007230 |
Prostaglandin G2 Lipid Maps MS Standard
|
|
- |
>99%
|
|
|
2008-05-01
|
53.159208103131
|
prostaglandin-g2-lipid-maps-ms-standard
|
PGG2
|
LMFA03010009 endoperoxides cyclooxygenases prostaglandins PGG2 cox-2 PGHS-1 PGHS-2 cox1 cox2 cox-1 synthases PGHS1 PGHS2 lipids mass spectrometry liquid gas chromatography LC- GC- standards |
53.159208103131
|
| 17015 |
Prostaglandin H1
|
|
52589-22-7 |
>95%
|
|
|
|
54.498383977900
|
prostaglandin-h1
|
PGH1
|
endoperoxides cyclooxygenases metabolites PGH1 prostaglandins PGHS1 synthases cox-1 cox1 PGHS-1 |
54.498383977900
|
| 17020 |
Prostaglandin H2
|
|
42935-17-1 |
>95%
|
|
|
|
141.098321823205
|
prostaglandin-h2
|
PGH2
|
PGH2 endoperoxides cyclooxygenase vasoconstrictors prostaglandins PGHS2 syntahses cox-2 cox2 PGHS-2 atherosclerosis |
141.098321823205
|
| 10007231 |
Prostaglandin H2 Lipid Maps MS Standard
|
|
- |
>99%
|
|
|
2008-05-01
|
41.660407458563
|
prostaglandin-h2-lipid-maps-ms-standard
|
PGH2
|
LMFA03010010 PGH2 endoperoxides cyclooxygenase vasoconstrictors prostaglandins PGHS2 syntahses cox-2 cox2 PGHS-2 atherosclerosis lipids mass spectrometry liquid gas chromatography LC- GC- standards |
41.660407458563
|
| 10002 |
Prostaglandin HPLC Mixture
|
|
- |
>98% for each compound
|
|
|
|
40.501390423573
|
prostaglandin-hplc-mixture
|
PG HPLC Mixture
|
PGE1 PGE2 PGF2alpha PGF2.alpha. 6-keto-PGF1alpha 6-keto-PGF1.alpha. mixtures prostaglandins chromatography |
40.501390423573
|
| 18220 |
Prostaglandin I2 (sodium salt)
|
|
61849-14-7 |
>99%
|
|
|
|
104.684802370443
|
prostaglandin-i2-sodium-salt
|
Prostacyclin; Epoprostenol; PGI2
|
PGI2 metabolites prostaglandins salts Na+ COX cyclooxygenases atherosclerosis |
104.684802370443
|
| 18300 |
Prostaglandin I3 (sodium salt)
Exclusive |
|
68324-96-9 |
>99%
|
|
✓ |
|
101.291160220994
|
prostaglandin-i3-sodium-salt
|
PGI3 (Na salt)
|
w-3 omega-3 PGI3 prostaglandins atherosclerosis .omega.-3 salts Na+ |
101.291160220994
|
| 100023 |
Prostaglandin I Synthase (murine) Polyclonal Antibody
|
|
- |
|
|
|
2004-06-30
|
10.323301104972
|
prostaglandin-i-synthase-murine-polyclonal-antibody
|
PGIS; Prostacyclin Synthase; PGI Synthase
|
antibodies antisera antiserum western blots blotting wb IHC immunohistochemistry prostaglandins prostacyclins synthases receptors atherosclerosis immunoblotting |
10.323301104972
|
| 18500 |
Prostaglandin J2
|
|
60203-57-8 |
>95%
|
|
|
|
59.075785319652
|
prostaglandin-j2
|
PGJ2
|
PGJ2 PGD2 metabolites PPARs prostaglandins peroxisome proliferator-activated receptors |
59.075785319652
|
| 10007233 |
Prostaglandin J2 Lipid Maps MS Standard
|
|
60203-57-8 |
>95%
|
|
|
2009-01-05
|
34.108492501973
|
prostaglandin-j2-lipid-maps-ms-standard
|
PGJ2
|
PGJ2 PGD2 metabolites PPARs prostaglandins peroxisome proliferator-activated receptors MS mass spectrometry standards PGs |
34.108492501973
|
| 18800 |
Prostaglandin K1
|
|
69413-73-6 |
>98%
|
|
|
|
0.146961325967
|
prostaglandin-k1
|
PGK1
|
PGK1 9,11-diketones PGE1 PGD1 prostaglandins |
0.146961325967
|
| 18900 |
Prostaglandin K2
|
|
- |
≥98%
|
|
|
|
89.593093922652
|
prostaglandin-k2
|
PGK2
|
PGK2 9,11-diketones prostaglandins PGE2 PGD2 |
89.593093922652
|
| 10007236 |
Prostaglandin K2 Lipid Maps MS Standard
|
|
- |
≥98%
|
|
|
2009-01-16
|
89.978867403315
|
prostaglandin-k2-lipid-maps-ms-standard
|
PGK2
|
PGK2 9,11-diketones prostaglandins PGE2 PGD2 PGs MS mass spectrometry standards |
89.978867403315
|
| 10005 |
Prostaglandin Metabolite HPLC Mixture
|
|
- |
>98% for each compound
|
|
|
|
15.363395278754
|
prostaglandin-metabolite-hplc-mixture
|
PG Metabolite HPLC Mixture
|
metabolites prostaglandins 13,14-dihydro-15-keto-PGD2 13,14-dihydro-15-keto-PGE2 13,14-dihydro-15-keto-PGF2alpha 13,14-dihydro-15-keto-PGF2.alpha. 11b-PGF2alpha PGF2beta PGF2.beta. 11.beta.-PGF2.alpha. 11beta-PGF2alpha mixtures chromatography 9beta-PGF2alpha 9b-PGF2alpha. 9.beta.-PGF2. alpha. COX cyclooxgenase HPLC high pressure liquid chromatography |
15.363395278754
|
| 514012 |
Prostaglandin Screening EIA Kit
|
|
- |
|
|
|
|
361.939565903709
|
prostaglandin-screening-eia-kit
|
Prostaglandin Screening ELISA Kit; PG Screening EIA Kit
|
solid plates PGE2 PGF2alpha prostaglandins measures PGF2.alpha. kits eias enzyme immunoassays ELISAs screens cyclooxygenase assays |
361.939565903709
|
| 10501 |
Prostaglandin Screening Library I (96-Well)
Exclusive |
|
- |
|
|
✓ |
2009-07-27
|
20.847826887661
|
prostaglandin-screening-library-i-96-well
|
Prostaglandin Compound Screening Library 1
|
PGF2alpha PGF2.alpha. Lutalyse vasoconstriction bronchoconstriction prostaglandins endocrinology prostaglandin f2alpha f2 alpha PGF1alpha PGF1.alpha. f1 alpha PGF1b PGF1.beta. f1 beta HTS high thoroughput screening |
20.847826887661
|
| 10502 |
Prostaglandin Screening Library II (96-Well)
Exclusive |
|
- |
|
|
✓ |
2009-07-29
|
25.553895027624
|
prostaglandin-screening-library-ii-96-well
|
Prostaglandin Compound Screening Library 2
|
PGE2 metabolites EP1 EP2 EP3 EP4 Vasodilation prostaglandins brain sleep platelets aggregation. H-PGDS synthases mast cells hematopoietic allergic allergy asthmatic anaphylaxis hypotension inhibits inhibitors inhibition beta-trace .beta.-trace b-trace neurochemistry |
25.553895027624
|
| 10503 |
Prostaglandin Screening Library III (96-Well)
Exclusive |
|
- |
|
|
✓ |
2009-08-19
|
22.428871349644
|
prostaglandin-screening-library-iii-96-well
|
Prostaglandin Compound Screening Library 3
|
PGA metabolites EP1 EP2 EP3 EP4 Vasodilation prostaglandins brain sleep platelets aggregation. H-PGDS synthases mast cells hematopoietic allergic allergy asthmatic anaphylaxis hypotension inhibits inhibitors inhibition beta-trace .beta.-trace b-trace neurochemistry PGJ |
22.428871349644
|
| 13745 |
(R)-Butaprost
|
|
69648-38-0 |
>98%
|
|
|
|
19.222085635359
|
-r-butaprost
|
TR 4978; 15-deoxy-16R-hydroxy-17-cyclobutyl PGE1 methyl ester; (±)-15-deoxy-16R-hydroxy-17-cyclobutyl PGE1 methyl ester
|
PGE2 prostaglandins 5,6-dehydro-butaprost free acids PGE1 EP2 receptors binding selectivity |
19.222085635359
|
| 10006045 |
(R)-Butaprost (free acid)
|
|
- |
>98%
|
|
|
2004-11-09
|
20.071726519336
|
-r-butaprost-free-acid
|
15-deoxy-16R-hydroxy-17-cyclobutyl PGE1; (±)-15-deoxy-16R-hydroxy-17-cyclobutyl PGE1
|
PGE2 prostaglandins 5,6-dehydro-butaprost free acids EP2 receptors binding selectivity carboxylic acid selective analogs C-16 (R)-epimers |
20.071726519336
|
| 70052 |
(S)-(−)-1,1'-Bi-2-naphthol
|
|
18531-99-2 |
>98%
|
|
|
|
535.445856353591
|
-s-1-1-bi-2-naphthol
|
(S)-BINOL
|
chiral asymmetric reduction reduces 15-keto prostaglandins 15S-alcohols 15(S)-alcohols |
535.445856353591
|
| 10023 |
(S)-AL 8810
|
|
- |
>98%
|
|
|
|
18.037707182320
|
-s-al-8810
|
|
antangonists FP receptors PGf2alpha PGF2.alpha. prostaglandins analogs C-15 epimers (S)-AL-8810 (S)-AL8810 S-AL8810 |
18.037707182320
|
| 10951 |
Sampling Tubes with Indomethacin
|
|
- |
|
|
|
2011-06-01
|
0E-12
|
sampling-tubes-with-indomethacin
|
|
spi-bio spibio COX inhibitors ex-vivo thromboxane B2 TXB2 PGs prostagandins cyclooxygenase anticoagulant sampling tubes blood metabolites |
0E-12
|
| 14060 |
SC-19220
|
|
19395-87-0 |
>96%
|
|
|
|
62.085182320441
|
sc-19220
|
|
PGE2 antagonists antinociceptives EP1 receptors selective prostaglandins SC19220 SC 19220 |
62.085182320441
|
| 500431 |
STAT-8-Isoprostane EIA Kit
|
|
- |
|
|
|
|
166.449739542225
|
stat-8-isoprostane-eia-kit
|
STAT-8-Isoprostane ELISA Kit; iPF2α-III Alkaline Phosphatase EIA Kit; STAT-8-iso Prostaglandin F2α EIA Kit; STAT-8-epi Prostaglandin F2α EIA Kit
|
solid plates oxidative injury stress reactive oxygen species 8-isoprostanes 8-epi-PGF2.alpha. 8-epi-PGF2alpha 8-iso-PGF2.alpha. 8-iso-PGF2alpha prostaglandins free radicals ROS peroxidation lipids measures kits eias enzyme immunoassays ELISAs assays |
166.449739542225
|
| 14765 |
Sulprostone
|
|
60325-46-4 |
>98%
|
|
|
|
196.931767955800
|
sulprostone
|
|
16-phenoxy-PGE2 EP3 agonists selective analogs receptors |
196.931767955800
|
| 10005440 |
Tafluprost
|
|
209860-87-7 |
>98%
|
|
|
2004-10-05
|
236.322872928176
|
tafluprost
|
AFP-168
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular acids 17-phenyl trinor-PGF2.alpha. 17-phenyl trinor-PGF2alpha 15-deoxy-15,15-difluoro PGF analogs 16-phenoxy hypotensive |
236.322872928176
|
| 10005439 |
Tafluprost (free acid)
|
|
209860-88-8 |
>98%
|
|
|
2004-09-22
|
41.529889502762
|
tafluprost-free-acid
|
AFP-172
|
eyes glaucoma prostaglandins agonists FP receptors ophthalmology ophthalmological intraocular AFP172 hypotensives pressure IOP |
41.529889502762
|
| 10011348 |
Taprostene (free acid)
Exclusive |
|
108945-35-3 |
≥95%
|
|
✓ |
2009-11-11
|
59.629788213627
|
taprostene-free-acid
|
CG 4203; Rheocyclan
|
prostacyclins PGI2 receptors IP IP1 EP4 vascular smooth muscles relaxation analogs potential antagonists tissues preparations CG-4203 CG4203 SE63 SE-63 SE 63 |
59.629788213627
|
| 70031 |
TBS-Corey Lactone Aldehyde
|
|
64091-14-1 |
≥95%
|
|
|
|
37.491712707182
|
tbs-corey-lactone-aldehyde
|
|
intermediates aldehydes prostaglandins preparations analogs synthesis tert-butyl-dimethylsilyl |
37.491712707182
|
| 13369 |
tetranor-PGAM
Exclusive New |
|
52510-53-9 |
≥98%
|
|
✓ |
2011-12-15
|
89.640463671084
|
tetranor-pgam
|
tetranor-Prostaglandin A Metabolite
|
tetranor-PGEM PGE2 urine metabolites prostaglandins E2 biomarkers inflammation diseases therapeutic metabolism biosynthesis tetranor PGAM tetranorPGAM PGA-M PGE-M |
89.640463671084
|
| 12850 |
tetranor-PGDM
Exclusive |
|
- |
≥90%
|
|
✓ |
2008-04-08
|
87.929546410956
|
tetranor-pgdm
|
tetranor-PGD Metabolite
|
metabolites urinary PGD2 prostaglandins D2 urine PGD-M |
87.929546410956
|
| 10009039 |
tetranor-PGDM-d6
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
2007-06-28
|
57.067671963972
|
tetranor-pgdm-d6
|
tetranor-Prostaglandin D Metabolite-d6
|
deuterated deuterium GC/MS GC-MS LC/MS LC-MS mass spectrometry PGD-M |
57.067671963972
|
| 501001 |
tetranor-PGDM EIA Kit
Exclusive |
|
- |
|
|
✓ |
2009-06-15
|
76.698017488723
|
tetranor-pgdm-eia-kit
|
tetranor-Prostaglandin D Metabolite ELISA Kit
|
solid plates prostaglandins PGs metabolites acetylcholinesterases tracers enzymes immunoassays EIAs kits measures measurements hemoatopoietic-type H-PGDS synthases isoforms PGD2 allergen-stimulated mast cells pro-inflammatory mediators allergic reactions 7-transmembranes G protein-coupled receptors GPCRs human mouse murine LC-MS liquid chromatography mass-spectrometry creatinine competitive quantifications assays PGD-M |
76.698017488723
|
| 13564 |
tetranor-PGDM lactone
Exclusive New |
|
- |
≥90%
|
|
✓ |
2012-01-19
|
136.243374969973
|
tetranor-pgdm-lactone
|
tetranor-Prostaglandin D Metabolite lactone
|
urine PGD2 prostaglandins D2 tetranor PGDM PGs allergic allergy asthma anaphylaxis sleep body temperature inhibits inhibition inhibitor platelets aggregation vascular smooth muscles urinary metabolites humans mouse biomarkers biosynthesis lactones PGD-M |
136.243374969973
|
| 14840 |
tetranor-PGEM
Exclusive |
|
24769-56-0 |
≥98%
|
|
✓ |
|
83.351637066672
|
tetranor-pgem
|
tetranor-Prostaglandin E Metabolite
|
metabolites urinary markers PGE1 PGE2 urine metabolites PGE-M |
83.351637066672
|
| 314840 |
tetranor-PGEM-d6
Exclusive |
|
- |
≥99% deuterated product
|
|
✓ |
|
82.235177335365
|
tetranor-pgem-d6
|
tetranor-Prostaglandin E Metabolite-d6
|
GC/MS deuterium isotopes tetranor-PGEM-d6 internal standards prostaglandins deuterated LC/MS GC-MS LC-MS mass spectrometry metabolites urinary markers PGE-M |
82.235177335365
|
| 10007216 |
tetranor-PGEM Lipid Maps MS Standard
|
|
24769-56-0 |
≥98%
|
|
|
2008-12-13
|
61.738353591159
|
tetranor-pgem-lipid-maps-ms-standard
|
tetranor-Prostaglandin E Metabolite
|
metabolites urinary markers PGE1 PGE2 urine metabolites MS mass spectrometry standards PGE-M |
61.738353591159
|
| 16840 |
tetranor-PGFM
Exclusive |
|
23109-94-6 |
>98%
|
|
✓ |
|
29.606461124870
|
tetranor-pgfm
|
tetranor-Prostaglandin F Metabolite
|
metabolites PGF2alpha PGF2.alpha. urinary urine markers PGF2α PGF-M |
29.606461124870
|
| 10007228 |
tetranor-PGFM Lipid Maps MS Standard
|
|
23109-94-6 |
>98%
|
|
|
2008-12-18
|
25.066505524861
|
tetranor-pgfm-lipid-maps-ms-standard
|
tetranor-Prostaglandin F Metabolite
|
metabolites PGF2alpha PGF2.alpha. urinary urine markers PGF2α MS mass spectrometry standards PGF-M |
25.066505524861
|
| 13363 |
tetranor-PGJM
Exclusive New |
|
- |
≥98%
|
|
✓ |
2011-12-15
|
98.053975360386
|
tetranor-pgjm
|
tetranor-Prostaglandin J Metabolite
|
urine metabolites metabolism PGD2 prostaglandins D2 PGs tetranor-PGDM tetranor PGJM tetranorPGJM allergic allergies asthma anaphylaxis sleep temperature inhibits inhibition inhibitors platelets aggregation vascular smooth muscles urinary humans mouse mice biomarkers biosynthesis C-9 C9 C 9 PGJ-M PGJ-M |
98.053975360386
|
| 13632 |
Tiaprost
New |
|
71116-82-0 |
≥95%
|
|
|
2012-01-27
|
90.141074278698
|
tiaprost
|
Iliren
|
prostaglandins PGs analogs PGF2α estrus endometritis parturition veterinary medicine luteolysis |
90.141074278698
|
| 10162 |
Treprostinil
|
|
81846-19-7 |
>98%
|
|
|
2005-08-30
|
218.580605605111
|
treprostinil
|
Remodulin®
|
primary pulmonary hypertension PPH arterial vascular resistance stable analogs prostacyclins increase plasma half-life vasodilatory inhibits inflammatory cytokines inhibition inhibitors GM-CF human alveolar macrophages NF-KB NF-.kappa. translocations nucleus NF-kappaB nfkb nf-kb NF-.kappa.B atherosclerosis Tyvasos Tyvaso® |
218.580605605111
|
| 16440 |
U-44069
|
|
56985-32-1 |
>98%
|
|
|
|
351.954530386740
|
u-44069
|
9,11-dideoxy-9α,11α-epoxymethano Prostaglandin F2α; 9,11-epoxymethano Prostaglandin H2; 9,11-dideoxy-9α,11α-epoxymethano PGF2α
|
endoperoxides methanoepoxy PGH2 thromboxanes analogs prostaglandins U44069 TP receptors agonists atherosclerosis |
351.954530386740
|
| 16450 |
U-46619
|
|
56985-40-1 |
>98%
|
|
|
|
227.299350257979
|
u-46619
|
9,11-dideoxy-9α,11α-methanoepoxy Prostaglandin F2α; 9,11-dideoxy-9α,11α-methanoepoxy PGF2α
|
endoperoxides PGH2 thromboxanes vasoconstriction analogs TP receptors agonists U46619 atherosclerosis |
227.299350257979
|
| 16465 |
U-51605
|
|
64192-56-9 |
>98%
|
|
|
|
49.377216280602
|
u-51605
|
|
diazo endoperoxides inhibitors U51605 analogs PGH2 PGIs synthase prostaglandins inhibits thromboxanes atherosclerosis |
49.377216280602
|
| 16680 |
Unoprostone
|
|
120373-36-6 |
>98%
|
|
|
|
27.097591160221
|
unoprostone
|
13,14-dihydro-15-keto-20-ethyl Prostaglandin F2α; 13,14-dihydro-15-keto-20-ethyl PGF2α
|
prostaglandins PGF2alpha PGF2.alpha. analogs hypotensive hypotension intraocular pressure ophthalmological eyes ophthalmology iop glaucoma |
27.097591160221
|
| 16681 |
Unoprostone isopropyl ester
|
|
120373-24-2 |
>98%
|
|
|
|
32.210961325966
|
unoprostone-isopropyl-ester
|
Rescula; 13,14-dihydro-15-keto-20-ethyl Prostaglandin F2α isopropyl ester
|
prostaglandins hypotensive hypotension analogs PGF2alpha PGF2.alpha. eyes ophthalmology ophthalmological intraocular esters iop glaucoma PGF2a PGF2α |
32.210961325966
|
| 10003 |
Vasoactive Eicosanoid HPLC Mixture
|
|
- |
>98% for each compound
|
|
|
|
22.412469613259
|
vasoactive-eicosanoid-hplc-mixture
|
|
11-dehydro-TXB2 2,3-dinor-6-keto-PGF1.alpha. 2,3-dinor-6-keto-PGF1alpha 2,3-dinor-TXB2 12-HHTs 12(S)-HHTrEs 12-HHTrEs 12(S)HHTrEs thromboxanes prostaglandins eicosanoids mixtures 2,3-dinor-PGF1.alpha. 2,3-dinor-PGF1alpha chromatography atherosclerosis |
22.412469613259
|
| 13673 |
ZK118182 isopropyl ester
Exclusive |
|
154927-31-8 |
≥98%
|
|
✓ |
2010-11-05
|
0E-12
|
zk118182-isopropyl-ester
|
|
intraocular pressure IOP glaucoma PGD2 agonists DP receptors hypertension Hexadecanoylcarnitine
Palmitoylcarnitine
Palmitylcarnitine |
0E-12
|
| 12650 |
Δ12-Prostaglandin D2
Exclusive |
|
64072-89-5 |
>98%
|
|
✓ |
|
65.255267034991
|
-12-prostaglandin-d2
|
Δ12-PGD2
|
D12-PGD2 metabolism prostaglandins decomposition .DELTA.12-PGD2 DELTA12-PGD2 |
65.255267034991
|
| 18550 |
Δ12-Prostaglandin J2
|
|
87893-54-7 |
≥95%
|
|
|
|
73.702974217311
|
-12-prostaglandin-j2
|
Δ12-PGJ2
|
delta12-PGJ2 d12-PGJ2 .DELTA.12-PGJ2 antitumor antimitotic PPARgamma PPAR.gamma. PPARs peroxisome proliferator-activated receptors prostaglandins ligands |
73.702974217311
|
| 10007234 |
Δ12-Prostaglandin J2 Lipid Maps MS Standard
|
|
87893-54-7 |
≥98%
|
|
|
2009-01-20
|
58.310709023941
|
-12-prostaglandin-j2-lipid-maps-ms-standard
|
Δ12-PGJ2
|
delta12-PGJ2 d12-PGJ2 Δ12-PGJ2 antitumor antimitotic PPARgamma PPARγ PPARs peroxisome proliferator-activated receptors prostaglandins ligands MS mass spectrometry standards PGs anti-tumor |
58.310709023941
|
| 15230 |
Δ17-6-keto Prostaglandin F1α
|
|
68324-95-8 |
>98%
|
|
|
|
5.768563535911
|
-17-6-keto-prostaglandin-f1
|
ω-3 6-keto PGF2α
|
omega-3 PGI3 metabolites prostaglandins .DELTA.17-6-keto-PGF1.alpha. d17-6-keto-PGF1alpha DELTA17-6-keto-PGF1alpha .omega.-3 w-3 |
5.768563535911
|
| 13090 |
Δ17-Prostaglandin E1
|
|
7046-45-9 |
>99%
|
|
|
|
27.313057090239
|
-17-prostaglandin-e1
|
5,6-dihydro PGE3; Δ17-PGE1
|
PGE3 metabolites prostaglandins .DELTA.17-PGE1 D17-PGE1 DELTA17-PGE1 |
27.313057090239
|
| 16460 |
Δ17-U-46619
|
|
- |
>98%
|
|
|
|
74.246914866901
|
-17-u-46619
|
|
d17-u-46619 delta17-u-46619 .delta.17-u-46619 thromboxanes TXA3 analogs agonists d17-u46619 delta17-u46619 .delta.17-u46619 atherosclerosis |
74.246914866901
|